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Almost 80 % of all breast cancers (BCs) are dependent on the estrogen receptor 
alpha (ER) for their growth (termed ER+ BC), while the rest are negative for the expression 
of ER (ER- BC) (~ 20-25 %). Most ER+ BCs (more than 90 %) and around 50 % of ER- BCs 
express the androgen receptor (AR). AR is an important BC biomarker, with prognostic and 
therapeutic potential. AR is a tumor-suppressor in ER+ BC, where it inhibits estrogen-
stimulated growth of tumours through down-regulation of key ER-regulated cell cycle 
genes and activation of good outcome genes. AR has been suggested to play a role in 
promoting a basal to luminal lineage transition in normal mouse mammary epithelial cells. 
Despite the role of AR in ER- BCs being controversial, AR positivity has been shown to be 
associated with improved disease-free survival and more benign clinical and pathologic 
factors (e.g. lower tumor grade and smaller tumor size) in ER- BCs. In the recent past, the 
GATA3 transcription factor (TF) has been characterized as an important regulator of ER 
signalling and mediates normal mammary gland development and cell lineage 
determination. GATA3 is expressed exclusively in the luminal epithelial cell population, 
plays an essential role in mammary development and specification, and actively maintains 
the luminal epithelial differentiation in the adult mammary gland. To date, the role of 
GATA3 in AR signalling in the context of BC, in the presence or absence of ER, has not been 
investigated. Therefore, the aim of this thesis was to further investigate and characterise 
the cross-talk between AR and GATA3 in the presence or absence of ER, using a variety of 
cell-line models, clinical samples and where possible, patient-derived xenografts (PDXs). I 
first investigated the functional interplay between GATA3 and AR in inducing the luminal 
epithelial lineage in breast cancer cells regardless of ER expression. Since the inhibitory 
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role of AR in ER+ BCs is well established, I then investigated whether GATA3 is involved in 
AR-induced growth inhibition in ER+ BC models in response to ER and/or AR activation. 
Findings of this PhD thesis showed: 
• GATA3 is a novel AR interacting protein independent of ER 
expression in normal mammary tissues and different BC subtypes. 
• Stimulation of BC cells with estrogen or androgen hormones 
reprograms the GATA3 cistrome in ER+ and ER- BC cell lines and ER+ PDX models. 
• GATA3 and AR co-regulate the expression of essential luminal 
epithelial markers in both ER+ and ER- cell lines and ER+ PDXs, indicating a key 
collaborative role for GATA3 and AR in luminal epithelial differentiation of the 
breast cells regardless of the ER expression. 
• AR requires the presence of GATA3 at genomic loci associated with 
AR-mediated growth inhibition in ER+ BC to inhibit the E2-stimulated growth in 
these models. 
Collectively, the generated data from this thesis suggest a cooperative role for AR 
and GATA3 TFs in suppressing the tumour growth of ER+ BCs and in driving the luminal-
lineage identity in mammary glands and BC contexts. Also, the findings of this thesis 
provide novel insight into the cross-talk between ER, GATA3, and AR in BC, highlight the 
signalling complexity of TFs in this disease and provide the basis for further investigations 
into AR and GATA3 co-operative genomic activity and the direct consequences of this for 
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1. Chapter-1: Introduction 
1.1. Mammary gland development and breast cancer 
1.1.1. Mammary gland development  
The human mammary gland is a dynamic glandular organ composed of two major 
mammary epithelial cell lineages. The inner layer of polarized luminal epithelial cells lines 
the lumen of the mammary ducts and alveoli, while basal cells form the outer 
myoepithelial layer (Figure 1) (Cardiff & Wellings 1999; Smalley & Ashworth 2003). During 
lactation, production of milk depends on the action of the ductal and alveolar luminal cells 
that make up the ductal network and secrete the milk components into the ductal lumen, 
while myoepithelial cells allow the expulsion of milk (Inman et al. 2015). Transplantation 
and genetic lineage tracing studies prove there is a differentiation hierarchy of stem and 
progenitor cells that create and maintain the mammary epithelium in both mice and 
humans (reviewed in (Feng et al. 2018)). Mammary stem cells (MaSCs) exist as a very small 
proportion of bi- or multi-potent cells in the mammary gland. MaSCs are undifferentiated 
cells with self-renewal ability that can undergo differentiation into various committed 
progenitors and differentiated cells (Lloyd-Lewis et al. 2017). MaSCs are located in a 
suprabasal niche (MaSC-specific cellular microenvironment) within the mammary gland 
and are poised to respond to extracellular cues that regulate MaSC fate and differentiation 
to maintain the self-renewal and multilineage differentiation capacity (Lloyd-Lewis et al. 
2017; Oakes, Gallego-Ortega & Ormandy 2014). According to the model of mammary 
epithelial hierarchy, a common progenitor cell becomes committed to the luminal or 
myoepithelial lineage, then further differentiates into differentiated ductal, alveolar or 
myoepithelial cells (Figure 2) (Lloyd-Lewis et al. 2017; Shackleton et al. 2006). Different 
mammary cell lineages are identified by expression of specific markers such as cytokeratin 
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(CK)18, CK8, and CK19 for luminal cells, and CK5, CK14 and p63 for myoepithelial cells 
(O'Hare et al. 1991). During early development, the polarized luminal epithelial cells end 
in terminal ducts with their associated acinar structures, termed the terminal end buds 
(TEBs), comprising an outer layer of cap cells (myoepithelial progenitors) and a multilayer 
inner core of body cells, which contains the luminal cell progenitors. During puberty, these 
ducts invade and elongate through the fatty stroma in a process known as branching 
morphogenesis (Figure 3) (Chou, Provot & Werb 2010). The mammary stroma consists of 
a heterogeneous cell population of fibroblasts, adipocytes, macrophages, eosinophils, and 
mast cells, which collectively play an important role in facilitating branching and ductal 
elongation (Chou, Provot & Werb 2010). During the lifetime of the female, the mammary 
gland epithelium and surrounding stroma continually undergo drastic remodelling in 
structure and function during oestrous cycling (mice) or menstrual cycling (human), 
pregnancy and lactation, allowing the mammary epithelium to continually adapt to meet 
its physiological requirements. During these reproductive stages, mammary cells retain 
many properties important during development including proliferation, invasion, 
differentiation, resistance to apoptosis, and angiogenesis that are also associated with 
















Figure 1: Ductal structure (Visvader 2009) 
Image shows the two different epithelial cell subtypes resident in the mammary ducts, 
including luminal and myoepithelial cells. These epithelial cells are surrounded by the 
basement membrane, which separates them from the stroma containing a heterogeneous 
cell population of fibroblasts, adipocytes, macrophages, eosinophils, and mast cells that 
play an important role in facilitating branching and ductal elongation. Suprabasal stem cells 
are located in the myoepithelial layer, but do not reach the lumen. The ductal lumen is 







Figure 2: Human breast epithelial hierarchy and cell type differentiation within the 
mammary epithelium (Created with BioRender.com) 
The hierarchical organisation from a breast stem cell and progenitor cells is shown 
schematically. MaSCs are bi- or multi-potent cells with the capability of self-renewal by 
dividing. Luminal and myoepithelial progenitor cells are derived from a common 
progenitor cell. Transformation into luminal and myoepithelial progenitor lineage occur(s) 
subsequently, whereby the luminal progenitor cells differentiate into either ductal or 






Figure 3: Schematic representation of a terminal end bud (Visvader 2009) 
Schematic of a developing mammary duct and it’s corresponding stroma. The mammary 
ducts are lined by epithelium that is composed of an inner luminal epithelial cell layer and 
an outer myoepithelial cell layer. The immature ducts terminate in structures call the 
terminal end buds (TEBs), which invade through the fat pad during pubertal development. 
The cap cells at the tip of the TEB differentiate into myoepithelial lineage on the outer side 
of the TEB. The body cells generate transit cells of a luminal epithelial lineage to form the 
central TEB mass. As the TEB invades into the fat pad, the ductal lumen is progressively 
formed as central body cells undergo apoptosis and the remaining outer cells differentiate 
into luminal epithelial cells. 
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1.1.2. Breast cancer incidence and mortality 
Breast cancer is the most common malignancy worldwide, affecting millions of 
women annually in both developed and developing countries (Bray et al. 2018). It is 
estimated that 19,974 new cases of breast cancer (167 males and 19,807 females) will be 
diagnosed in 2020, in Australia (Australia 2020). Furthermore, 3,031 deaths from breast 
cancer will likely be recorded by the end of 2020 (33 males and 2,997 females) (Australia 
2020). In 2016, breast cancer was the second most commonly diagnosed cancer in 
Australia and the most commonly diagnosed cancer among females. However, according 
to WHO, breast cancer has now overtaken lung cancer as the world’s mostly commonly-
diagnosed cancer up to 2020 (WHO 2020). This indicates that despite advances in 
treatment, breast cancer is still one of the leading causes of cancer-related mortality 
among women, and that its incidence is continuously rising (Australia 2020). 
 
1.1.3. Histological classification of breast cancer 
Breast cancer occurs in any of the cells comprising the mammary gland and exhibits 
a wide scope of morphological features, different immunohistochemical profiles, and 
unique histopathological subtypes that have a specific clinical course and outcome. Based 
on which cell-of-origin is involved, breast cancers can be divided into two broad 
classifications: carcinomas and sarcomas. Carcinomas are breast cancers arising from the 
epithelial component of the breast and sarcomas are a much rarer form of breast cancer 
(<1 % of primary breast cancer) arising from the stromal components of the breast. Most 
breast cancers are carcinomas, which are further subclassified into non-invasive (or in situ), 
locally invasive (90-95 % of all breast cancer types), or metastatic, based on their 
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invasiveness relative to the primary tumour sites. Two main types of breast tissues are 
ducts and lobules. In situ breast cancers classified into two groups of “Ductal carcinoma in 
situ, (DCIS)” and “Lobular carcinoma in situ, (LCIS)”. DCIS, or intra-ductal carcinoma, is 
breast cancer in the lining of the milk ducts that has not yet invaded nearby tissues. LCIS 
or lobular neoplasia arise from the lobules of the milk-producing glands of the breast, but 
are limited within the walls of the lobules. Invasive carcinomas are composed of two 
groups: Invasive Ductal Carcinoma (IDC), which accounts for ~80 % of all breast cancers 
(most common type of breast cancer), and Invasive Lobular Carcinoma (ILC), that accounts 
for approximately 10–15 % of all breast cancers (reviewed in (Feng et al. 2018)).  
 
1.1.4. Molecular classification of breast cancer and cellular origins 
Breast cancer is a heterogeneous disease with respect to its molecular and cellular 
attributes. Therefore, establishing tumour classifications that could be clinically useful in 
terms of prognosis or prediction of the disease is very challenging. Breast cancers also vary 
in terms of prognosis and clinical outcomes (Ellsworth et al. 2017; Perou et al. 2000). Based 
on the fact that the biological diversity of tumours may be derived from differing 
transcriptional programs, gene expression profiling by microarray was introduced for the 
first time by Perou et al., in 2000, to provide prognostic information beyond standard 
histological assessment (Perou et al. 2000). Very soon after that, Sorlie et al., (2001) 
refined the molecular classification of breast carcinomas into 4 main categories (Normal-
like, Luminal epithelial, Basal-like and human epidermal growth factor receptor 2 (HER2)-
overexpressing) based on the variation in gene expression patterns derived from 
complementary DNA (cDNA) microarrays (Sørlie et al. 2001; Sorlie et al. 2003). With the 
27 
 
advance of gene expression profiling techniques, intrinsic molecular subtypes have been 
further refined for better understanding of the biological complexity of breast cancer and 
to increase its clinical utility. In 2009, Parker et al., developed the PAM50 gene set, which 
added significant prognostic and predictive value to standard clinical variables (including 
tumour size, histologic grade and node status) (Parker et al. 2009) and classified breast 
tumours into Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like sub-
groups (Figure 4) (Parker et al. 2009). 
Luminal A (accounting for 50-60 %) and Luminal B (accounting for 15-20 %) of all 
breast cancers express the estrogen receptor (ER) and are the most differentiated breast 
cancer subtypes with the best prognoses. The luminal A subtype also expresses the 
progesterone receptor (PR), but does not over-express HER2, and has low levels of Ki-67 
(a proliferative marker), so they are more indolent with a slower growth over time in 
comparison with all the other molecular subtypes. Luminal A tumours also show less 
frequent and less extensive lymph nodal involvement. Conversely, the luminal B subtype 
has variable expression of PR (low level of expression or no expression (+/-)) and is 
sometimes HER2+ (overexpressed with or without gene amplification), and has higher 
expression of Ki-67, consistent with their faster tumour growth compared to luminal A. 
These molecular variations partially explain why the luminal B subtype is associated with a 
worse prognosis compared with luminal A. Also, luminal B tumours are associated with a 
greater potential risk of local-regional recurrence compared to luminal A (Fragomeni, 
Sciallis & Jeruss 2018; Reis-Filho & Pusztai 2011). ER is considered the main oncogenic 
driver of Luminal A and Luminal B breast cancers. Therefore, targeting ER is the main 
therapeutic strategy. The anti-estrogen Tamoxifen has been clinically used over the last 30 
years as a central treatment component of ER+ breast cancer subtypes (Castrellon 2017). 
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More recently, aromatase inhibitors (AI) have also become standard-of-care, especially in 
post-menopausal women (EBCTCG 2015).  
The HER2-enriched subtype makes up 10-15 % of all breast cancers. These are 
characterized by the absence of ER and PR expression, high expression of HER2 and 
proliferation-associated genes, and low expression of the luminal and basal genes. HER2-
enriched cancers grow faster than luminal cancers and have a worse prognosis. They can 
be treated with targeted therapies aimed at the HER2 protein, such as Herceptin (or 
Trastuzumab) (reviewed in (Feng et al. 2018)). 
Basal-like breast cancers (15-20 % of all cases) are characterised as ER-negative, PR-
negative and HER2-negative and are consequently termed Triple Negative Breast Cancer 
(TNBC). TNBC behaves more aggressively than other breast cancer subtypes, making it a 
high-grade breast cancer with very poor outcomes. Unlike other breast cancer subtypes 
that have the possibility of targeted therapies, TNBC’s non-surgical treatment has been 
limited to conventional chemotherapy, until recent approval of the PARP inhibitor Olaparib 
for BRCA1 and BRCA2 mutation carriers, who are more likely to develop TNBC (Feng et al. 
2018). 
The normal-like subtype has high expression of genes known to be expressed by 
adipose tissue and other non-epithelial cell types. This subtype is similar to luminal A, with 
the same pattern of receptor expression (ER+, PR+, HER2-) and low levels of Ki-67. 
Although luminal A and normal-like breast cancer subtypes are associated with the best 
disease outcomes, the prognosis of normal-like breast cancer is still slightly worse than 
luminal A, maybe due to the different gene expression patterns or lack of PR (ER+, PR±, 
HER2-, Low Ki67) (Feng et al. 2018). 
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Even though molecular subtyping of breast tumours predicts the outcome of the 
disease, patient response to a specific targeted therapy or to chemotherapy remains 
variable, possibly due to intra-tumoural heterogeneity and the evolution of treatment 
resistance. Also, each breast cancer subtype originates from distinct breast epithelial 
lineages that serve as the ‘cell-of-origin’ (Figure 5). Therefore, a better understanding of 
both breast tumour heterogeneity and cellular origin of the tumour cells may improve 







Figure 4: Molecular classification of breast cancer subtypes (Created with 
BioRender.com) 
Breast cancer is a heterogeneous disease and the intrinsic biological subgroups have been 
identified and are classified into five molecular subtypes with different prognoses as 








Figure 5: Potential relationships between stem and progenitor cells and different breast 
cancer subtypes (Created with BioRender.com) 
The diagram depicts the proposed association between of the cell-of-origin for different 
tumour types with their closest normal epithelial counterpart based on gene expression 




1.1.5. Endocrine therapy for ER-positive breast cancer 
Luminal breast cancers (~80 % of all cases) are considered ‘hormone responsive’ as 
defined by expression of ER, PR, or both. Drugs that prevent ER activity, generally known 
as endocrine therapy, are standard-of-care treatment for ER-positive (ER+) breast cancer 
patients (Castrellon 2017). One of the first anti-estrogen strategies to directly target ER are 
a class of therapies called selective estrogen receptor modulators (SERMs), such as 
Tamoxifen. These drugs compete with estrogens by binding to ER with high affinity. This 
leads to a conformational change in the structure of the ER protein, preventing ER 
transcriptional activity in breast epithelial cells (Fisher et al. 2005). Evidence has shown 
that ER+/PR+ patients benefit from targeted endocrine therapies more than ER+/PR- 
patients (Higgins & Stearns 2009); the Tamoxifen response rate in ER+/PR+ disease is about 
80 %, however for ER+/PR- this is decreased to approximately 40 % (Higgins & Stearns 
2009). It has been shown that 5 years of adjuvant Tamoxifen therapy alone in ER+ patients 
reduces the annual breast cancer death rate by 31 %, independent of the use of 
chemotherapy, patient age, PR status, or other tumour characteristics such as nodal status 
(EBCTCG 2005). Despite its clinical success, resistance to Tamoxifen therapy is common. 
About two thirds of Tamoxifen-resistant tumours maintain ER expression and their growth 
still depends on ER function (Ali et al. 2016; Kilker et al. 2004). Therefore, other hormone 
therapies are used to control tumour growth. AIs prevent estrogen production by blocking 
the aromatase enzyme from converting androgen pre-cursors into estrogen. AIs, including 
Anastrozole and Letrozole, are considered more effective than Tamoxifen in 
postmenopausal women because they reduce the risk of recurrent disease, especially at 
distant sites (Thürlimann et al. 2005). For instance, in metastatic ER+ breast tumours, 
Anastrozole is currently considered the first-line treatment for postmenopausal women 
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(Miller 2003). However, Due to the large amount of aromatase substrate present in the 
ovary of premenopausal women, treatment with AIs is less effective in inhibiting ovarian 
estrogen production in these women (Winer 2005). Fulvestrant is one of a newer 
generation of ER antagonists known as selective estrogen receptor degraders (SERDs). 
Fulvestrant is a complete degrader and works by binding to the ER, inducing destabilization 
and degrading the ER protein (Howell 2005; Howell et al. 2004). Data from two phase III 
trials demonstrated that Fulvestrant 250 mg (once-monthly intramuscular injection) is at 
least as effective as Anastrozole (1 mg/day orally) in the treatment of postmenopausal 
women with Tamoxifen-resistant advanced breast cancer and is well tolerated (Osborne 
et al. 2002; Robertson et al. 2003). Despite the benefits of these different endocrine 
therapies, all are associated with development of resistance where the treatment becomes 
non-effective and patients undergo relapse months or years after the initial treatment. 
Endocrine resistance is a major clinical issue and the cause of most breast cancer-related 
death. 
 
1.1.6. Endocrine resistance  
Although many patients benefit from endocrine therapy, de novo (primary 
endocrine resistance) and/or acquired resistance occurs in approximately 40 % of all 
patients with ER+ breast cancer (Davies et al. 2011). De novo resistance is described as 
relapse in the first 2 years of adjuvant endocrine therapy or progression of disease (PD) 
in the first 6 months of first-line endocrine therapy for metastatic ER+ breast cancer. 
Acquired (secondary) resistance is described as relapse while on adjuvant endocrine 
therapy after the first 2 years, or PD after 6 months from starting endocrine therapy for 
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metastatic ER+ breast cancer (Cardoso et al. 2014). Several mechanisms of both types 
of endocrine resistance have been hypothesized: 
1) Loss of ER expression (15-20 % of resistant patients). Such tumours are no 
longer driven by estrogen, so it is obvious that the lack of ER expression will 
result in de novo resistance to antiestrogen therapy (Fan, Chang & Fu 2015; 
Osborne & Schiff 2011). 
2) ER mutations resulting in constitutive activity of ER or reduced Tamoxifen 
binding affinity. These mutations allow tumour growth and confer resistance 
to Tamoxifen. Although ER mutation rates appear to be rare in primary 
breast cancers (TCGA 2012), they are more frequent among metastatic and 
pre-treated ER+ breast cancers (Murphy & Dickler 2016; Toy et al. 2013). 
Also, ER mutations emerge after prolonged periods of AI therapy in over 20 
% of patients with early-stage disease years or decades after diagnosis 
(Davies et al. 2011). 
3) Upregulation of growth factor pathways such as EGFR, HER2, PI3K-AKT-
mTOR and RAF/MEK/ERK (Masoud & Pagès 2017; Murphy & Dickler 2016; 
Osborne & Schiff 2011).  
4) Cell cycle checkpoint alterations. For instance, amplification of Cyclin D1, 
which is involved in progression through the G1-S phase, is a common event 
in ER+ tumours, identified in 29 % of luminal A cancers and 58 % of luminal 
B cancers (Murphy & Dickler 2016). 
There is widespread on‑going investigation aimed at identifying new therapeutic 
strategies to circumvent the emergence of endocrine resistance and to minimize side 
effects. For instance, recent studies indicate that reprogramming, rather than blocking ER 
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activity, could be an alternative strategy for primary ER+ disease (Lim et al. 2016; 
Mohammed et al. 2015; Peters et al. 2009). This new strategy will be discussed further in 
later sections. 
 
1.2. Nuclear receptors and cancer  
1.2.1. Nuclear receptor structure and classifications 
Estrogens, progesterone, and androgens are sex steroid hormones that act 
biologically through binding to specific intracellular nuclear receptors (NR). NRs are a large 
superfamily of ligand-activated TFs that directly bind to a specific DNA sequence near 
target genes to modulate their transcriptional activity. Some NRs (e.g. ER, PR, and 
androgen receptor (AR)) have key roles as pro-proliferative TFs that can drive 
tumorigenesis (Stallcup et al. 2003). Almost all NRs are structurally similar, having distinct 
well-defined functional domains (Figure 6): 1) the amino-terminal domain (NTD) (A-B 
region), which is highly variable in both sequence and size, has an unknown 3D structure 
and is involved in transcriptional activation by binding to transcriptional co-regulators; 2) 
the DNA-binding domain (DBD) (C region), which is the most highly conserved domain 
among NRs; 3) C-terminal ligand binding domain (LBD) (E region), which is recognised by 
specific ligands that bind to its hydrophobic ligand binding pocket; 4) the hinge region (H) 
(D region), which links the DBD and LBD domains to provide stability and flexibility to the 
nuclear receptor; and 5) a highly variable C-terminal domain (CTD) (F region) that is poorly 
understood (Henderson, Ponder & Ross 2003). The CTD may be involved in transcriptional 
activity, ligand-receptor interactions, or interaction with co-regulators among various NRs 
(Pawlak, Lefebvre & Staels 2012). The DBD recognises hormone response elements (HREs) 
36 
 
on DNA and is also required for the formation of receptor dimers (Edwards 2000). The 
hinge region is not just a flexible bridge between the DBD and LBD, but it often contains 
DNA minor groove binding residues at the C-terminal end of the DBD that flank HREs and 
directly participate in DNA binding. Therefore, the hinge region is also termed as a carboxyl 
terminal extension (CTE) of the DBD. The hinge region also contains a nuclear localisation 
sequence (NLS) comprised predominantly of lysine residues, which plays key role in 
translocation of the receptors from the cytoplasm to the nucleus (Edwards 2000). The LBD 
contains a domain termed the activation function domain-2 (AF-2). In most NRs, the AF-2 
domain is essential for recruiting transcriptional co-activators (e.g. p160/SRC). AF-2 is also 
required for releasing co-repressor (e.g. NCOR, SMRT) interactions with co-regulators (e.g. 
p300/CBP and CARM1) and chromatin remodelling proteins (e.g. Histone Deacetylase 
(HDACs)) in a ligand-dependent manner, favouring transcriptional activation (Bain et al. 
2007; Melmed et al. 2015; Rastinejad 2001). The NTD region contains a potent 
transcriptional activation domain called activation function domain-1 (AF-1). In contrast to 
AF-2, the ligand-independent AF-1 sequence demonstrates weak sequence conservation 
within the NR superfamily (Takimoto et al. 2003). 
NRs can be divided into 3 distinct categories based on sensitivity to their ligands: 1) 
Ligand-regulated receptors have high affinity for their ligands and include receptors for 
steroid hormones, thyroid hormones, and the fat-soluble vitamins A and D. The ligands of 
steroid hormone receptors (e.g. glucocorticoid (GR), mineralocorticoid (MR), estrogen 
(ER), androgen (AR), and progesterone (PR) receptors) are exclusively synthetised from 
endogenous endocrine sources. These classic endocrine receptors bind to DNA as 
homodimers and their ligands are regulated by negative-feedback control of the 
hypothalamic-pituitary axis (Chawla et al. 2001; Melmed et al. 2015). These receptors are 
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subclassified into two classes based on dimerization capabilities, and the ability to 
recognise specific hormone response elements: a) Class I includes AR, PR, GR, and MR, 
which undergo homodimerization, and recognise structurally similar HREs due to the 
highly conserved sequence that comprises the DBD of each receptor (De Vos et al. 1993; 
Denayer et al. 2010; Henderson, Ponder & Ross 2003). Importantly, it has also been 
documented that AR has the ability to bind as a monomer to single half-site motifs in 
chromatin (Massie et al. 2007); b) Class II includes estrogen receptor-alpha (ERα) and 
estrogen receptor-beta (ERβ) isoforms; which bind to a distinct set of HREs and can homo 
or heterodimerise (Glass 1994; Pace et al. 1997); 2) Orphan receptors are so called since 
no endogenous ligand has been yet discovered for them, such as the Rev-Erb receptor, 
RORs (receptor tyrosine kinase-like orphan receptors), NGFI-B, NURR1, and NOR1 (Mazaira 
et al. 2018); and 3) Adopted receptors were once orphan receptors, but are now adopted 
by their newly established ligands. Adopted receptors that have low affinity to their ligands 
include PPAR, LXR, FXR, PXR, CAR, thyroid hormone (TR), retinoic acid (RAR), vitamin D 








Figure 6: Nuclear receptor structure  
The schematic structure of a typical nuclear receptor is shown here: The N-terminal region 
(A-B domain) of nuclear receptors can harbor a transcriptional activation function domain 
known as Activation Function domain-1 (AF-1). The DNA binding domain (DBD) (C domain) 
functions in recognition of HREs on DNA and formation of receptor homodimers. The 
ligand binding domain (LBD) (E domain) interacts with the specific ligands of a receptor. 
Also, the second activation function domain (AF-2) is located at the C-terminal region of 
the LBD, which acts in recruiting the transcriptional activators in a ligand-dependent 
manner, receptor dimerization, and interaction with co-regulators. The DBD and LBD are 
linked through a hinge region (D domain). The C-terminal domain known as the F domain 




1.2.2. Nuclear receptor mechanism of action 
Nuclear receptors are transcriptional regulators that function dynamically in the 
cell to either stimulate or repress gene transcription. The maturation of some nuclear 
receptors (AR, GR, and MR) occurs in the cytoplasm, where they are in a hetero complex 
with Heat Shock Proteins (HSP) (e.g. hsp70, hsp90) and other co-chaperones (e.g. p23) 
(Echeverria & Picard 2010). The first step of signal transduction is the direct binding of 
ligands to the LBD domain of their receptors. Ligand binding causes an allosteric change in 
the receptor structure, which causes dissociation of the NR from co-chaperones. This leads 
to stabilization and activation of the receptor, followed by dimerization and 
phosphorylation events leading to translocation from the cytoplasm to the nucleus (Figure 
7) (Echeverria & Picard 2010). In contrast, ER and PR can undergo translocation from the 
cytoplasm into the nucleus in an un-liganded state (Echeverria & Picard 2010). The 
canonical action of ER and PR involve binding to their ligands with a concomitant 
dissociation from heat shock and chaperone proteins, followed by receptor homo- or 
hetero-dimerization (e.g. ERα with ERβ; PRA with PRB) inside the nucleus (Figure 8) 
(Echeverria & Picard 2010). Once activated in the nucleus, the DBD domains of activated 
NRs recognise and bind to specific DNA response elements (such as androgen response 
elements (AREs), estrogen response elements (EREs), and progesterone receptor elements 
(PREs) for AR, ER, and PR, respectively) in the regulatory regions of target genes inside the 
nucleus (Echeverria & Picard 2010). The transcriptional output is mediated through the 
interplay between co-regulators and the transcriptional machinery, which form nuclear 
receptor co-regulatory binding complexes. Normal NR signalling controls the development 
and homeostasis of reproductive tissues, which can be co-opted in pathological conditions 
such as cancer (Lim et al. 2016; Perou et al. 2000). Therefore, mutations to, or aberrant 
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expression of, nuclear receptors and their co-regulatory factors can also participate in the 







Figure 7: Schematic illustration of androgen receptor signalling  
Testosterone is converted to its more potent metabolite 5-α-dihydrotestosterone (DHT) 
via the 5-α-reductase enzyme. Both testosterone and DHT can bind to and activate AR, but 
DHT has greater affinity and potency. In the absence of ligand, AR is predominantly 
localised in the cytoplasm in an inactive multi-protein complex with heat shock proteins 
such as Hsp-90 and Hsp-70 and co-chaperone proteins such as p23. The canonical action 
of the AR involves binding to its ligand with a concomitant dissociation from heat shock 
and chaperone proteins, and phosphorylation of the receptor. Activated receptors 
translocate to the nucleus and homo-dimerize, then bind to AREs located near the target 
genes. AR then forms a multi-protein complex along with co-regulatory interactors and 
pioneer factors (e.g. FOXA1, that is known to facilitate AR binding at AREs) and recruits the 






Figure 8: Schematic illustration of estrogen receptor signalling 
In the absence of estrogen (E2), ER is predominantly localised in the nucleus in an inactive 
multi-protein complex with heat shock proteins such as Hsp-90 and Hsp-70 and co-
chaperone proteins such as p23. The canonical action of the ER involves binding to its 
ligand with a concomitant dissociation from heat shock and chaperone proteins, receptor 
homo-dimerization and binding to EREs located within the promoter/enhancer regions of 
target genes. ER then forms a multi-protein complex along with co-regulatory interactors 





1.2.3. Technology advancements in nuclear receptor function studies 
Understanding of nuclear receptor control of gene regulation has remarkably 
advanced during the two last decades. Contemporary technologies such as chromatin-
immunoprecipitation (ChIP) combined with tiled DNA oligonucleotide microarray analysis 
-on-ChIP and ChIP-sequencing (ChIP-seq) (Figure 9) has allowed genome-wide mapping of 
NR DNA binding (cistrome) and function (Carroll et al. 2005; Carroll et al. 2006; Lupien & 
Brown 2009; Massie et al. 2007; Wang, Q et al. 2007). For instance, it was historically 
thought that ER binds to EREs located exclusively in the promoter region of target genes; 
however, with the advent of ChIP-seq technology, which reveals genome-wide cis-
regulatory binding events of any DNA-binding factor, we now know that ER is preferentially 
recruited to enhancer regions of target genes upon estrogen stimulation (Carroll et al. 
2005). These enhancer elements modulate target gene expression by forming chromatin 
loops with promoter containing chromatin regions (Sanyal et al. 2012). Similarly, it has 
been shown that while AR binds to AREs located in close proximity (10-15 bp) of the 
transcriptional start site (TSS) of its target genes, AREs are more often located in distal 
upstream genomic regions (100-200 kb) (Lupien & Brown 2009; Massie et al. 2007; Wang, 
Q et al. 2007). Furthermore, sequencing technologies have led to discovery of multiple 
binding motifs for other TF co-regulators in the vicinity of NR binding sites, such as 
Forkhead box protein A1 (FOXA1), GATA2, and Oct-1 that bind in a non-promoter specific 
manner in order to make regulatory loops with NRs (Carroll et al. 2005; Wang, Q et al. 
2007). FOXA1 is a member of the Forkhead class of DNA-binding proteins that have been 
well studied in breast and prostate cancers, playing a central role in ER and AR signalling, 
respectively as a common ER and AR co-regulator (Lupien et al. 2008; Robinson, JL et al. 
2014). It has been shown that nearly 60 % of the ER cistrome in MCF-7 (breast) and 70 % 
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of the AR cistrome in LN-CaP (prostate) cancer cell lines overlap with FOXA1 binding 
events. FOXA1 binds to compacted chromatin and opens it to facilitate chromatin 
accessibility to ER and AR (Lupien et al. 2008; Robinson, JL & Carroll 2012; Robinson, JL et 
al. 2014). Studies to date indicate that ER binding to DNA is more reliant on FOXA1 than 
AR binding to DNA (Bernardo et al. 2010; Carroll et al. 2005; Laganière et al. 2005; 
Robinson, JL & Carroll 2012; Wang, Q et al. 2007; Wang, Q et al. 2009).  
RNA-sequencing (RNA-seq) is another recently-developed technique which uses 
next generation of sequencing (NGS) to profile the whole set of cellular RNA transcripts, 
termed as the transcriptome (Wang, Z, Gerstein & Snyder 2009). A huge number of studies 
currently use the RNA-seq approach in determining the differentially expressed genes 
upon various experimental conditions, and measuring the levels of transcripts and their 
isoforms (Wang, Z, Gerstein & Snyder 2009). Collectively, ChIP-seq and RNA-seq 
approaches provide valuable, comprehensive information with regards to NR cistromes 
and transcriptomes (Figure 10). 
Nuclear receptors can also interact with DNA in an indirect manner through 
tethering to other partner proteins (Sanchez et al. 2002). Rapid immunoprecipitation mass 
spectrometry of endogenous protein (RIME) is a novel method that has been introduced 
recently to enable the study of protein-protein interactions (PPIs), especially for TF 
complexes on chromatin (Mohammed et al. 2016). RIME can be used in parallel with ChIP-
seq experiments to provide information on both the cistrome and interactome (a complete 
set of molecular interactions in a particular cell, specifically protein-protein interactions 




My host lab, the Dame Roma Mitchel Cancer Research Laboratory (DRMCRL), has 
expertise in ChIP-seq, RNA-seq and RIME technologies, providing the opportunity to test 
my hypothesis with regards to investigation of the complexity of hormonal cross-talk 






Figure 9: Chromatin-immunoprecipitation (ChIP)- sequencing (Created with 
BioRender.com) 
Different steps of ChIP-seq are described briefly in this figure as follows: 1) Cells are 
expanded and treated as per experimental protocol, cross-linked with formaldehyde and 
quenched with glycine. Cells are harvested, lysed, nuclear fractioned in specific buffers and 
pelleted; 2) chromatin is fragmented using a sonication machine and magnetic beads are 
prebound with the antibody against the protein of interest, then the sonicated DNA is 
incubated with magnetic beads prebound with antibody and immunoprecipitation (IP) is 
conducted overnight; 3) cross-linked chromatin is reverse cross-linked to release the DNA, 
which is purified and; 4) sequenced using next generation sequencing (NGS) technologies, 
5) Raw fastq files are generated and bioinformatically possessed to create BAM, BED, and 






Figure 10: RNA-sequencing (RNA-seq) (Created with BioRender.com) 
RNA-seq steps are described briefly in this figure as follows: 1) Cells are grown and treated 
according to experimental design, and harvested; 2) total RNA is extracted; and 3) mRNAs 
(or sometimes total RNA) are purified; and 4) fragmentated; 5) a cDNA library is generated 
from isolated RNA through reverse transcription; 6) Adapter sequences are ligated to the 
3’ and 5’ end of the double-stranded cDNA and the final cDNA library is amplified by 
polymerase chain reaction (PCR) using parts of the adapter sequences as primers; 7) then 
sequenced; 8) reads are mapped against a reference genome; 9) Raw data is processed 
and analysed using various computational tools depending on the goal of the experiment 





Figure 11: Rapid immunoprecipitation mass spectrometry of endogenous protein (RIME) 
(Created with BioRender.com) 
Different steps of the RIME technique are described briefly in this figure as follows: 1) Cells 
are grown in their normal (or experimental) condition, then cross-linked with 
formaldehyde and quenched by glycine; 2) Cells are washed and harvested in PBS. The 
nuclear fraction and pellet preparation are done in specific buffers; 3) chromatin is 
fragmented using a sonication machine; 4) Magnetic beads are prebound with the 
antibody against the protein of interest; 5) Sonicated chromatin is then incubated with 
magnetic beads prebound with antibody; 6) immunoprecipitation (IP) is conducted; 7) The 
beads are washed and bead-bound proteins are digested; 8) Digested peptide mixtures are 
diluted and analysed by Nano-LC-MS/MS; 9) Raw MS data files are processed to achieve 
the detailed results including peptide sequences, peptide scores, ion scores, expect values, 
and Mascot scores. 
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1.2.4. Estrogen receptor function in normal and malignant breast tissue  
Unlike other human organs, mammary gland development mainly occurs with the 
approach of puberty (Russo & Russo 2004). Hormones impinge on a subset of luminal 
mammary epithelial cells (MECs) that express hormone receptors and act as sensor cells 
translating and amplifying systemic signals into local stimuli. The ovarian hormones, 17β-
oestradiol (E2) (the most potent estrogen) and progesterone (P4) (a potent ligand of PR) 
play a pivotal role in mammary gland development, differentiation and proliferation of 
MECs (Brisken & O'Malley 2010). E2 exerts its biological functions through specific ligand-
inducible ERα (Figure 12.a) and ERβ (Figure 12.b) receptors. These receptors are encoded 
by separate genes located on different chromosomes, yet share considerable sequence 
homology (Nilsson et al. 2001). The gene for ERα (ESR1) was cloned in 1986 by two groups 
(Green et al. 1986; Greene et al. 1986) and the gene for ERβ (ESR2) was cloned in 1996 
(Kuiper et al. 1996). The ERα gene has 8 exons and is localised to chromosome 6q24-27. 
The ERα protein is composed of 595 amino acids with a molecular weight of 65 kilo dalton 
(KDa) (Edwards 2000). The ERβ gene is located on chromosome 14q23.2, spanning ~61.2 
kb. The ERβ protein is produced from eight exons. The full-length human ERβ protein 
includes 530 amino acids with an estimated molecular weight of 59.2 kDa (Ogawa et al. 
1998). 
The growth stimulatory effect of ERα on normal breast epithelial cells and breast 
cancer cells has been well studied. For instance, an in vitro study showed that a selective 
ERα agonist increased the proliferation of the HC11 normal mouse breast cell line 
(Helguero et al. 2005). Moreover, knockout (KO) mouse studies have clearly demonstrated 
that ERα is indispensable for the postnatal structural and functional development of the 
mammary gland, while ERβ is not (Feng et al. 2007). Mammary glands in female ERαKO 
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mice did not develop with the onset of puberty, and TEB formation, ductal elongation and 
side-branching were prevented (Curtis Hewitt, Couse & Korach 2000; Feng et al. 2007). In 
addition to ERα, as a critical TF in regulating epithelial cell proliferation and ductal 
morphogenesis during postnatal mammary gland development, knockout mouse studies 
have also revealed several ERα co-regulators that are known to play crucial role in 
mammary gland development (Lonard, David M & O'Malley 2007) such as SRC-3/AIB1 
(Onate et al. 1995), cAMP responsive element binding protein (CREB) (CBP/p300) and ATP-
dependent chromatin remodelling complexes like SWI/SNF (Lonard, D. M. & O'Malley 
2006). More than 200 co-regulators, each with a specific expression level, have been 
identified for ERα and are considered critical mediators of cell-specific regulation of ERα 
target gene expression (Smith & O'Malley 2004). Notably, the expression level of each co-
regulator may influence its ability to modulate the transcriptional potential of ERα in 
response to E2 (Brisken & O'Malley 2010). The critical contribution of ERα to breast cancer 
progression has also been studied well in the literature. E2 treatment of ERα+ breast 
cancer cell lines (MCF-7 and T-47D) increased proliferation, which was then reversed 
following treatment with the anti-estrogen Tamoxifen (Aspinall et al. 2004). Clinical studies 
have identified that ERα expression in women diagnosed with breast cancers is higher than 
its expression in normal epithelium of women with no disease (Khan et al. 1998). Another 
study has also reported an increase in the level of ERα expression at the early stages of 
breast cancer progression, with a further increase in pre-malignant lesions (Shoker et al. 






Figure 12: Schematic illustration of estrogen receptor isoforms  
The estrogen receptor has two isoforms, ERα (a) and ERβ (b). The DBDs of the ER isoforms 
have very high homology (96 %), while their LBDs are only about 59 % homologous. The 
main differences between ER isoforms are in the NTDs, which share only 30 % of sequence 
identity. The isoform ERα has an extended NTD, which allows for more transcriptional 
activation, whereas, ERβ has a shorter NTD and so a shorter AF-1, which makes the ERβ 
less transcriptionally active compared with ERα. However, some studies have shown that 
the AF-1 differences alone are not sufficient to explain these behaviors (reviewed at (Souza 




1.2.5. Androgen receptor function in normal and malignant breast  
In general, current understanding of androgenic activity and AR signalling has been 
developed through investigating the role of androgens and AR in male reproductive 
physiology and prostate cancer. Androgens have a crucial role in male reproductive 
biology, being essential for the development and maintenance of the male urogenital 
organs such as prostate, seminal vesicles and epididymis (Murashima et al. 2015). Despite 
the fact that androgens are usually considered male hormones, they are also present in 
the circulation of women at physiologically relevant levels (Burger 2002; McNamara, K et 
al. 2010), playing critical biological roles in normal breast physiology and breast 
carcinogenesis (Dimitrakakis & Bondy 2009; Yeh et al. 2003).  
 
1.2.5.1. Androgen receptor gene and protein structure 
The intracellular mediator of the genomic effects of androgens is the AR, located 
on chromosome Xq11-12 (Brown et al. 1989). The human AR gene was first cloned in the 
late 1980s (Tilley et al. 1989). The AR coding sequence is comprised of 8 exons, which 
encode approximately 917 amino acids, depending on the length of polymorphic CAG and 
GGN (N for any nucleotide) microsatellite regions within exon 1. The molecular weight of 
AR is approximately 98.8 KDa (varies depending on size of the microsatellites). Post 
translational modifications (e.g. phosphorylation) may increase the molecular weight of 
AR up to 110 KDa when analysed by SDS polyacrylamide gel electrophoresis. The full-length 
AR is comprised of the same functional domains as ER (Tilley et al. 1989) (Figure 13). Two 
key functional sub-domains of the AR are located in the NTD domain including the 
polyglutamine (poly-Q) and polyglycine (poly-G) tracts (Henderson, Ponder & Ross 2003). 
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Interestingly, it has been shown that the longer poly-Q repeat region is associated with 
reduced AR transactivation capacity and increased risk of developing breast cancer in 
women over 40 years old of age, in comparison with a shorter poly-Q repeat (Elhaji et al. 







Figure 13: Schematic illustration of the androgen receptor gene and protein structures  
The full-length androgen receptor gene and protein structures are shown in this figure. 
The AR coding sequence is comprised of 8 exons, which encodes up to 920 amino acids 
depending on the length of polymorphic CAG and GGN (N for any nucleotide) regions, with 
an approximate molecular weight of 98.8 KDa. The full-length AR is comprised of the same 




1.2.5.2. Androgens and androgen receptor signalling in normal breast tissue 
In contrast with the established growth stimulatory effects of estrogens in normal 
and malignant breast epithelial cells, direct androgen action in the normal growth and 
development of the mammary gland is still controversial and poorly defined. Androgens 
have been shown to play a protective role in female breast tissue through repression of 
the basal and estrogen-stimulatory effects on breast epithelial growth and proliferation 
(Castellano et al. 2010; Dimitrakakis & Bondy 2009; Gonzalez-Angulo et al. 2009; Peters et 
al. 2009). For instance, a 40 % reduction in E2-stimulated growth of mammary epithelial 
cells of ovariectomised rhesus monkeys has been observed following treatment with 
Testosterone (the major circulating androgen hormone) (Zhou et al. 2000). In a study by 
Peters et al 2009, DHT (the most potent natural AR agonist) treatment of female C57/BL6 
mice from mid-puberty (5-12 weeks of age) reduced ductal extension of the mammary 
glands by 40 % compared with the placebo-treated mice (Peters et al. 2011). However, 
DHT treatment post-puberty (12-21 weeks of age) had no effect on ductal growth of the 
mammary gland (Peters et al. 2011). Anti-androgens reversed the anti-growth effects of 
androgens on normal breast epithelial cells (Peters et al. 2011). An increase in cellular 
proliferation and branching in response to Flutamide (an AR antagonist) treatment 
throughout the mammary gland of post-pubertal mice has been observed in the same 
study by Peters et al (Peters et al. 2011). Likewise, treatment of intact cycling monkeys 
with Flutamide also resulted in a significant increase in mammary epithelial cell 
proliferation (Dimitrakakis et al. 2003). The importance of direct androgen signalling in the 
growth and development of the normal mammary gland has been further illustrated by 
several AR-knockout (ARKO) female mouse studies (Shiina et al. 2006; Yeh et al. 2003). In 
particular, it has been shown that AR is essential for normal fertility in the female 
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population since ARKO mice showed dysfunctional ovulation and impaired follicular 
growth (Walters, Simanainen & Handelsman 2010). In a study by Yeh et al., a Cre-lox 
systemic knockout strategy was used to generate female ARKO mice, genotyped as AR −/− 
ACTB Cre+, in which estrogen target organs, including the mammary gland, ovary, oviduct, 
and uterus of adult mice with homologous deletion of AR weighed 15-23 % less as 
compared with their age-matched control mice (4-, 6-, and 12-week old mice) (Yeh et al. 
2003). The phenotype of these pre-pubertal female ARKO mice at the age of 4 and 6 weeks 
demonstrated a 30-50 % reduction in ductal extension, reduced numbers and size of TEBs, 
and a 50 % reduction in epithelial cell proliferation compared to the AR+/+ wild-type mice 
(Yeh et al. 2003). Also, reduced secondary and tertiary branching was observed in the 
mature mammary glands of 8-20-week old ARKO mice, indicating the important role of AR 
in mammary gland development (Yeh et al. 2003). The phenotype observed in the model 
used in the above study is almost exactly the same as the PR null mouse (Lydon et al. 1995), 
suggesting that the ovarian defects of ARKO mice could be the explanation for the 
observed mammary gland phenotype. Another potential explanation for the phenotype 
observed in the above study is a reduction in MAPK and ER signalling in the mammary 
glands. In an independent study, Shiina et al., (2006) observed that 8-week-old female 
homozygous ARKO (CMV-Cre) mice in comparison with wild-type (Wt) female mice 
exhibited a substantial reduction in mammary ductal branching and elongation (Shiina et 
al. 2006). During pregnancy, the retarded ductal branch numbers were partially restored 
but still contained less milk-producing alveoli than Wt glands. These observations indicated 
that mammary ductal morphogenesis was impaired during pubertal development, 
pregnancy, and lactation in ARKO (CMV-Cre) mice, whereas AR functions as a stimulator of 
mammary ductal differentiation (Shiina et al. 2006). Therefore, in female mice, AR is 
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thought to be required for normal development of the mammary glands by modulating 
ductal branching and epithelial cell proliferation. 
Although breast cancer research has mainly focused on ER, the molecular profiles 
of subsets of ER and PR negative primary breast carcinomas has been shown to be still 
hormonally regulated (Doane et al. 2006). This suggests the involvement of other steroids 
and/or their receptors such as the most abundantly expressed NR in breast cancer, AR. 
 
1.2.5.3. Androgen receptor expression in breast cancer 
ER+ breast cancers, which are currently defined by the detection of ER in at least 1 
% of cells within the tumour biopsy (Hammond et al. 2010), are more likely to have AR 
expression compared with other sub-types of breast cancer (Hu, R et al. 2011; Loibl et al. 
2011; Park et al. 2011), with luminal A cancers expressing AR more frequently than luminal 
B (Yu et al. 2011). The co-expression of ER and AR in the majority (80-90 %) of breast 
tumour cells suggests that the effects of estrogen and androgen on growth and survival of 
breast cancer cells are critically integrated (Peters et al. 2009; Santagata et al. 2014). AR 
has been detected in up to 85 % of primary breast cancers and up to 75 % of metastatic 
lesions (McNamara, KM et al. 2014; Moinfar et al. 2003; Park et al. 2010) and is typically 
present in a greater proportion of breast tumours (>90 %) (Agoff et al. 2003; Park et al. 
2010) than ER (>75 %) (Allred, Brown & Medina 2004). Importantly, AR has been 
introduced as an independent predictor of breast cancer survival (Ricciardelli et al. 2018) 
with a favourable prognostic indication (reviewed at (Hickey, T et al. 2012; Ricciardelli et 
al. 2018)) that is significantly associated with reduced risk of relapse, longer survival (Yu et 
al. 2011) and better outcomes among patients with ER+ tumours (Park et al. 2011). 
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In general, ER- breast cancers are more aggressive with poorer survival prognoses 
compared with ER+ breast cancers (sub-chapter 1.1.4) (Barcellos-Hoff 2013). ER- breast 
cancers can be generally divided into HER2+ and TNBC subgroups. Molecular apocrine 
(MA) is a subgroup of HER2+/ER- breast cancers that is derived from luminal tumours that 
undergo apocrine metaplasia, a common process in normal breast tissue in which cells lose 
their ER expression through an unknown biological mechanism, leading to their ancestral 
androgen-driven, apocrine fate (Iggo, Richard 2018). Almost 12 % of all breast cancer 
subtypes are considered as MA tumours, characterised by high AR and a gene expression 
profile akin to that of ER+ luminal subtypes despite lack of ER (Doane et al. 2006; Farmer 
et al. 2005; Iggo, RD 2011). In order to further understand the molecular basis of TNBC, 
Lehmann et al., assessed 21 publicly available data sets of primary human breast cancers 
and classified TNBC into 3 main groups: 1) Basal-like (including BL-1 and BL-2), 2) 
Mesenchymal-like (including mesenchymal (M) and mesenchymal stem–like (MSL), and 3) 
Luminal androgen receptor (LAR) (Lehmann et al. 2011). Interestingly, the LAR subgroup is 
heavily enriched in hormonally regulated pathways including steroid synthesis and 
androgen/estrogen metabolism, thought to be due to relatively higher expression of AR 
(at both mRNA and protein levels) in this TNBC subgroup compared to the others, and 
expression of downstream AR targets and coactivators (e.g. DHCR24, ALCAM, FASN, FKBP5, 
APOD, PIP, SPDEF, and CLDN8) (Lehmann et al. 2011). The MDA-MB-453 breast cancer cell 
line has been widely used as a model of the MA BC subtype due to high levels of AR and 
HER2 expression, however, some studies classified MDA-MB-453 as LAR because it does 
not have amplification of the HER2 gene (Espinosa Fernandez et al. 2020; Tseng et al. 
2017). The expression of AR in MA tumours is associated with histological evidence of 
apocrine differentiation (Niemeier et al. 2010). The correlation between AR and patient 
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outcome is still unclear in ER- breast cancers. Some studies have shown that AR is 
correlated with improved disease-free survival (DFS) and overall survival (OS) (Luo et al. 
2010; Qu et al. 2013; Vera-Badillo et al. 2014) in ER- breast cancer patients. However, 
others claimed that there is no clear association between AR expression and outcomes of 
ER- breast cancer (Hu, R et al. 2011; Park et al. 2011; Peters et al. 2009; Vera-Badillo et al. 
2014). High heterogeneity within the ER- breast subtype could be an explanation for these 




1.2.5.4. Androgen receptor signalling in ER+ breast cancer 
Androgens have been shown to inhibit both basal and estrogen-stimulated 
proliferation of ER+/AR+ breast cancer cell lines such as MCF-7 (Hickey, T et al. 2012; 
Macedo et al. 2006; Ortmann et al. 2002), ZR-75-1 (Birrell et al. 1995; Poulin, R, Baker & 
Labrie 1988) and T-47D (Birrell et al. 1995; Cops et al. 2008; Greeve et al. 2004; Ortmann 
et al. 2002). This growth inhibition can be reversed by anti-androgens or silencing AR, 
indicating a protective role for androgens against the development and progression of ER+ 
disease (Birrell et al. 1995; Cops et al. 2008; Dimitrakakis & Bondy 2009; Macedo et al. 
2006). As expected, the inhibitory effect of DHT is not observed in cell lines that do not 
express AR, including the MDA-MB-231 and BT-20 TNBC cell lines, which indicates the 
essential requirement of AR expression to mediate the growth inhibitory effects of 
androgens on breast cancer cells (Birrell et al. 1995). Also, it has been demonstrated that 
AR can inhibit the transactivation activity of ER in human breast cancer cells through 
competitive binding of the AR to EREs associated with estrogen-regulated genes (Peters et 
al. 2009). Historically, non-aromatizable AR agonists such as Fluoxymesterone have been 
used as a hormonal therapy for advanced breast cancer with an efficacy comparable with 
Tamoxifen (Tormey et al. 1983). Combinational therapy of Fluoxymesterone and 
Tamoxifen was more effective than Tamoxifen alone in cases of advanced breast cancer 
(Ingle et al. 1991). Despite having clinical benefits, therapeutic use of androgenic agents to 
treat breast cancer fell from favour due to their side effects, which included increased 
aggressive behaviour, hirsutism and masculinization (McNamara, KM et al. 2014). 
Enobosarm, which is a novel well-tolerated, non-steroidal, selective AR modulator (SARM) 
with an agonistic effect on AR in ER+ cells, has shown promise in a phase II trial of women 
with advanced, hormone-sensitive breast cancer (Overmoyer et al. 2014; Yuan et al. 2020). 
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Taken together, these studies highlight the growth inhibitory effects of androgens through 
the AR signalling axis in malignant ER+ breast tissues, resulting in protection against cancer 
progression due to the reduction of cell proliferation and tumour growth. 
 
1.2.5.5. Androgen receptor signalling in ER- breast cancer 
Contrary to growth-inhibitory effects in the ER+ context, androgens have been 
shown to promote the proliferation of some ER- breast cancer cell lines, including the 
MDA-MB-453 model of MA breast cancer (Birrell et al. 1995; Doane et al. 2006; Ni et al. 
2011). AR antagonism or AR knock down inhibits growth of this cell line, suggesting AR as 
having oncogenic activity (Birrell et al. 1995; Lehmann et al. 2011; Robinson, J et al. 2011). 
Interestingly, the global AR DNA binding events in MDA-MB-453 cells have been shown to 
be more similar to the ER cistrome in MCF-7 cells, compared to the AR cistrome in LN-CaP 
prostate cancer cells, where AR stimulates cell growth (Robinson, J et al. 2011). This 
suggests that when ER is absent, AR binds to and regulates ER cis‐regulatory elements, 
resulting in a transcriptional programme reminiscent of ER‐mediated transcription in 
luminal breast cancers (Robinson, J et al. 2011). This may potentially explain the oncogenic 
role of AR in the MA breast cancer subtype. Other proposed mechanisms for the growth-
stimulatory effects of androgens in MA BC include 1) androgen-induction of WNT7B and 
HER3 expression levels leads to activation of Wnt/β-catenin and HER2 signalling pathways, 
which are required for androgen-induced proliferation of these cells (Ni et al. 2011); 2) 
androgen-induced activation of PI3K/AKT pathway through activation of HER2/HER3 
signalling, leads to enhanced phosphorylation of MAD1 and subsequently increases the 
oncogenic function of MYC (Ni et al. 2013); 3) androgen-induction of ERK phosphorylation 
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through activation of HER2 signalling, increases cell proliferation (Naderi & Hughes-Davies 
2008). The AR-ERK feedback loop in MA tumours has been investigated as a potential 
therapeutic option using the AR inhibitor Flutamide and the MEK inhibitor CI-1040 in vitro 
and in vivo (Naderi, Chia & Liu 2011). The combination therapy showed a synergic 
inhibitory effect on the viability of MDA-MB-453, HCC-1954 and HCC-202 MA cells using 
the MTT metabolic assay (a proxy for proliferation), and tumour growth of MDA-MB-453 
xenografts in vivo (Naderi, Chia & Liu 2011). The MFM-223 cells line is classified as a model 
of the LAR subtype (due to being negative for HER2 expression), and unlike MDA-MB-453 
cells, their growth is suppressed by androgens (Hackenberg et al. 1991; Lehmann et al. 
2011). Importantly, the divergent proliferative effects of androgens in AR+/ER- breast 
cancer models highlight the fact that inhibiting AR will likely not benefit all ER- patients 
and that careful investigation into the mechanisms of context-specific AR signalling in 
needed. This is supported by the underwhelming clinical benefit rates (19 %) reported for 
the AR antagonist Bicalutamide in TNBC (Gucalp et al. 2013).  
 
1.2.6. Nuclear receptor cross-talk in cancer 
While it is becoming very apparent that steroid receptors play a crucial role in 
breast cancer alone, what has not been clearly investigated in depth is how they act 
together. Nuclear receptor cross-talk studies reveal the fact that co-activation of steroid 
receptors can affect each other’s function and change the cellular response. Steroid 
hormones regulate a wide range of physiological processes by activating multiple receptors 
simultaneously inside a cell, where their combined action modulates the development and 
differentiation of the mammary gland. Consistent with this pivotal role, there is evidence 
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of nuclear receptors cross-talk is also linked to breast cancer (De Bosscher et al. 2020; 
Swinstead, Paakinaho & Hager 2018). Genome-wide studies have provided important 
information on nuclear receptor genomic cross-talk. NR cell-based assays are often 
configured to monitor ligand-modulated reporter gene expression. As TFs, NRs directly 
control gene expression by binding to HREs. The steroid NRs can interact with HREs in 
mouse mammary tumor virus (MMTV) promoter sequences that has been used in cross-
talk studies. MMTV is a retrovirus that is transmitted either endogenously through the 
germ line or exogenously as infectious viral particles in the mother’s milk. Although the 
virus is latently transforming, MMTV does not encode an oncogene (reviewed in (Grimm 
& Nordeen 1998)). MMTV is almost exclusively expressed in the mammary gland (reviewed 
in (Grimm & Nordeen 1998)). The activity of the MMTV promoter is greatly enhanced by 
steroid hormones, most notably glucocorticoids and progestins (reviewed in (Grimm & 
Nordeen 1998)). The ER agonist E2, but not ER antagonists, significantly supress GR-
mediated transcription in MCF-7 cells co-transfected with a MMTV-Luc (mouse mammary 
tumor virus promoter luciferase) reporter and GR reporter constructs using luciferase 
reporter assays (Kinyamu & Archer 2003). Since GR-mediated chromatin remodelling has 
been shown to be facilitated by the BRG1 chromatin-remodelling complex, the effect of 
estrogens on GR-dependent recruitment of BRG1 to the MMTV promoter was also 
investigated using ChIP-PCR. Interestingly, BRG1 association with the MMTV promoter was 
inhibited by E2 in the MCF-7-MMTV-GR cells (Kinyamu & Archer 2003). More recently, 
simultaneous co-activation of ER and GR was shown to reprogram the binding landscape 
of each other at specific recognition sites in an engineered murine breast cancer cell line 
(Miranda et al. 2013). GR reprograms chromatin accessibility for ER, through recruiting 
chromatin remodellers (SWI/SNF complexes) and assisting ER to bind to chromatin upon 
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co-treatment with E2 and a GR agonist (Dexamethasone; (DEX)) compared with E2 
treatment only (Miranda et al. 2013). At the same time, ER activation causes changes in 
the chromatin structure at glucocorticoid receptor elements (GREs) allowing for GR 
recruitment at those sites upon DEX and E2 co-treatment compared with DEX-treatment 
only (Miranda et al. 2013). This highlights that induction of each steroid receptor, during 
mammary gland differentiation or initiation and development of breast cancer, can be 
critical for shaping the binding profiles of the other and subsequent cellular responses to 
hormone stimulation (Miranda et al. 2013).  
The PR has also been shown to modulate ER genomic activity in BC. In support of 
earlier findings (Ballaré et al. 2003), the novel RIME technique revealed that activation of 
PR under estrogenic conditions increased the physical protein interaction of PR with ER 
and other known ER cofactors such as NRIPI, GATA3, and TLE3 in T-47D and MCF-7 ER+ BC 
cells (Mohammed et al. 2015). Consequently, activated PR re-directed ER chromatin 
binding in T-47D and MCF-7 cells, resulting in a unique transcriptome correlated with a 
good clinical outcome of the disease (Mohammed et al. 2015). Progesterone significantly 
inhibited E2-induced growth of ER+ MCF-7 and T-47D cell line xenografts in NSG mice and 
ex vivo primary ER+ breast tumour explants (Mohammed et al. 2015). A combination of 
progesterone treatment with the ER antagonist Tamoxifen in estrogenic conditions 
showed an increased anti-growth effect compared with progesterone or Tamoxifen alone 
in both MCF-7 and T-47D xenografts (Mohammed et al. 2015). Therefore, the functional 
significance of ER and PR cross-talk is regulation of a gene expression program associated 
with low tumorigenicity; hence, better disease outcome. 
Finally, ER and AR cross-talk has been indicated in multiple ER+ breast cancer 
studies. AR activation with its agonists (e.g. DHT, Testosterone) inhibits the growth 
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stimulatory effect of estrogens on ER+ breast cancer cells including ZR-75-1, T-47D, and 
MCF-7 (Ando et al. 2002; Lapointe et al. 1999; Need et al. 2012; Panet-Raymond et al. 
2000; Peters et al. 2009; Poulin, R. et al. 1989). A direct interaction between the LBD of 
ERα (not ERβ) and the NTD domain of AR has been shown in yeast and mammalian two-
hybrid systems but not using more contemporary techniques and physiologically relevant 
models (Panet-Raymond et al. 2000). Also, co-transfected AR and ERα expression vectors 
in CV-1 cells (well-used models for transfection studies) revealed the impact of AR and ERα 
in modulating the transactivation activity of the other (Panet-Raymond et al. 2000). The 
ERα effect on AR activity was shown to be E2-dependent, where E2 had no effect on the 
AR system unless ERα was co-transfected (Panet-Raymond et al. 2000). Similarly, E2-
induced ERα activity was dramatically suppressed by AR co-expression in the presence of 
androgen using the double reporter construct in the same cells (Panet-Raymond et al. 
2000). These findings suggest another explanation for the physiological interplay among 
androgens and estrogens where direct interaction of receptors may allow for an additional 
level of NR cross-talk that increases the complexity of steroid signalling pathways (Panet-
Raymond et al. 2000). Although the direct interaction between ER and AR has been shown 
in two-hybrid systems, Peters et al., could not detect a strong interaction between 
endogenous AR and ER proteins in T-47D breast cancer cells (Peters et al. 2009). They 
suggest another contributing mechanism of ER and AR cross-talk in these cells, where AR 
inhibits the E2-stimulated growth (Peters et al. 2009). In the ER+ breast cancer context, AR 
competes with ER for binding to regulatory regions of ER target genes (Need et al. 2012; 
Peters et al. 2009), which highlights the importance of the ratio of AR:ER expression in the 
regulation of breast cancer cell proliferation and predicting clinical outcome (Ando et al. 
2002; Cochrane et al. 2014; Peters et al. 2009; Qu et al. 2013; Vera-Badillo et al. 2014). 
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Interestingly, it has been shown that the AR:ER expression ratio influences the activity of 
steroid receptor co-activator ARA70 (NCOA4) in ER+ breast cancer cells (Lanzino, M et al. 
2005). Although ARA70 increased E2-dependent gene expression in MCF-7 cells in a low 
AR:ER ratio condition, induction of a high AR:ER ratio caused ARA70 to interact with AR to 
antagonise ER signalling (Lanzino, M et al. 2005). Also, androgen-induced reduction in 
expression levels of ER and MYC have been reported as a potential mechanism of action 
of androgens in prohibiting breast cancer cell growth (Dimitrakakis et al. 2003). Ligand-
dependent AR-mediated inhibition of Cyclin-D1 (CCND1) at the mRNA and protein levels 
reduced the proliferation of MCF-7 breast cancer cells, depicting another mechanism of 
growth-inhibitory effects of AR by modulating cell cycle pathways (Lanzino, M. et al. 2010). 
Apart from ARA70, cofactors common to AR and ER and their roles in AR/ER cross-talk have 
not been widely investigated. One aim of this thesis was to reveal novel co-factors that 
may influence AR/ER transcriptional activity. 
 
1.2.7. NR co-regulators and cancer  
It has been shown that NR co-regulators are not exclusively “bridging” molecules 
that simply link NRs and the RNA pol II transcriptional machinery, but have vast enzymatic 
processes, which modulate transcription, including chromatin modification and 
remodelling, initiation, elongation and termination of RNA pol II-mediated transcription, 
mRNA splicing and translation, and post translational modifications (PTMs) of NRs, other 
co-regulators and/or histones (Lonard, David M & O'Malley 2007). Co-regulators act as 
partner molecules that help in forming large protein complexes to modulating NR target 
gene activity (Manavathi, Samanthapudi & Gajulapalli 2014). Co-regulators can be other 
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TFs that bind DNA and may positively or negatively influence the transcriptional activity of 
NRs. Co-regulators that increase the transcriptional activity of NRs through their intrinsic 
histone acetyltransferase (HAT) activity or by recruiting HATs to the chromatin are referred 
to co-activators, while those that reduce transcription through recruiting the HDACs and 
compacting the chromatin structure are called co-repressors (Lonard, David M & O'Malley 
2007). By modulating gene expression regulated by hormones, growth factors and 
cytokines, co-regulators can promote pathological processes associated with cancer, 
including cell proliferation, differentiation, carcinogenesis and metastasis (Lonard, David 
M & O'Malley 2007). Pioneer factors are an example of co-regulators that can associate 
with compacted chromatin to facilitate the binding of additional TFs. NRs can also tether 
to these factors (Jozwik & Carroll 2012). For instance, FOXA1 and GATA2/3 are examples 
of pioneer factors that open the chromatin to modulate NR DNA binding (Jozwik & Carroll 
2012). Although FOXA proteins usually open the compacted chromatin structure, FOXA1 
can also recruit additional factors, such as TLE proteins, to promote chromatin 
inaccessibility (Sekiya & Zaret 2007). This unique property of FOXA1 results from their 
structural similarity to linker histone proteins (Clark et al. 1993). FOXA1 is an ER co-
regulator that its presence is essential for almost all ER-binding events in the genome in 
ER+ breast cancer context (Carroll et al. 2005). Also, FOXA1 acts as an AR co-regulator in 
prostate cancer, where its knock-down results in a reprogramming of AR and in an altered 
gene expression program (Sahu et al. 2011). The GATA family of NR co-regulators 
prominently contribute to the development of many cancer types in human patients. For 
instance, GATA2 is an AR co-regulator, playing key role in prostate cancer progression (He 
et al. 2014). GATA3 is an ER co-regulator that plays a critical role in cell fate decisions during 
mammary gland development and cancer progression (Theodorou et al. 2013). However, 
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whether GATA3 impacts AR signalling in breast cancer is unknown. Therefore, this thesis 
aimed to investigate the role of GATA3 on AR signalling in breast cancer. 
 
1.3. Role of the GATA3 transcription factor in the mammary 
glands 
1.3.1. GATA family members, their similar protein structure and DNA 
binding features  
Specification and maintenance of differentiated cell types arising from multipotent 
progenitor cells is a fundamental aspect of development. The specification of cell fate is 
mediated in part by hierarchical networks of TFs and cis-regulatory elements that control 
their genomic activity. TFs are often organized into multi-gene families and play essential 
roles in activating and/or repressing target genes that dictate specific cell fates (reviewed 
in (Lentjes et al. 2016)). The GATA family of TFs, of which there are six (GATA1 to GATA6), 
in mammals, are such master regulators. GATA family members are located on six distinct 
chromosomal regions in the human genome (Figure 14) and share common structural 
features (reviewed in (Lentjes et al. 2016)). Lineage-specific GATA factors play complex and 
widespread roles in cell fate decisions and tissue morphogenesis. GATA family members 
are classified into two subfamilies of hematopoietic (GATA1, 2, 3) and cardiac (GATA4, 5, 
6) factors based on their tissue-specific expression patterns (Lentjes et al. 2016; Tremblay, 
Sanchez-Ferras & Bouchard 2018). GATA1 and GATA2 play key roles in erythroid and 
myeloid lineages, whilst GATA4, GATA5, and GATA6 are found in mesoderm and 
endoderm‐derived tissues and organs including liver, heart, and intestines where they are 
involved in smooth muscle differentiation and endoderm formation (Patient & McGhee 
2002). Conversely, GATA3 is expressed in both hematopoietic (e.g. T cells (Frelin et al. 
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2013; Tindemans et al. 2014)) and non-hematopoietic tissues such as the kidney (Grote et 
al. 2008), central nervous system (van Doorninck et al. 1999), skin (Kaufman et al. 2003) 
and mammary glands (Kouros-Mehr et al. 2006), where it plays a key regulatory role in 
developmental pathways. Importantly, GATA family members share different degrees of 
homology at the amino acid level. Although the zinc finger motifs are more than 70 % 
homologous among all the six GATA members in humans, the total protein homology 
between different family members is variable. For instance, there is an approximate 55 % 
homology between GATA2 and GATA3 and only 20 % homology between GATA3 and 
GATA4 (reviewed in (Zaidan & Ottersbach 2018)). 
GATA family members have two transactivation domains (TAD) at their amino 
terminus (N-terminal domain), which diverge considerably among GATA factors, and two 
highly conserved zinc-finger DNA binding domains at their carboxyl terminus (C-terminal 
domain) called ZnFn1 (N-finger) and ZnFn2 (C-finger) (Figure 15) (Morrisey et al. 1997). All 
GATA family members recognize a hexa-nucleotide consensus recognition element of 5′-
(A/T) GATA (A/G)-3′ on DNA, which is centred on the GATA motif in the regulatory regions 
of target genes. ZnFn2 is necessary and sufficient for GATA proteins to recognise and bind 
to the consensus sequence (Yang, HY & Evans 1992). ZnFn1 binds the GATA recognition 
sequence independently of ZnFn2, especially for GATA2 and GATA3, but with a slightly 
different sequence preference (5’-GATC-3’). ZnFn1 chromatin binding stabilizes the GATA-
DNA interactions (reviewed in (Bates et al. 2008)). In addition, both zinc fingers can 
contribute to self-association of GATA proteins and interaction with other protein 
partners, including other TFs or other GATA family members (Bates et al. 2008; Crispino et 
al. 2001; Trainor, Ghirlando & Simpson 2000; Wilkinson-White et al. 2015). It has been 
shown that GATA factors can form homo or heterodimers in vivo and in vitro (reviewed in 
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(Bates et al. 2008)). This is thought to have key roles in mediating combinatorial and 
synergistic transcriptional regulation by GATA factors, and also in the assembly of high-
order protein DNA complexes (reviewed in (Bates et al. 2008). 
GATA factors can modulate the chromatin structure as pioneer factors, which open 
compacted chromatin, implicating GATA factors in the epigenetic control of chromosome 
structure during progressive stages of developmental pathways, including erythroid or 
mammary epithelial cell differentiation (Chen et al. 2012). For instance, GATA3 functions 
as a pioneer TF by inducing de novo formation of enhancers at previously closed chromatin, 
probably by recruiting a nucleosome remodeller (Takaku et al. 2016). Another mechanism 
by which GATA proteins contribute to transcriptional regulation is by facilitating 
chromosomal looping to mediate long-range control of gene expression. For example, 
structural studies using the chromosome conformation capture (3C) technique 
demonstrated an important role for GATA3 and STAT6 in the formation and maintenance 
of long-range chromatin interactions at the T helper type 2 (TH2) locus control region (LCR) 
(Spilianakis et al. 2005). The genomic region of the TH2 cytokine locus covers more than 
120 kilobases (kb) and encodes genes for the Il4, Il5 and Il13 cytokines (Spilianakis et al. 
2005). Also, it has been shown that GATA1 and its co-factor Friend-of-GATA proteins 1 
(FOG1) can directly occupy looped enhancers and target gene promoters at the β-globin 
locus in fetal liver erythroblasts (Vakoc et al. 2005). GATA1 has been shown to affect higher 
order chromatin organization during suppression of the Kit gene in erythroid cells (Jing et 
al. 2008). Kit encodes a receptor tyrosine kinase that is essential for normal 
haematopoiesis, and is expressed in haematopoietic stem cells and lineage progenitor cells 
during early erythropoiesis (Broudy 1997; Munugalavadla et al. 2005). In immature 
erythroid cells, a distal enhancer bound by GATA2 is in physical proximity with the active 
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Kit promoter. Upon cell maturation, GATA1 displaces GATA2 and triggers a loss of the 
enhancer/promoter interaction (Jing et al. 2008). This exchange of GATA1 and GATA2 on 
the chromatin mediates a transition in looped chromatin organization of the Kit gene (Jing 
et al. 2008). Downregulation of Kit upon terminal erythroid differentiation occurs in 
association with complete exchange of GATA1 for GATA2 (Jing et al. 2008). Since this thesis 
specifically involves GATA3 in breast cancer, I will now focus on the role of GATA3 in 




GATA1 (Xp11.23) _ chrX:48,644,962-48,652,718 (GRCh37/hg19) _ size: 7,757 bases 
 
 
GATA2 (3q21.3) _ chr3:128,198,265-128,212,030 (GRCh37/hg19) _ size: 13,766 bases 
 
 
GATA3 (10p14) _ chr10:8,095,567-8,117,164 (GRCh37/hg19) _ size: 21,598 bases 
 
 
GATA4 (8p23.1) _ chr8:11,534,468-11,617,511 (GRCh37/hg19) _ size: 83,044 bases 
 
 
GATA5 (14q11.2) _ chr20:61,038,553-61,051,026 (GRCh37/hg19) _ size: 12,474 bases 
 
 
GATA6 (18q11.2) _ chr18:19,749,404-19,782,491 (GRCh37/hg19) _ Size: 33,088 bases 
 
 
Figure 14: Chromosomal location of GATA family members  








Figure 15: The GATA family of proteins  
Members of the GATA family are sub-classified as GATA1, 2, 3 and GATA4, 5, 6 based on 
their tissue-specific expression patterns and their structural similarity. They contain two 
highly conserved zinc finger motifs (ZnFn) in the DBD domain, a less conserved 
transactivation domain (TAD) in the N-terminal domain, and a conserved nuclear 




1.3.2. The GATA3 transcription factor 
The GATA3 gene (located on chromosome 10p14) consists of six exons along 20 kb 
of genomic DNA and encodes a 444 amino acid protein that must translocate into the 
nucleus to exert its transcriptional activity (Figure 16). Like all GATA factors, GATA3 
contains an NLS to direct the protein into the nucleus (Chook & Blobel 2001). Nuclear 
transportation of GATA3 from the cytoplasm is mediated by p38 MAPK activity through 
phosphorylation of serine residues on GATA3, leading to a protein-protein interaction with 
the nuclear transporter protein importin-α at the NLS site (Maneechotesuwan et al. 2007). 
Importin-a is one of the nuclear import proteins that plays an important role in 
transporting large proteins from the cytoplasm into the nucleus (Conti et al. 1998; Goldfarb 
et al. 2004). It has been previously shown that deletion of the NLS in GATA3 (aa 249–311) 
prevents its nuclear localization (Yang, Z et al. 1994). Furthermore, the affinity of the 
interaction between importin-α and the GATA3 NLS is a key parameter in determining 
nuclear transport efficiency, which may be directly enhanced by GATA3 phosphorylation 
(Chook & Blobel 2001; Goldfarb et al. 2004; Stochaj & Silver 1992). Structural studies and 
further mutational analyses revealed that the two ZnFns of GATA3 bind to two proximal 
5’-GAT-3’ sequences that are located in the same major groove of the DNA in different 
positions (ZnFn1 binds to the SHL5.5 position and ZnFn2 binds to SHL6.5 position in the 
nucleosome) (Tanaka et al. 2020). Also, the strand orientation of the sequence between 
ZnFn1 and ZnFn2 is not random, suggesting the importance of specific engagement of 
GATA3 zinc fingers with DNA in the outcome of its chromatin binding (Chen et al. 2012; 
Tanaka et al. 2020). Mutation of one of the two 5′-GAT-3′ sequences substantially reduced 
the ZnFn binding affinity of GATA3, indicating that both 5′-GAT-3′ sequences are required 
for high affinity ZnFn binding to the nucleosome (Tanaka et al. 2020). Preferential 
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positioning of GATA3 has been observed near the periphery of the nucleosome, which is 
considered to be more accessible for TF binding, compared to central positions in the 
nucleosome structure (Tanaka et al. 2020). These data indicate that the rotational position 
of the nucleosomal 5′-GAT-3′ sequences is an essential factor for stable GATA3 binding to 
the nucleosome periphery. 
Genome-based technologies like ChIP-seq and assay for transposase-accessible 
chromatin using sequencing (ATAC-seq) have been used in a recent study to explore the 
mechanistic basis by which GATA3 functions as a pioneer TF in a cellular reprogramming 
event relevant to BC, the mesenchymal to epithelial transition (MET), following ectopic 
expression of GATA3 in a typically GATA3-negative breast cancer cell line (MDA-MB-231) 
(Takaku et al. 2016). It has been previously demonstrated that ectopic expression of GATA3 
promotes MET in MDA-MB-231 cells, with a consequent reduction in metastatic capacity 
(Chou et al. 2013). At the individual locus level, many GATA3 binding sites, including MET-
associated gene loci, exhibited increased accessibility in GATA3 over-expressing cells 
(Takaku et al. 2016). In some instances, GATA3 pioneered new binding sites in inaccessible 
chromatin and reprogrammed the local chromatin structure to be accessible after its 
binding (~1/4 loci). However, mostly GATA3 bound to pre-accessible chromatin and 
modestly increased the width of the accessible region (~1/2 loci). At the rest of the target 
loci, GATA3 bound inaccessible sites and failed to remodel local structures (~1/4 loci). 
Therefore, the chromatin structure at these loci remained refractory to transposition 
following GATA3 ectopic-expression (Takaku et al. 2016). Interestingly, GATA3-mediated 
alterations in local chromatin accessibility was dependent on presence of a functional 
TAD1 domain. Deletion of the TAD1 did not alter the chromatin binding ability of GATA3, 
but crippled chromatin reprogramming ability, resulting in failure to induce MET (Takaku 
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et al. 2016). The data presented in this study provided key mechanistic insights into GATA3-
mediated chromatin reprogramming during MET, and suggested unexpected complexity 
to TF pioneering. 
Multiple proteins are known to mediate GATA3 cell-specific transcriptional activity. 
In TH2 cells, GATA3 directly interacts with Smad3, an intracellular signal transducer of TGFβ, 
and mediates the recruitment of Smad3 to GATA3 binding sites independently of Smad3 
binding to DNA (Blokzijl, ten Dijke & Ibanez 2002). This synergistic cooperation of GATA3-
Smad3 complexes promoted transcription of IL-5 and IL-10 cytokines (Blokzijl, ten Dijke & 
Ibanez 2002). It has been evident in human mammary tumours that, as tumour grade 
increases, GATA3 expression is silenced through various mechanisms such as DNA 
methylation (Carr et al. 2012). FOXM1 is a negative regulator of GATA3 and has been 
shown to repress transcription of GATA3 and subsequent protein expression in vivo 
through induction of hypermethylation of the CpG islands at the GATA3 promoter, in 
association with DNA methyl transferase 3b (DNMT3b) (Carr et al. 2012). Acute loss of 
FOXM1 resulted in remarkable enhancement in GATA3-mediated differentiation of luminal 
epithelial cells in mouse mammary glands (Carr et al. 2012). Also, in the breast cancer 
context, at loci where GATA3 pioneered the opening of inaccessible chromatin, co-factors 
such as the SWI/SNF complex can be recruited, leading to nucleosome eviction and 








Figure 16: GATA3 Functional domains and protein structure  
The GATA3 gene is located on chromosome 10p14, contains 6 exons and its protein is 
composed of 444 amino acids harbouring two amino terminal transactivation domains 
(TAD1 and TAD2), and two zinc-finger motifs (ZnFn1 and ZnFn2). The ZnFn2 binds to DNA 
containing the canonical GATA motif, (A/T) GATA (A/G). However, ZnFn1 seems to have 
broader specificity. The ATG is the translation start codon located in exon 2 and the TAG is 
the translation stop codon located in exon 6. The nuclear localization sequence, or NLS, is 





1.3.3. Role of GATA3 in normal mammary gland development and 
differentiation 
GATA3 plays an integral role in luminal cell differentiation in the mammary glands 
(Asselin-Labat et al. 2007). However, little is known about GATA3-mediated transcriptional 
regulation of luminal lineage genes. Efforts to understand luminal cell differentiation in 
mouse mammary glands have mostly focused on ER, which is only expressed in 
approximately half of the mature luminal cells and is present in fibroblasts and other 
stromal cells (Cheng et al. 2004). GATA3 has been shown to have a key role in the 
development and differentiation of mammary ducts (Kouros-Mehr & Werb 2006). It has 
been identified as the most highly enriched TF in microarray screening of mammary 
epithelial cells in both the TEB and the mature duct microenvironment of pubertal mice 
(Kouros-Mehr & Werb 2006). In human breast tissue, normal ducts and lobules were 
focally positive for GATA3 expression, with generally increased expression in malignant 
cells (Yoon et al. 2010). During mouse embryonic development, GATA3 expression is 
detected in primordial mammary buds and is limited only to the luminal epithelial layer, 
not the myoepithelium (Shackleton et al. 2006; Stingl et al. 2006). Similar to what has been 
seen in ERKO mice (Feng et al. 2007), targeted loss of GATA3 in mouse mammary glands 
through MMTV-Cre mediated deletion of floxed-GATA3 led to defects in mammary 
branching morphogenesis (Kouros-Mehr et al. 2006). GATA3KO mice failed to form TEBs 
during puberty, showed irregular luminal diameters, deficiencies in side branching and 
invasion of the epithelium into the stroma (Asselin-Labat et al. 2007; Kouros-Mehr et al. 
2006). In mice, GATA3 expression has also been shown to be necessary to maintain the 
differentiated state of luminal epithelial cells in the adult mammary glands after 
completion of mammary development (Kouros-Mehr et al. 2006). GATA3 plays a significant 
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role in the lineage determination and maturation of mammary epithelial cells by pushing 
mammary cells into the luminal cell fate (Asselin-Labat et al. 2007; Kouros-Mehr et al. 
2006; Naylor & Ormandy 2007). Targeted deletion of GATA3 from mammary progenitor 
cells (MMTV-Cre; GATA3flox/flox) blocks luminal cell differentiation, whereas forced 
expression of GATA3 in mammary stem-cell-enriched populations promotes 
differentiation into luminal cells (Kouros-Mehr et al. 2006). During pregnancy in mice, 
GATA3 participates in luminal epithelial differentiation required for lobuloalveolar 
development (Asselin-Labat et al. 2007). It also has been shown that lack of GATA3 
perturbed differentiation and proliferation of luminal cells, which caused severely 
impaired lactogenesis, yielded smaller lobuloalveolar units, and decreased the 
characteristic markers of alveolar differentiation (Asselin-Labat et al. 2007). GATA3-
depleted adult mammary glands have demonstrated severe luminal cellular defects such 
as disorganization of the duct and decreased cell–cell adhesion, which are important 
properties for invasion and metastasis (Kouros-Mehr et al. 2006). Interestingly, 
detachment from the basement membrane and caspase-mediated luminal cell death 
results from long term GATA3 deletion in adult mammary epithelial cells (Kouros-Mehr et 
al. 2006).  
Taken together, these findings indicate that GATA3 is necessary for normal 
mammary gland development, ductal elongation and branching, luminal epithelial 





1.3.4. GATA3 and breast cancer progression 
Given the essential role of GATA3 in determining the epithelial cell lineage in the 
mammary gland, it is not surprising that GATA3 plays a role in breast cancer biology and 
prognosis. GATA3 is a prominent marker of the luminal pattern of gene expression, 
however, it is expressed in all BC subtypes to some extent. The overall positivity of GATA3 
is 99.51 % in luminal A-like, 97.70 % in luminal B-like, 68.50 % in HER2 overexpressing and 
20.16 % in TNBC tumours (Shaoxian et al. 2017). Importantly, several microarray studies 
found expression of GATA3 as one of the best predictors of ER positive status among 
primary breast cancers (Hoch et al. 1999; Kouros-Mehr, Kim, et al. 2008). Accordingly, 
GATA3 has been shown to be expressed strongly in ER+ cell lines (MCF-7, T-47D) but not 
in ER-negative lines (MDA-MB-231, HBL-100) through cDNA microarray analysis (Hoch et 
al. 1999). Meta-analysis using the Oncomine Research Platform confirmed increased 
GATA3 expression in ER+ cancers compared with ER- cancers throughout 17 studies (Fang, 
Chen & Weigel 2009). As expected from its normal function, GATA3 is a strong predictor 
of tumour differentiation, ER status and clinical outcome (low GATA3 expression was a 
predictive of poor clinical outcome in all patients as well as ER+ subtype) in breast tumours, 
with independent prognostic significance above conventional variables (reviewed at 
(Kouros-Mehr, Kim, et al. 2008)). Absence of GATA3 expression is associated with tumour 
types with a propensity for invasive growth and a poor prognosis, larger tumor size, 
positive lymph node status, higher histology grade, ER-negative status, HER2 
overexpression as well as increased risk for recurrence and metastasis (Mehra et al. 2005). 
Interestingly, a positive regulatory loop has been found between ER and GATA3 in T-47D 
breast cancer cells (Eeckhoute et al. 2007). ER binds to a regulatory element 10 kb 
downstream of the GATA3 transcription start site and regulates the expression of GATA3 
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(Eeckhoute et al. 2007). GATA3 binds to two enhancer sites within the ER gene which are 
required for RNA pol II recruitment at the ER promoter and regulates ER expression 
(Eeckhoute et al. 2007).  
The direct role of GATA3 in breast cancer pathogenesis and progression has been 
investigated using the MMTV-PyMT mouse model of breast cancer that develops 
spontaneous mammary tumours that progress from ER+ hyperplasia to an ER-, poorly 
differentiated adenocarcinoma (Kouros-Mehr, Bechis, et al. 2008). Therefore, PyMT mice 
serves as an excellent model to understand the tumour progression process, and are very 
comparable to human breast carcinomas (Lin et al. 2003). Microarray analysis revealed a 
high correlation between downregulation of luminal differentiation genes and tumour 
progression in this model. Partial loss of GATA3 expression occurred during the transition 
from adenoma (5-week tumour) to early carcinoma (8-week tumour), however, the 
tumour cells in late carcinomas (18-week tumour) and metastatic cells in the lungs were 
consistently GATA3 negative (Kouros-Mehr, Bechis, et al. 2008). Moreover, restoration of 
GATA3 expression in late- stage carcinomas was sufficient to induce luminal differentiation 
markers (e.g. E-cadherin and β-casein), as well as a significant reduction in dissemination 
to distant sites and metastatic seeding (Kouros-Mehr, Bechis, et al. 2008). These data 
indicate that GATA3 negatively impact the breast cancer progression.  
 
1.3.5. Role of GATA3 in tumour invasion and metastasis 
The established hallmarks of cancer include sustaining of proliferative signalling, 
escaping from growth suppressors and resisting programmed cell death, angiogenesis, 
immortality and the ability of the cells to invade and metastasise (Hanahan & Weinberg 
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2011). Metastasis is a multistage biological process consisting of extracellular matrix 
remodelling, dissemination from the original organ and spreading of the tumour cells 
through the circulation, then finally reaching and surviving in distant organs. During 
metastasis, the cancer cells lose their epithelial features and differentiated status and gain 
stem-like and mesenchymal properties leading to increased motility and other aggressive 
behaviours (Valastyan & Weinberg 2011). This transformation of epithelium-derived 
tumour cells from epithelial to a mesenchymal phenotype is called the epithelial to 
mesenchymal transition (EMT) (Valastyan & Weinberg 2011). GATA3, as a critical negative 
regulator of tumour features, suppresses the expression of key EMT proteins and reduces 
invasion of breast cancer cells in vitro and in vivo (Chou et al. 2013; Dydensborg et al. 2009; 
Yan et al. 2010). It has been shown using microarray analysis of primary tumours that 
GATA3 negatively regulates the expression of several genes associated with breast cancer 
lung metastasis such as ID1, ID3, KRTHB1, LY6E and RARRES3 (Dydensborg et al. 2009). 
Conversely, GATA3 up-regulated the expression of genes encoding known inhibitors of 
lung metastasis including DLC1 and PAEP in tumours developing from GATA3-
overexpressing LM2 cells, which are derived from the highly aggressive MDA-MB-231 
model (Dydensborg et al. 2009). Of note, the LM2 cells express significantly lower levels of 
GATA3 compared with the parental MDA-MB-231 strain. These data are consistent with 
microarray data from human breast cancer patients, indicating a strong positive 
correlation between high expression of GATA3 and absence of metastases, specifically to 
the lungs (Dydensborg et al. 2009). Similarly, another study showed that tumours derived 
from basal BC cell lines, 4T1 (mouse) and MDA-MB-231 (human), that over-expressed 
GATA3 decreased lung metastases and altered the tumour microenvironment through 
induction of microRNA (miR)-29b (anti-metastatic microRNA) expression in vivo (Chou et 
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al. 2013). Increased expression of miR-29b resulted in down-regulation of pro-metastatic 
genes through repression of targets in the tumour microenvironment such as ANGPTL4, 
LOX, MMP9, VEGF-A, ITGA6 and ITGB1, thereby suppressing lung metastasis (Chou et al. 
2013). Forced expression of GATA3 in MDA-MB-231 cells promotes the cells to undergo 
MET transition and reduces cell invasiveness through reduction of vimentin, N-cadherin, 
and MMP-9 expression (mesenchymal markers) and an increase of E-cadherin expression 
(an epithelial marker) (Yan et al. 2010). Consistently, GATA3 expressing MDA-MB-231 cells 
displayed a cuboidal-like epithelial phenotype identical to MCF-7 cells (Yan et al. 2010). 
Also, injecting GATA3 expressing MDA-MB-231 cells into the mammary fat pad of 
immunocompromised mice resulted in development of smaller tumours without distal 
metastasis, contrary to mice bearing empty vector controls, supporting a tumour 
suppressive role for GATA3 in blocking tumour development and metastasis independent 
of ER signalling (Yan et al. 2010). Further investigations in the same study has shown that 
GATA3 knockdown in the non-invasive ER+ breast cancer cell line MCF-7, reduced the 
expression level of E-cadherin and triggered fibroblastic transformation. Also, tumours 
derived from MCF-7 GATA3-depleted cells developed quicker and the mice showed shorter 
survival rate and distant metastasis to lung and liver (Yan et al. 2010). Taken together, 
these findings suggest a critical role for GATA3 in inhibiting the invasive behaviour and 
metastatic features of ER- breast tumours via inhibition of EMT. 
 
1.3.6. GATA3 cooperates with ER and FOXA1 as a definitive luminal complex 
in ER+ breast cancer 
ER drives growth in the majority of human breast cancers through regulation of 
genes associated with tumour growth. ER occupies distal enhancers (Carroll et al. 2005) 
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and brings them to the proximity of promoters of the regulated target genes by estrogen-
induced chromosomal loops (Pan et al. 2008). GATA3 is an important ER co-regulator, 
playing a pivotal role in mediating enhancer accessibility and transcriptional potential at 
the ER regulatory regions in ER+ breast cancer cells (Theodorou et al. 2013). GATA3 has 
been shown to be an ER interacting protein in MCF-7 cells (Mohammed et al. 2013), human 
PDX tumours and primary human breast cancer clinical tissues using the powerful 
approach of RIME and qPLEX-RIME, respectively (Papachristou et al. 2018). The qPLEX-
RIME technique is an unbiased proteomic technique that enables comprehensive mapping 
of endogenous protein interactomes with higher sensitivity and statistical robustness 
compared to traditional RIME (Papachristou et al. 2018). Serandour et al., developed a new 
genomic approach termed ChIP-exonuclease (ChIP-exo), which uses an exonuclease to 
trim the ChIP’d DNA to a precise distance from the crosslinking site (Rhee & Pugh 2011, 
2012), to gain clearer insights into the spatial relationship between GATA3, FOXA1 (as two 
key ER-associated TFs), and ER (Serandour et al. 2013). In the latter study, GATA3 motifs 
were shown to be adjacent to the central ERE, however, the Forkhead motifs were further 
away from the ERE motifs. This suggested structure shows how these three key factors 
form to define a transcriptionally active cis-regulatory element in luminal ER+ breast 
cancers (Lacroix & Leclercq 2004). GATA3 and FOXA1 are both estrogen-regulated genes 
(Eeckhoute et al. 2006; Eeckhoute et al. 2007) that are highly correlated with ER expression 
in ER+ breast cancers (Lacroix & Leclercq 2004). ER, FOXA1, and GATA3 are definitive genes 
for ER+ luminal breast cancer tumours (Perou et al. 2000; Sorlie et al. 2003) and their 
expression is required for establishment of an E2-responsive ER complex (Kong et al. 2011). 
Ectopic expression of GATA3, FOXA1 and ER in ER-, estrogen-unresponsive MDA-MB-231 
cells partially restored ER binding capacity and transcriptional activity (Kong et al. 2011). 
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Furthermore, E2-stimulation of ER+ MCF-7 breast cancer cells resulted in the formation of 
a tripartite enhanceosome complex of ER, FOXA1, and GATA3 which co-localizes at 
common binding sites across the genome to induce ER target gene transcription through 
recruitment of RNA Pol II and p300 to the chromatin (Kong et al. 2011). Both FOXA1 and 
GATA3 are known ER pioneer factors, where they independently associate with compacted 
chromatin and directly facilitate chromatin accessibility for ER (Carroll et al. 2006; 
Theodorou et al. 2013). FOXA1 is required for ER to bind to DNA and exert its estrogen-
induced transcriptional activity (Carroll et al. 2005). In contrast, GATA3 is not critical for ER 
binding but loss of GATA3 induces redistribution of about a third of all E2-stimulted of ER 
binding events (Theodorou et al. 2013). ER binding events gained upon GATA3 depletion 
had a low dependency on GATA3 presence, however, the lost ER binding events were 
GATA3 dependent. Also, it has been shown that sites that lose their ER binding affinity 
upon GATA3 depletion are also depleted of active histone marks (H3K4me1 and H3K27ac), 
suggesting that GATA3 mediates these enhancers directly, likely as a pioneer factor 
(Theodorou et al. 2013). These findings also suggest that GATA3 is required for ER to bind 
to chromatin lacking active histones. The GATA3 independent ER binding events occurred 
at sites exhibiting elevated occupancy of FOXA1 and active histone marks (Theodorou et 
al. 2013). The remaining ER sites that were not changed upon GATA3 loss, occurred at 
enhancers with active histone marks that are occupied with both GATA3 and FOXA1, 
indicating less dependency of these ER sites to the presence of GATA3, but more 
dependence on FOXA1. GATA3-mediated ER redistribution was associated with changes in 
gene expression (Theodorou et al. 2013). The up-regulated genes were significantly 
correlated with the “stronger” ER binding events that occurred in the absence of GATA3 
(e.g. TRAK1, TGFB1, and FGFR3) whereas the down-regulated genes were significantly 
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correlated with the “weaker” ER binding events upon silencing GATA3 (e.g. CA12, CAV1, 
and METRNL) (Theodorou et al. 2013). GATA3 has been shown to directly bind to the 
FOXA1 promoter in primary mammary epithelial cultures of adult mice (Kouros-Mehr et al. 
2006). This study has identified FOXA1 as a putative member of the GATA3 genetic 
regulatory network. Expression of GATA3 and FOXA1 is strongly correlated in mammary 
and breast cancer microarray datasets (Usary, Jerry et al. 2004). Moreover, the 
overexpression of GATA3 was shown to upregulate FOXA1 expression, suggesting that 
GATA3 activates gene expression (Usary, Jerry et al. 2004). Furthermore, genome-wide 
mapping of FOXA1 after GATA3 depletion in MCF-7 cells revealed that GATA3 also 
modulates the FOXA1 chromatin binding profile, suggesting that GATA3 acts upstream of 
FOXA1 in determining the ER binding profile (Theodorou et al. 2013). Collectively, these 
data suggest an important role for GATA3 in ER signalling by facilitating ER DNA binding to 
a subset of regulatory sites at compacted chromatin, and by mediating FOXA1 as its 
required co-regulator. 
 
1.3.7. GATA3 mutations in breast cancer 
GATA3 mutations were reported in humans for the first time by Van Esch et al., in 
2000, identified in a family with a rare disease called HDR syndrome characterised by 
hypoparathyroidism, sensorineural deafness and renal disease (Van Esch et al. 2000). 
Following that, in 2004, six different GATA3 heterozygous mutations were identified in 
breast cancer tissues and breast tumour-derived cell lines (Usary, J. et al. 2004). Very 
quickly after that, GATA3 was shown to be one of the most frequently mutated genes in 
primary breast cancers, with approximately 10 % incidence rates (Banerji et al. 2012; 
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Chanock et al. 2007; Stephens et al. 2012). Now there are more than 70 GATA3 somatic 
mutations reported in breast cancers (Gaynor et al. 2013). The majority of these mutations 
(>95 %) are found in ER+ luminal A or B breast cancer subtypes (Gaynor et al. 2013). Most 
GATA3 mutations are rare or unique frameshift indels distributed along the 3’ end of the 
gene structure (Figure 17) (Pereira et al. 2016). Four groups of frameshift mutations have 
been identified for GATA3 including, 1) ZnFn2 mutations, which occur within the C terminal 
zinc finger; 2) truncating mutations, located downstream of the C terminal zinc finger; 3) 
extension mutations, which occur in exon 6 and disrupt the stop codon, and 4) splice 
mutations, which mainly occur between intron 4 and exon 5 (Takaku et al. 2018). 
Depending on the location of the mutations in the GATA3 gene, they are predicted to 
differentially influence protein production, such as truncated or extended proteins (Usary, 
J. et al. 2004). Due to the relatively high frequency of GATA3 mutations in primary breast 
cancers, they were first considered driver mutations (reviewed in (Takaku, Grimm & Wade 
2015)). Although some show tumour-promoting functions (Cohen et al. 2014; Gustin et al. 
2017; Takaku et al. 2018), GATA3 mutations are paradoxically associated with longer 
patient survival (Pereira et al. 2016) and improved response to endocrine therapy (Ellis et 
al. 2012). Jiang et al., collated the clinicopathologic characteristics of patients with breast 
cancers harbouring GATA3 mutations from two separate cohorts (The Cancer Genome 
Atlas (TCGA), n=934) and the Fudan University Shanghai Cancer Centre (FUSCC), n=308) 
and examined the association of GATA3 somatic mutations with patient survival rate (Jiang 
et al. 2014). They detected GATA3 mutations in 8.8 % and 14.9 % of patients with luminal-
like breast cancer in TCGA and FUSCC cohorts, respectively, and noted that they were 
significantly associated with improved overall survival and favourable disease‐free 
outcome. This was also observed in patients with luminal disease who had received 
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adjuvant endocrine therapy, indicating a potential predictive value for endocrine therapy 








Figure 17: Distribution of GATA3 mutations in breast tumors (Takaku et al. 2018) 
Takaku et al., classified GATA3 mutations into 5 groups as depicted in the figure, including 
1) Splice site mutations; 2) ZnFn2 mutations; 3) Truncation mutations; 4) Extension 
mutations; and 5) Missense mutations. The mutation data shown in this figure was 
obtained from the METABRIC cohort via the cBio Cancer Genomics Portal. The missense 
and truncation mutations are dispersed along the GATA3 protein sequence. However, 
most GATA3 mutations are localized in exon 5 and 6. ZnFn2 mutations and extension 
mutations exclusively occur in the second zinc-finger motifs and far end of CTD domain, 
respectively. Infrequent splice site mutations are shown in dark blue localized in exon 4 




The most common GATA3 mutation, X308 splice, has recently been investigated in 
a study involving carrier patients (66/231 tumours) of a Molecular Taxonomy of Breast 
Cancer International Consortium (METABRIC) cohort (Hruschka et al. 2020). These patients 
were significantly associated with signatures of good prognosis after endocrine therapy, 
smaller tumour size, lower tumour stage and grade, PR expression, and improved 
outcomes compared to patients without GATA3 X308 splice mutations or those carrying 
other GATA3 mutations (Hruschka et al. 2020). Importantly, this mutation was exclusively 
observed in patients with ER+ tumours (Hruschka et al. 2020). Also, investigating 
differentially expressed genes in tumours harbouring X308 splice mutations compared 
with all the other tumours revealed a negative correlation with gene signatures of bad 
prognosis and strong down-regulation of cell cycle and inflammation-associated genes 
(e.g. E2F2, E2F4, PCNA and MKI67), which is consistent with the favourable prognosis of 
these patients (Hruschka et al. 2020). The X308 splice mutation of GATA3 reduced ER 
enrichment to chromatin, especially at enhancer regions in mutant T-47D cells upon E2-
stimulation compared with the hormone-starved control cells, suggesting that this 
mutation interferes mainly with the fine-tuning of ER-dependent transcription, which is in 
consistent with the pioneering role of GATA3 (Hruschka et al. 2020). In addition, the X308 
splice GATA3 mutation interfered with the progesterone-induced antiproliferative 
function of PR in T-47D cells expressing mutated GATA3 compared to the control cells 
(Hruschka et al. 2020). These data showed that the GATA3 X308 splice mutation interferes 
with both ER and PR signalling, suggesting a crucial role of GATA3 as a co-factor for both 
ER and PR. 
The D336fs frameshift mutation is another common GATA3 mutation in primary 
human breast cancers, having been reported 16 times in TCGA and METABRIC datasets 
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(Gustin et al. 2017). The MCF-7 model is the best example of an ER+ BC line carrying a 
heterozygous frameshift mutation (D336fs) in the second zinc finger of GATA3, which 
makes it a useful model to study this clinically relevant phenomenon. As a result of this 
mutation, MCF-7 cells express both the full length GATA3 protein, as well as a truncated 
protein (approximately 37 kDa) which has significantly higher steady state levels compared 
to the full-length variant (Adomas et al. 2014). The D336fs mutation does not affect nuclear 
localization of GATA3 in MCF-7 cells, or in the T-47D ER+ BC cell line in which mutant GATA3 
is induced (Adomas et al. 2014), however, the mutant form of GATA3 was present in the 
cytoplasm of the cells. This suggests that this truncation mutation has impaired interaction 
with chromatin and is readily translocate from the nucleus to the cytoplasm (Adomas et 
al. 2014). It has been shown that the GATA3 cis-regulatory profile in MCF-7 cells bearing 
the mutation is bigger than in T-47D cells (wild-type GATA3), however, no major functional 
differences among genes associated with the GATA3 cistrome was identified. This may 
suggest that excess binding events in MCF-7 cells are not transcriptionally functional 
(Adomas et al. 2014). It has been suggested that the bigger GATA3 cistrome in MCF-7 cells 
could be due to a compromised ability of the mutant protein to recognise the specific 
GATA3 motif (Adomas et al. 2014). However, the proportion of GATA3 peaks containing 
the GATA3 motif was almost identical between the two lines, suggesting that the mutation 
did not influence chromatin binding specificity in MCF-7 cells (Adomas et al. 2014). 
Although GATA3 mutations are widely thought to be LOF, Takaku et al., 
demonstrated for the first time that not all mutations in the GATA3 TF are equivalent to 
each other in terms of patient prognosis (Takaku et al. 2018). ZnFn2 mutations impact 
breast cancer through both gain (GOF) and loss of function. Patients with a mutation in the 
GATA3 ZnFn2 region had significantly worse survival (10-year survival rate) compared to 
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patients carrying the wild-type GATA3 allele or other GATA3 mutations such as splice site 
mutations, suggesting that ZnFn2 mutations might be more damaging than complete loss 
of the binding domain (Takaku et al. 2018). Systematic gene expression analysis of 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-ed T-47D cells 
harbouring a ZnFn2 2-nucleotide deletion mutation at arginine 330 (R330) position of 
GATA3 gene, indicated that a more aggressive gene signature was found in ZnFn2 mutant 
cells compared to the parental T-47D cells (Takaku et al. 2018). R330fs mutant T-47D 
tumours in nude mice had a higher growth rate, determined by a significantly higher 
luminescent signal compared to control mice (Takaku et al. 2018). Also, ChIP-seq analysis 
has shown that the GATA3 R330fs mutation induces redistribution of GATA3 binding 
events on the chromatin, resulting in upregulation of genes including TWIST1 and SNAIL2 
(consistent with up-regulation of cell movement- and invasion-related pathways) and 
downregulation of genes such as PR, which is consistent with reduced cell differentiation-
related and development-related pathways (Takaku et al. 2018). Since expression of PR is 
a key prognostic marker in breast cancer, its down-regulation is associated with a weaker 
anti-proliferative effect of progesterone and worse prognosis of the disease (Purdie et al. 
2014). Additionally, activated-PR has been shown to direct ER cistrome within breast 
cancer cells, resulting in a unique gene expression programme that is associated with good 
clinical outcome (Mohammed et al. 2015). This indicates that the GATA3 ZnFn2 mutations 
play a role in modulating PR expression and progesterone sensitivity (Takaku et al. 2018). 
Although there are accumulating studies revealing the functional effect of the GATA3 
mutations, the mechanism by which various types of mutations contribute to clinical 





GATA3 is a regulator of ER signaling in ER+ BC (Eeckhoute et al. 2007) and plays 
important roles in development and differentiation of the mammary gland (Asselin-
Labat et al. 2007; Kouros-Mehr et al. 2006). Most ER+ BCs also express the AR 
(Ricciardelli et al. 2018), which has been shown to inhibit estrogen-induced growth of 
this disease subtype (Hickey, TE et al. 2021). Given the importance of AR in ER+ BC, 
there has been increasing interest in targeting the AR to treat ER+ BC. In ER- BC patients, 
AR positivity is also associated with improved disease-free survival and clinical and 
pathologic prognostic factors (e.g. lower tumour grade, smaller tumour, and increasing 
age) (Agoff et al. 2003), but its role in this disease context is controversial (Hickey, T et 
al. 2012). One key TF that has been strongly correlated with AR expression in BCs (both 
ER+ (Boto & Harigopal 2017) and TNBC (Kim et al. 2016)) is GATA3. To elicit its 
transcriptional activity, AR does not function alone, but within a transcriptional complex 
along with several co-regulatory proteins that are implicated in a diverse number of 
cellular functions. However, no study has broadly investigated the AR interacting 
proteins in different BC subtypes, to date, and no study has specifically examined the 




1.5. Hypothesis and Aims 
I hypothesise that, 1) GATA3 is an important AR co-regulatory protein that 
contributes to AR-mediated growth inhibition in ER+ breast cancer and 2) GATA3 promotes 
AR-mediated cellular reprogramming associated with luminal lineage identity in a breast 
cancer context. These hypotheses are investigated using a variety of cell-based and PDX 
models of breast cancer, using modern next-generation sequencing techniques and 
different proteomic approaches including RIME. 
Aim 1: Determine whether activation of AR and/or ER alters the GATA3 cistrome 
in breast cancer cells;  
Aim 2: Examine whether GATA3 impacts the growth-inhibitory effect of AR in 
ER+ breast cancer; 
Aim 3: Investigate the significance of GATA3 and AR interaction in breast cancer 
Aim 4: Assess the pre-clinical significance of AR and GATA3 interactions in ER+ 




AR interacts with GATA3 to induce a luminal 
epithelial phenotype in breast cancer through 
regulation of lineage-restricted genes   
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The following chapter includes a manuscript formatted for submission to Genome 
Biology journal, followed by supplementary figures and extended data. This chapter makes 
up a significant proportion completed as a part of this PhD. A general discussion of this 
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Background: GATA3 transcription factor is considered critical for luminal development 
and differentiation in normal and malignant mammary epithelial cells (MECs). The 
androgen receptor (AR) has also been associated with luminal gene expression profiles in 
breast cancer, independent of the estrogen receptor (ER), and has been shown to promote 
a basal to luminal phenotype transition in mouse MECs. To date, the potential interaction 
of GATA3 and AR in transcriptional regulation of lineage driver genes in breast cancer has 
never been investigated. 
Results: Our unbiased proteomic analysis identified GATA3 as a novel AR interacting 
protein in a variety of breast cancer cell types regardless of ER expression. We showed that 
AR and GATA3 interact in the cytoplasm and nucleus of normal and malignant breast 
epithelia, an interaction increased by androgen treatment. Androgen stimulation of breast 
cancer cells also induced nuclear translocation of AR and GATA3 and resulted in 
enrichment of co-localized AR and GATA3 chromatin binding events. Using ER+ and/or ER- 
breast cancer cell lines and ER+ patient-derived xenograft (PDX) models of breast cancer, 
we identified a conserved subset of AR agonist-induced AR and GATA3 co-occupied cis-
regulatory elements across all models. Knockdown experiments indicated that GATA3 acts 
as an AR co-regulator to upregulate transcription of known luminal-lineage genes (e.g. EHF, 
AQP3, and KDM4B). Also, we showed an induction in the chromatin accessibility at those 
subsets of common AR-GATA3 cis-regulatory elements, which drive the luminal lineage 
identity in breast cancer upon androgen stimulation. 
101 
 
Conclusions: Our findings show a cooperative role for AR and GATA3 in driving the 
luminal-lineage identity in mammary epithelial cells. Also, our data explains the association 
between AR and luminal gene profiles in breast cancer.  
 
Introduction  
Breast cancer (BC) is the most common malignancy worldwide (Bray et al. 2018) 
and approximately 80 % of cases are considered to be driven by oncogenic estrogen 
receptor alpha (ER) signalling. Breast tumors expressing ER, termed as ER+, can be 
molecularly characterised into Luminal A and B subtypes. Since the luminal A subtype does 
not express the human epidermal growth factor 2 (HER2) and has a lower level of ki67 
expression compared to the luminal B subtype, it is associated with a slightly better 
prognosis (Reis-Filho & Pusztai 2011). The remaining 20-25 % of breast cancer cases are 
negative for the expression of ER (termed as ER-) and are divided into HER2+, Basal-like, 
and normal-like molecular subtypes (Parker et al. 2009; Sørlie et al. 2001). Interestingly, 
the majority of ER+ breast cancers (more than 90 %) (Ricciardelli et al. 2018) and about 50 
% of all ER- breast cancers (Niemeier et al. 2010; Park et al. 2010) express AR. There is 
currently a lot of interest in the role of AR in breast cancer, but its actions may differ among 
breast cancer subtypes (Hickey et al. 2012).  
The AR has been shown by numerous clinical studies to be an independent 
predictor of breast cancer survival and outcome of ER+ breast cancer (Ricciardelli et al. 
2018). In ER+ breast cancers, AR was able to interfere with ER-dependent transcriptional 
activity through competitive binding to select estrogen response elements (EREs) (Peters 
et al. 2009). However, using genome-wide methodologies, it has very recently been shown 
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that competitive binding to EREs is not the key mechanism by which AR inhibits the 
stimulatory effect of ER in breast cancer cells (Hickey et al. 2021). In the latter study, AR 
was shown to be a tumour-suppressor in ER+ BC, where it inhibits estrogen-stimulated 
growth of ER+ BC by reducing recruitment of ER, and its co-activators p300, and SRC3, to 
chromatin at key cell cycle genes, leading to growth arrest (Hickey et al. 2021).  
The role of AR in ER- breast cancers is still equivocal. Despite some trials reporting 
that AR positivity in ER- breast cancer cases is associated with poor prognosis (Choi et al. 
2015; Jiang et al. 2016), there are several other studies that showed AR expression either 
is not correlated with prognosis (Jongen et al. 2019; Zaborowski et al. 2019) or is associated 
with a better prognosis (Guiu et al. 2018; Kucukzeybek et al. 2018). AR positivity has also 
been shown to be associated with improved disease-free survival and more benign clinical 
and pathologic factors (e.g. lower tumor grade and smaller tumor) in ER- BC (Hu, XQ et al. 
2017; Luo et al. 2010). While AR activity has been increasingly investigated in AR+/ER− 
breast cancers (Farmer et al. 2005; Iggo, R 2018; Iggo, RD 2011), the specific role of AR 
signaling in this disease context is not well understood. 
Since AR is a transcription factor that interacts with multiple co-regulatory proteins 
that control its transcriptional activity, we undertook the first unbiased proteomic analysis 
of AR in ER+ and ER- BC contexts in order to better understand AR function in this disease.  
 
Results 
GATA3 is a novel AR interacting protein in breast cancer 
To identify AR interacting proteins in breast cancer cells, we used an unbiased 
proteomic approach called RIME (Rapid Immunoprecipitation Mass spectrometry of 
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Endogenous proteins) (Mohammed et al. 2016). Briefly, asynchronous AR+/ER+ (ZR-75-1 
and T-47D) and AR+/ER- (MFM-223 and MDA-MB-453) breast cancer cell lines were cross-
linked and AR protein complexes immunoprecipitated from purified chromatin prior to 
peptide digestion and identification by mass spectrometry. To identify high confidence 
interactors, three independent replicates representing consecutive passages of cells were 
performed for each cell line. Identification of AR and several established AR interacting 
proteins (e.g. different members of the SWI/SNF chromatin remodelling complex and heat 
shock proteins) highlights the accuracy and robustness of our RIME datasets across all in 
vitro models (Supplementary 1-A, Extended data 1-1), and alludes to conservation of some 
features of AR signalling across different breast cancer contexts. We identified 110, 59, 130 
and 119 AR interacting proteins in ZR-75-1, T-47D, MFM-223, and MDA-MB-453 cells, 
respectively, grouped into unique and common AR interacting proteins between 2 or more 
breast cancer models using an up-set plot (Figure 1-A). Interestingly, while FOXA1 is a 
known AR interactor in prostate cancer (PCa) (Paltoglou et al. 2017; Robinson et al. 2014; 
Stelloo et al. 2018), and has been shown to influence AR activity in MDA-MB-453 breast 
cancer cells (Robinson et al. 2011), it was not detected in all breast cancer models (FOXA1 
was only detected in MDA-MB-453 3 replicates and 1 replicate of MFM-223 cells). A total 
of eleven proteins were identified that interacted with AR in all breast cancer cell lines 
investigated (Figure 1-A,B). We further classified these interacting proteins by their 
molecular function into DNA-binding transcription factors, RNA binding proteins and 
proteins with either catalytic, transferase, or SNARE (Soluble NSF attachment protein 
receptor) activities (Figure 1-B). Interestingly, GATA3 was identified as one of the DNA-
binding transcription factors that interacted with AR in all models (Figure 1-A-B). Four 
unique GATA3 peptides were consistently detected across all the cell lines and exclusively 
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belong to the homo sapiens GATA3 protein, confirming the authenticity of GATA3 as a 
candidate AR interacting protein in breast cancer cells regardless of ER status 
(Supplementary 1-B,C). Since GATA3 is a critical regulator of luminal epithelial 
differentiation in mammary glands (Kouros-Mehr et al. 2008) and AR has also been 
implicated in promotion of a luminal mammary epithelial cell phenotype in mice (Tarulli et 
al. 2019), and is associated with a luminal gene signature in human ER- breast cancers 
(Lehmann et al. 2011; Robinson et al. 2011), we focused the current study on the 
interaction between AR and GATA3 in breast cancer. 
Interaction between AR and GATA3 was confirmed using the Proximity Ligation 
Assay (PLA) in all four cell lines (Figure 1-C, Supplementary 2-A). Activation of AR by the 
most potent natural ligand, 5-α-dihydrotestosterone (DHT), significantly increased the 
number of AR-GATA3 interactions (Figure 1-D, Supplementary 2-B,C), which further 
increased with time (Supplementary 2-D). Surprisingly, some AR-GATA3 interactions were 
also detected under hormone-deprived conditions (Figure 1-C, Supplementary 2-D), 
suggesting that hormone activation of AR enhanced but was not required for interaction 
with GATA3. The AR-GATA3 interaction was further validated by co-immunoprecipitation 
(Co-IP) assays (Figure 1-E,F). Pull down with AR was associated with detection of GATA3 in 
all four breast cancer cell lines, and the GATA3 signal was increased upon treatment with 
DHT (Figure 1-E), consistent with the PLA results. Reciprocal pull down of GATA3 was 
associated with detection of AR in a DHT-dependent manner in the ER- breast cancer cell 
lines (Figure 1-F), but AR was not detected in the ER+ breast cancer cell lines regardless of 
DHT treatment (Supplementary 2-E). The latter observation is likely due to substantially 
lower AR protein levels in ER+ compared to the ER- breast cancer lines (Supplementary 2-
F) and the fact that Co-IP methodology is less sensitive than RIME and PLA methodologies. 
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To show that AR interacts with GATA3 in primary tissues, we conducted PLA for 
clinical ER+/AR+ (n=2) and ER-/AR+ (n=2) malignant breast tissues, and observed AR-
GATA3 interactions in all cases (Figure 1-G). More interactions were evident in ER+ tissues 
compared with the ER- tissues (Figure 1-G, Supplementary 2-G), which is consistent with 
the fact that GATA3 expression is higher in ER+ compared to ER- breast cancers (Fararjeh 
et al. 2018). Interestingly, we also observed AR-GATA3 interactions in the epithelial cells 
of non-malignant breast tissues from reduction mammoplasties (n=2). Although 
observational, these data indicate that an interaction between AR and GATA3 occurs in 
normal and malignant clinical contexts. 
GATA3 nuclear translocation is induced upon hormone stimulation in breast 
cancer 
In PLA experiments, we observed both nuclear and cytoplasmic interaction 
between AR and GATA3 in vitro (Supplementary 3-A) and in vivo (Supplementary 3-B), so 
we assessed whether AR activation would induce nuclear translocation of AR and GATA3 
via dual label immunofluorescence (IF). Androgen (DHT) stimulation caused translocation 
of AR in all cell line models, an expected feature indicative of AR activation (Figure 2-A-D). 
Notably, DHT also induced nuclear translocation of GATA3 with strong co-localization 
between the two factors (Figure 2-A-D), suggesting that AR and GATA3 are translocated as 
a complex. Since GATA3 is an important ER co-regulator in the ER+ breast cancer context, 
we investigated whether treatment with estrogen would have a similar effect on sub-
cellular localization of GATA3. Our findings showed that the most potent natural ER ligand, 
17-β-estradiol (E2) had a moderate effect on AR and GATA3 nuclear translocation 
(Supplementary 3-C,D). Strong co-localization of AR and GATA3 was sustained upon E2 
treatment, suggesting that this is an AR-mediated phenomenon, consistent with a previous 
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report of E2-induced AR nuclear translocation in ER+ but not ER- breast cancer cell lines 
(D'Amato et al. 2016). Indeed, when cells were treated with a combination of E2+DHT, AR 
and GATA3 co-localize in the nucleus of nearly all cells (Supplementary 3-C,D), similar to 
treatment with DHT alone (Figure 2-A-B). Collectively, this data suggests that AR and 
GATA3 interact in the cytoplasm of breast cancer cells in the absence of hormone, but 
activation of AR increases interaction and induces nuclear translocation of both factors 
into the nucleus as a complex. 
AR agonist-induced GATA3 cis-regulatory elements are co-occupied by AR at 
active chromatin loci 
Given that activated AR increased interaction with GATA3 (described in Figure 1-C-
F) and induced nuclear translocation of both factors (described in Figure 2-A-D), we next 
assessed the effect of AR activation in shaping the genome-wide chromatin binding profile 
(cistrome) of GATA3 in breast cancer. We performed GATA3 ChIP-seq in our four breast 
cancer cell lines following a 4-hour treatment with vehicle or DHT. Each experiment was 
performed using 3 independent biological replicates from consecutive passages of cells to 
generate consensus cistromes representing reproducible binding events. We also 
performed GATA3 ChIP-seq in tumours from two ER+/AR+ patient-derived xenograft 
models (PDXs) of endocrine resistant disease treated for 5 days in vivo with a vehicle 
control or an AR agonist (DHT or the selective AR modulator (SARM; Enobosarm), as 
previously reported (Hickey et al. 2021). We confirmed GATA3 expression in both PDX 
models (Supplementary 4-A-B) before performing ChIP-seq experiments. Principle 
component analysis (PCA) of the GATA3 ChIP-seq data revealed that treatment with AR 
agonist was the major source of variation between replicate experiments for each model 
(Supplementary 5-A-F), indicating a major impact of AR activation on the GATA3 cistrome 
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in breast cancer cells. DiffBind analysis revealed significant (FDR ≤ 0.05) alteration of 
GATA3 binding sites upon androgen stimulation in all our in vitro and in vivo breast cancer 
models (Supplementary 6-A-F). Although androgen stimulation mainly resulted in 
enrichment of new GATA3 binding sites, consistent with more GATA3 entering the nucleus, 
the HCI-005 PDX model showed a comparable number of significantly gained and lost 
GATA3 binding events (Supplementary 6-A-F). Notably, we observed a similar pattern of 
differentiated peaks across all the cell line models. Also, the GAR15-13 PDX model show 
similar patterns to cell lines models, however, HCI-005 show differences, possibly, due to 
various phenotypes of endocrine resistance. In order to assess the genome-wide 
relationship between GATA3 and AR chromatin occupancy following AR activation, we 
performed AR ChIP-seq co-incident with the GATA3 ChIP-seq in the MDA-MB-453 and 
MFM-223 ER- breast cancer cell lines and used our publicly available AR ChIP-seq data 
((Hickey et al. 2021), (GSE123770) for the ER+ breast cancer models (ZR-75-1, T-47D, 
Gar15-13, and HCI-005). Two-factor MA plots were generated to show the relationship 
between AR and GATA3 binding following AR activation in each model, revealing 5 
different sub-groups representing shared or unique AR and GATA3 binding events (Figure 
3-A-C, Supplementary 7-A-C). Notably, the majority of GATA3 binding events induced by 
AR activation were  co-occupied by AR (shown in red dots in MA plots) representing 84 % 
of total androgen-induced GATA3 binding sites in ZR-75-1, 94 % in T-47D, 82 % in MFM-
223, 86 % in MDA-MB-453, 80 % in Gar15-13 PDX, and 50 % in HCI-005 PDX models 
(Supplementary 7-D-I). These observations are consistent with the effect of AR activation 
on interaction and nuclear translocation of GATA3 and suggest that AR and GATA3 are 
either binding to their respective motifs in close proximity to each other or that one factor 
is tethering another. Discriminative DNA motif analysis of AR agonist-induced GATA3 
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binding sites identified AR response elements (AREs) among the most highly enriched 
motifs across all the breast cancer models (Figure 3-D, Supplementary 7-J, Extended-data-
2), although GATA3 motifs were also significantly enriched. Interestingly, loci 
corresponding to AR agonist-induced AR and GATA3 recruitment were located near known 
AR target genes in breast cancer cells (e.g. SEC14L2, C1orf116, ZBTB16, and RANBP3L) 
(Hickey et al. 2021), indicating that GATA3 may play a key role in AR-mediated transcription 
(Figure 3-A-C, Supplementary 7-A-C). To determine changes to the transcriptional 
activation status of chromatin associated with AR agonist-induced AR-GATA3 binding 
events, we performed histone H3 lysine 27 acetylase (H3K27ac) ChIP-seq in the ER- breast 
cancer models (Supplementary 8-A-C, Extended-data-3) and utilized our publicly available 
H3K27ac ChIP-seq data for the other models (Hickey et al. 2021). Heatmaps show an 
increased H3K27ac signal at the AR agonist-induced AR-GATA3 binding events across all 
breast cancer models, especially at stronger peaks (Figure 3-E-G, Supplementary 9-A-C). 
This suggests that in addition to an induction of AR-GATA3 binding events, androgen 
stimulation remodels the chromatin landscape at these newly gained AR-GATA3 binding 
sites. Examples of H3K27ac enrichment at loci co-occupied by AR and GATA3 at AR target 
genes is shown in Figure 3 (Figure 3-H). Taken with Figure 1 and Figure 2, our ChIP-seq data 
support the concept that activation of AR induces nuclear translocation of both AR and 
GATA3, and this results in new, transcriptionally active GATA3 DNA binding events that are 
closely associated with AR DNA binding sites.  
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AR agonist-induced AR-GATA3 cis-regulatory elements are associated with 
gene regulatory profiles involved in development and differentiation of the 
mammary epithelium 
To understand the biological significance of transcriptionally active AR agonist-
induced AR-GATA3 binding events at the transcriptomic level, we first annotated these 
binding events to potential targets by filtering for genes within a 100 kb distance from the 
transcription start sites (TSS) in each of our breast cancer models. We found thousands of 
candidate target genes associated with AR and GATA3 common bindings (Figure 4-A, 
Supplementary 10-A). Then, we conducted RNA-seq assays in all our in vitro ER+ and ER- 
breast cancer models for DHT-treated cells vs the unstimulated control cells. We also 
utilized in vivo RNA-seq data from ((Hickey et al. 2021), GSE123770) for the PDX models 
(Enobosarm or DHT vs vehicle datasets). After performing differential expression analysis 
for each model (Supplementary 10-B-G), we integrated the annotated genes from AR-
GATA3 common regions with the differentially expressed genes (DEGs) from RNA-seq data, 
narrowing down the list of candidates AR-GATA3 targets (Figure 4-A, Supplementary 10-
A). We then applied gene set enrichment analysis (GSEA) to these candidate AR-GATA3 
target genes to identify associated biological processes. This analysis uncovered Gene 
Ontology (GO) terms pertaining to development and differentiation of mammary epithelial 
tissue (such as mammary gland development, mammary gland duct morphogenesis, 
epithelial cell differentiation, cell-cell adhesion, and apical-junction assembly) (Figure 4-B-
D, Supplementary 11-A-C). Also, GSEA revealed positive enrichment of hallmark gene sets 
associated with canonical AR signalling and luminal differentiation (e.g., Androgen-
response, and apical-junction, early and late estrogen response, and IL2-STAT5-signalling), 
and suppression of gene sets related to proliferation and cell cycle (e.g., G2/M-checkpoint, 
E2F-targets, mitotic-spindle, and MYC-targets-V1) in vitro and/or in vivo (Figure 4-E,F, 
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Supplementary 12-A-C). Collectively, these data suggest that AR and GATA3 form a 
complex in which they coregulate genes involved in mammary gland development and 
differentiation. This led us to explore whether GATA3 is required for AR-mediated 
regulation of these target genes. 
GATA3 acts as an AR co-regulator in breast cancer cells  
To investigate whether DHT-induced GATA3 binding sites co-occupied by AR 
(shown in red in Figure 3) are AR-dependent events, we performed GATA3 ChIP-PCR in the 
presence or absence of siRNA-mediated AR knock-down in T-47D (as an ER+ model) and 
MDA-MB-453 (as an ER- model) cells at representative loci (e.g. SEC14L2, ZBTB16, and 
C1orf116) highlighted in Figure 5-A (Figure 5-A). Cells were treated with and without DHT. 
As a negative control, we also tested a GATA3 locus associated with the c-FOC gene that 
was not influenced by AR activation in any of the models. Silencing AR abolished DHT-
induced enrichment of GATA3 at representative loci in both models and, as expected, 
GATA3 enrichment was not altered by AR knockdown at the c-FOC locus (Figure 5-B). 
Furthermore, abolition of AR prevented DHT-induced expression of genes associated with 
these loci in both ER+ and ER- models (Supplementary 13-A). The efficacy of AR knock-
down and its effect on GATA3 protein expression in T-47D and MDA-MB-453 breast cancer 
cells was checked through western blotting (Supplementary 13-B,C). No significant effect 
on GATA3 protein expression was evident after silencing AR in either model, indicating that 
loss of GATA3 at AR-GATA3 co-occupied loci was not due to reduced levels of GATA3 
(Supplementary 13-B,C). Taken together, these results indicate that GATA3 binding at AR 
target genes is dependent on AR. 
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To determine whether GATA3 functions as an AR co-regulator at these loci, we 
assessed the effect of GATA3 silencing on the ability of AR to bind DNA and induce 
transcription at the same representative loci highlighted in Figure 5-A. As a negative 
control, we assessed AR binding at a locus associated with the FKBP5 AR target gene that 
is not co-occupied by GATA3. While silencing GATA3 significantly reduced DHT-induced 
enrichment of AR to representative loci, AR binding was not abolished (Figure 5-C). As 
expected, there was no significant change in AR enrichment at the FKBP5 GATA3-
independent locus after GATA3 knock-down (Figure 5-C). These data indicate that GATA3 
facilitates but is not critical for AR binding at DHT-induced co-occupied loci. Importantly, 
GATA3 knock-down significantly reduced DHT-induced transcript levels of the 
representative AR target genes (Supplementary 14-A), indicating that the reduction of AR 
binding at associated loci had a functional impact on AR transactivation capacity. The 
efficacy of GATA3 knock-down and its effect on AR protein expression level were checked 
by western blotting in the T-47D and MDA-MB-453 breast cancer cells (Supplementary 14-
B,C). Silencing GATA3 did not change the AR protein level in the T-47D and MDA-MB-453 
cells. This suggests that the reduction of AR binding in the absence of GATA3 is not due to 
reduced AR protein expression (Supplementary 14-B,C).  
AR agonist-induced modifications of the chromatin landscape at AR-GATA3 
binding events associates with regulation of lineage-restricted genes 
Since studies have shown a key role for GATA3 in promoting and maintaining the 
luminal epithelial phenotype in mammary glands (Kouros-Mehr et al. 2008; Kouros-Mehr 
et al. 2006), and AR has also been implicated in promotion of the luminal phenotype in 
mice (Tarulli et al. 2019), we specifically examined the relationship of AR and GATA3 at 
genes known to be important for establishment of the luminal lineage. Overlapping the 
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candidate AR-GATA3 DEG targets with GSEA luminal and basal signature gene sets 
(Extended-data-4), we identified tens of up-regulated luminal epithelial markers indicative 
of luminal phenotype promotion in all our luminal breast cancer models (Figure 6-A-C, 
Supplementary 15-A-C). Furthermore, among those basal marker genes that were down-
regulated upon androgen stimulation in each of our models, we found tens of basal genes 
that were direct targets of AR and GATA3 in each of our breast cancer models (Figure 6-A-
C, Supplementary 15-A-C). AR-GATA3 target genes that are located within transcriptionally 
active regions of chromatin include 33 up-regulated luminal marker genes (e.g., EHF, 
CNTNAP2, FGFR2, AQP3, SPDEF, KDM4B, and CLDN8) (Supplementary 15-D) and 8 down-
regulated basal marker genes (e.g. PALLD, ZNF519, SMAD3, and ELK3) that were commonly 
found across at least 3 out of 6 of our breast cancer models (Supplementary 15-E). The 
effect of AR and GATA3 knock-down on the DHT-induced binding enrichment of EHF, AQP3, 
KDM4B (luminal markers) (Supplementary 16-A-C) was assessed through ChIP-PCR 
experiments in T-47D and MDA-MB-453 cell lines. Silencing AR significantly abolished DHT-
induced enrichment of GATA3 at luminal representative loci in both ER+ and ER- breast 
cancer models, and silencing GATA3 negatively impacted the DHT-induced enrichment of 
AR binding at the selected luminal representative loci (Supplementary16). This shows, for 
the first time, that AR and GATA3 co-operate to promote a luminal phenotype in both ER+ 
and ER- contexts. Also, using qPCR, we assessed the effect of AR and GATA3 knock-down 
on the mRNA expression level of selected luminal targets in both of the in vitro models (T-
47D and MDA-MB-453) in DHT-treated cells compared with the vehicle-treated control 
cells (Figure 6-D,F). Knock-down of AR or GATA3 significantly reduced the DHT-induced 
mRNA expression level of luminal genes in vitro (Figure 6-D-F). 
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Collectively, our findings revealed that androgen stimulation induces AR-mediated 
translocation of GATA3 into the nucleus, resulting in a gain of new GATA3 binding sites 
that are predominantly associated with AR target genes, where GATA3 co-regulates AR 
function in promoting the expression of luminal epithelial driver genes and repressing the 
expression of the basal marker genes in breast cancer luminal models. 
 
Discussion 
Herein, we identified GATA3 as a novel AR interacting protein in breast cancer in 
vitro and in vivo models irrespective of ER expression. We showed that AR agonist 
stimulated breast cancer cells induced nuclear translocation of AR and GATA3, which 
suggests that AR and GATA3 are translocated as a complex. The knockdown experiments 
reveal that GATA3 acts as AR co-regulator in breast cancer, facilitates AR binding at DHT-
induced AR-GATA3 co-occupied loci and impacts on AR transactivation capacity. Exploring 
the relationship of AR and GATA3 at genes associated with the luminal phenotype revealed 
that the importance of AR-GATA3 interaction and function is in the promotion of luminal 
and repression of basal lineage-restricted genes, in breast cancer models in vitro and in 
vivo. 
Despite the fact that there are many known AR-associated factors in normal and 
malignant prostate epithelial cells that can shape AR function (Chmelar et al. 2007), 
including FOXA1 (Sahu et al. 2011) and GATA2 (He et al. 2014; Wu et al. 2014), the critical 
regulators are still being identified. Concerning the breast cancer context, there is huge 
gap in our knowledge regards lack of a comprehensive catalogue of AR interacting factors 
in different subtypes of the disease. Like ER, to elicit its transcriptional activity, AR does 
not function alone, but within a transcriptional complex. Although, they are some 
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literatures that investigated the ER-associated factors (e.g. FOXA1 (Carroll et al. 2005), 
PBX-1 (Magnani et al. 2011), AP-2γ (Tan et al. 2011) and GREB1 (Mohammed et al. 2013)) 
in breast cancer, possibly because ER is the driver transcription factor in majority of the 
breast tumours, investigation of AR interacting factors in breast cancer has never been 
studied before. Therefore, we undertook the first comprehensive unbiased proteomic 
analysis of AR using RIME in both ER+ and ER- breast cancer models to better understand 
AR function in this disease. We identified GATA3 as a novel AR interacting protein among 
all ER+ and ER- models. Although, FOXA1 has been shown to be required for AR DNA-
binding and functionality at a subset of bindings in molecular apocrine breast cancer cells 
(Robinson et al. 2011) we did not detect FOXA1 as a common AR interacting protein across 
all the models. In addition to GATA3, the other two transcription factors that interacted 
with AR in all models were JUNB and ERF, both previously reported as AR interacting 
proteins in prostate cancer (Paltoglou et al. 2017). However, due to the well-established 
role of GATA3 in mammary gland development and differentiation (Asselin-Labat et al. 
2007) we focused to reveal the significant of AR-GATA3 interactions within breast cancer. 
It has been previously shown that in the mammary gland, GATA3 is exclusively expressed 
in luminal epithelial cells (both ductal and alveolar) (Asselin-Labat et al. 2007), and 
regulates the differentiation of mouse mammary stem cells into mature luminal epithelial 
cells (Kouros-Mehr et al. 2008). GATA3 has also been shown to maintain the differentiated 
state of the mature luminal epithelium in the murine mammary gland (Kouros-Mehr et al. 
2006). Ectopic overexpression of GATA3, ER and FOXA1 in basal-like breast cancer cells has 
been shown to induce a luminal phenotype at the cellular and molecular levels (Kong et al. 
2011). Interestingly, in a study by Tarulli et al., 2019 AR has been shown to implicate in 
promotion of the luminal phenotype in mouse mammary epithelial cells in vivo, and its 
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inhibition increased basal cell activity in vitro (Tarulli et al. 2019). Interestingly, GATA3 
expression is more strongly correlated with AR than with ER in all clinical breast cancer 
subtypes (Boto & Harigopal 2017; Kim et al. 2016). Therefore, we hypothesized that GATA3 
may interact with AR to induce a luminal phenotype. Our data revealed a key role for AR-
GATA3 in promoting luminal lineage features in breast cancer in vitro and in vivo. We 
showed that GATA3 acts as an AR co-regulator, impacting the AR transcriptional activities 
at a subset of AR agonist-induced loci associated with altered expression of lineage-
restricted genes. For instance, EHF, KDM4B and AQP3 were identifies as AR-GATA3 luminal 
target genes that were up-regulated upon AR agonist stimulation across all the in vitro and 
in vivo breast cancer models. 
EHF is one of the epithelium-specific ETS (ESE) transcription factors that is highly 
expressed in the breast epithelium and contribute to the development of luminal 
progenitors from bipotent MaSCs during the luminal differentiation (Pellacani et al. 2016), 
however, GATA3 is critical for further differentiation into mature luminal cells (Kouros-
Mehr et al. 2006; Pellacani et al. 2016). Bioinformatic analysis of a mammary epithelial 
microarray dataset reveals EHF as an epithelial-specific transcription factor that may 
cooperate with GATA3 in its gene regulatory network (Kouros-Mehr & Werb 2006). EHF 
functions as a tumour-suppressor in prostate cancer through repressing expression of 
EZH2 and promoting expression of the tumour suppressor Nkx3.1 (Kunderfranco et al. 
2010). Also, EHF ectopic expression in prostate cancer cells inhibited stem like properties 
and promoted epithelial differentiation through repressing EMT drivers, such as TWIST1, 
ZEB2, NANOG and POU5F1 (Albino et al. 2012).  
KDM4B is a H3K9me3 / H3K9me2 histone demethylase that associates with 
activation or maintenance of gene expression (Gaughan et al. 2013). KDM4B is an ER co-
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regulator that interacts and forms a complex with GATA3 at the ER regulatory enhancers 
to regulate the ER expression in breast cancer cells (Gaughan et al. 2013). Also, KDM4B has 
been also showed to interact AR and regulates its signalling in endometrial (Qiu et al. 2015) 
and prostate cancer (Coffey et al. 2013). Mammary epithelial identity is partially shaped 
by the DNA methylation landscape, which varies between cell types (Huh et al. 2015). 
Genes that are highly expressed in mammary stem/progenitor cells (e.g. HOXA1 and 
TCF7L1) are hypomethylated (Bloushtain-Qimron et al. 2008), conversely, genes express in 
mature luminal cells including luminal-driver GATA3 transcription factor show more 
transcriptional activation, implying that DNA methylation is important in regulating the 
expression of lineage-specific transcription factors (Maruyama et al. 2011). It has been 
shown that KDM4B is essential for estrogen-dependent gene expression (Gaughan et al. 
2013) and also, it is an important regulator of mammary gland development and 
differentiation, involving in differentiation direction of mammary stem cells to luminal 
stem cells and mature luminal cells (Holliday et al. 2018).  
AQP3 is one of the aquaporin family members that express in mice and human 
MECs (Kaihoko et al. 2020). AQP3 has diffuse localization in the cytoplasm of ductal MECs 
and concentrated localization in the basolateral membrane of alveolar MECs during the 
late pregnancy and lactation periods (Kaihoko et al. 2020). AQP3 has been shown to be 
required for FGF2-induced migration of MDA-MB-231 cells (Cao et al. 2013). However, the 
role of AQP3 in breast cancer and in association with GATA3, AR has never been studied. 
Collectively, our findings suggest a novel aspect of transcription factor cooperation 
in lineage determination of normal mammary and breast cancer cells. however, further 
investigations are needed to reveal the details of AR-GATA3 regulation of luminal target 
genes in the context of breast cancer progression.   
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Material and Methods 
Cell culture 
ZR-75-1 (ATCC®CRL-1500TM), T-47D (ATCC®HTB-133TM), MFM-223 (DMSZ, ACC 
422), and MDA-MB-453 (HTB-131TM) breast cancer cell lines were obtained from 
American Type Cell Culture Collection (ATCC) (Manassas, VA, USA) or DSMZ-German 
Collection of Microorganisms and Cell Cultures GmbH (Leibniz-institute, DSMZ, Germany). 
All cell lines were routinely tested for mycoplasma infection and authenticity confirmed by 
short tandem repeat profiling (Cell Bank Australia). ZR-75-1 and T-47D were maintained in 
RPMI-1640 medium (Invitrogen) containing 10 % Foetal Bovine Serum (FBS) and 2 nM L-
Glutamine (Sigma). MFM-223 were cultured in EMEM (Invitrogen) containing 10 % FBS, 2 
nM L-Glutamine (Sigma), 1 x Non-essential Amino Acids (Sigma) and 1 x Insulin-Transferrin-
Sodium Selenite (Sigma). MDA-MB-453 cells were maintained in DMEM (Invitrogen) 
medium containing 10 % FBS, 2 nM L-Glutamine (Sigma) and 1 x Sodium Pyruvate (Sigma). 
All lines were incubated at 37 ˚C and 5 % CO2. For hormone stimulation experiments, cells 
were starved for 72 hours in 5 % dextran-coated charcoal stripped (DCC) FBS medium. 
Rapid immunoprecipitation mass spectrometry of endogenous proteins 
(RIME) 
The RIME technique was performed as described previously (Mohammed et al. 
2016). Briefly, cells (MDA-MB-453, MFM-223, ZR-75-1, and T-47D) were seeded at 
approximately 80 % confluence in their appropriate growth medium and cultured for 48 
hours cross-linked in 1 % formaldehyde for 7 minutes, quenched with 0.2 M Glycine, 
chromatin isolated then subjected to immunoprecipitation using magnetic beads pre-
bound with 10 µg of AR antibody (Santa Cruz Biotechnology, AR N20; sc-816). An on-bead 
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peptide digestion was performed and a 2-5 μl aliquot of diluted peptide mixture was 
analysed by Nano-LC-MS/MS. Peptides were identified using MS. Only those interacting 
proteins that were identified in 3 of 3 independent biological replicates were considered 
for further analysis. Additional filtering was achieved by excluding non-specific interactions 
that appeared in >1 of the 3 replicates of matching IgG negative controls. 
Proximity ligation assay (PLA) 
The ZR-75-1, T-47D, MFM-223 and MDA-MB-453 breast cancer cells were cultured 
in hormone depraved condition for 72 hours before seeding on top of sterilized coverslips 
in 6-well culture plates. Cells were treated with Ethanol (vehicle control), 10 nM E2 and/or 
10 nM DHT accordingly for 4 hours before fixation with 4 % Paraformaldehyde for 10 
minutes in room temperature. Cells were then permeabilized with 0.1 % Triton X-100 for 
an hour at room temperature and stained with AR (LS-Bio; LS-B3326) and GATA3 
(Invitrogen; 1A12-1D9) antibodies diluted in 10 % Donkey serum (in PBS) overnight at 4 ˚C. 
PLA probes were mixed and diluted 1/5 in Duolink In Situ Antibody diluent for 1 hour at 37 
˚C in a humid chamber. Ligation and amplification steps were conducted for 30 minutes 
and 100 minutes, respectively, at 37 ˚C according to the manufacturer's instructions 
(Duolink® PLA kit; Sigma-Aldrich). Cell nuclei were stained with DAPI (Invitrogen) before 
mounting with Duolink In Situ Mounting Medium. 
Confocal imaging 
Images were sequentially acquired on an Olympus FV3000 confocal microscope. 9 
sections that were systematically sampled at 20 x magnification were selected from 5 
random spots for each slide as technical replicates. Level adjustments were applied across 
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entire images. Quantification of the total number of the cells and the cytoplasmic and 
nuclear foci inside was performed using Fiji software (ImageJ). 
Immunofluorescent staining (IF) 
ZR-75-1, T-47D, MFM-223 and MDA-MB-453 breast cancer cells were cultured in 
DCC FBS media for 72 hours and then seeded on top of sterilized coverslips in 6-well plates 
and treated with Ethanol (vehicle control), 10 nM E2 and/or 10 nM DHT accordingly for 4 
hours before fixation with 4 % Paraformaldehyde for 10 minutes at room temperature. 
Permeabilization was performed with 0.05 % Triton X-100 (in PBS). Dual 
immunofluorescence staining with AR (LS-Bio; LS-B3326) and GATA3 (Invitrogen; 1A12-
1D9) antibodies was performed at 4 ˚C, overnight. Cells were incubated for 30 minutes at 
room temperature with secondary antibodies of Goat-anti-Rabbit (life Technologies; Alexa 
Fluor 568) and Goat-anti-mouse (life Technologies; Alexa Fluor 488) diluted in 10 % goat 
serum with the dilution of 1 in 400 before DAPI staining (Invitrogen) and mounting with 
Dako fluorescent mounting medium. Mounting media was air-dried for 24 hours before 
imaging. 
Slide scanning 
Immunofluorescent stained slides were scanned through the AxioScan.Z1 (ZEISS). 
Representative images were processed using ZEN 3.0 (blue edition) software (ZEISS). All 
representative images were taken with the scale of 10 um maintaining channel intensity 
range of DAPI in blue (black(250); white(2000)), GATA3 in green (black(400); white(1600)), 




Co-immunoprecipitation assay (Co-IP) 
ZR-75-1, T-47D, MFM-223, and MA-MB-453 cells were seeded at 9 x 106 cells/plate, 
9 x 106 cells/plate, 11 x 106 cells/plate, and 10 x 106 cells/plate, respectively, and treated 
with ethanol or 10 nM DHT accordingly for 4 hours before harvest. Cells were cross-linked 
with 1 % formaldehyde, quenched with 2 M Glycine pH 7.5, and collected by scraping. The 
cells were suspended in lysis buffer (10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM EDTA, 0.5 
mM EGTA, 0.1 % Na-Deoxycholate, and 0.5 % N-lauryl sarcosine) in the presence of 
protease inhibitors (Complete(R), Roche) and sonicated for 10 cycles of ‘30 seconds on, 30 
seconds off’, using a Diagenode Bioruptor. After centrifugation, the supernatant was 
collected and immunoprecipitated with protein A magnetic beads (Dynabeads®, 
Invitrogen) pre-bound with 5 ug/IP of GATA3 (Abcam; ab199428) or AR (Abcam; ab108341) 
at 4 °C overnight excluding the Input samples. The following day, the beads were washed 
4 times with the wash buffer (20 mM Tris HCL Ph 8, 50 mM NaCl, 1 mM EDTA, 0.1 % Tween 
20, and 2 mM DTT (MW 154.25)) at room temperature, eluted with 30 µL of 0.2 M Glycine 
pH 2.6, neutralized with 1 M Tris-HCL pH 8, and boiled at 95 °C for 10 minutes to elute 
associated proteins, prior to analysis by Western blotting.  
Western blotting 
Cells were harvested by scraping and lysed into Radioimmunoprecipitation assay 
(RIPA) buffer. Protein concentration was quantified by BCA protein assay (Thermo Fisher 
Scientific). Proteins were separated by SDS-PAGE on 10 % Criterion TGX Stain Free-gels 
(BIO-RAD) and then transferred to Amersham nitrocellulose blotting membranes (GE 
Healthcare). Blocking was carried out in 5 % skim milk in TBST for 2 hours. Immunoblotting 
for AR (Santa Cruz Biotechnology; N20; sc-816); ER (Santa Cruz Biotechnology; F-10; sc-
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8002); GATA3 (Abcam; ab199428); B-actin (Abcam; ab6376) and GAPDH (Merck Millipore; 
mab374) was performed overnight, then membranes were washed with PBS + 0.1 % 
Tween-20 for three 10-minutes rounds. HRP-coupled secondary antibodies (Goat anti-
Rabbit (Dako; 1:2000) or Rabbit anti-Mouse (Dako; 1:2000) were detected with Clarity 
Western ECL Substrate (BIO-RAD) and visualised using a BIO-RAD ChemiDoc (MP) imaging 
system. Veriblot (Abcam; ab131367) was used for the detection of the primary antibodies 
for Co-IP samples before ECL detection. 
siRNA knockdown experiments 
Pre-designed siRNAs against GATA3, AR and a negative (non-targeting) control 
siRNA (Allstar-Neg. Control siRNA) were purchased commercially (Extended-data-5). 
siGATA3-1 and -2 (10 nM each) were used in T-47D cells, siGATA3-3 and -4 (5 nM each) 
were used in MDA-MB-453 cells. Two siARs were used with the concentration of 10 nM for 
both cell line models, where appropriate. 5 and 10 nM of siControl was used T-47D and 
MDA-MB-453 cells, respectively. Cells were transfected with siRNAs by reverse 
transfection using RNAiMAX (Invitrogen) (0.5 ul/cm2) at the time of seeding according to 
the manufacturer's protocols (Thermo Fisher Scientific, Waltham, MA, USA). For ChIP-PCR 
experiments, cells were cultured in full media supplemented with siRNA transfection mix 
for 24 hours, then hormone deprived for 48 hours before treatment. However, cells were 
transfected with siRNA for 48 hours for qPCR experiments. 
RNA extraction and quantitative real-time PCR (qPCR) 
T-47D and MDA-MB-453 cells were seeded at 0.5 X 106 cells/well in 6-well plates 
and simultaneously transfected with siRNAs against GATA3 or AR. The medium and 
transfection mix were changed the following day to a hormone-depleted medium 
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supplemented with 5 % DCC-FBS. After 48 hours (media refreshed each day), both cell 
models were treated for 6 hours with Ethanol or 10 nM DHT, before collection with 
TriReagent (Sigma). Total RNA was extracted using Trizol (Sigma) followed by DNase 
treatment using the TURBO DNase Kit (Invitrogen) according to manufacturer’s protocol. 
Reverse transcription was performed with 500 ng of total RNA using the iScript cDNA 
Synthesis Kit (BIO-RAD). The resulting cDNA was diluted 1:10 and used for qRT-PCR. mRNA 
levels were normalised to GAPDH using the ΔΔCt method in BIO-RAD CFX-manager 
software, as previously described (Hu, DG et al. 2016). 
ChIP-sequencing (ChIP-seq) 
ZR-75-1, T-47D, MFM-223 and MDA-MB-453 cells were seeded in 15 cm plates at 9 
X 106,  9 X 106, 11 X 106, and 10 X 106 cells/plate, respectively, in their normal growth 
medium. Media was changed to phenol-red-free medium supplemented with 5 % DCC -
stripped FBS after 24 hours and cells were allowed to grow for 2 days prior to treatment 
with daily media changes. Cells were then treated with either Vehicle (Ethanol) or 10 nM 
DHT for 4 hours prior to fixation and harvest. Each experiment was done in three 
independent biological replicates representing consecutive passages of cells. Additionally, 
frozen tumour tissues left over from experiments with the endocrine-resistant ER+ PDX 
models of breast cancer (Gar15-13 and HCI-005) were used for ChIP-seq representing 
(Gar15-13; Enobosarm vs vehicle) and (HCI-005; DHT vs vehicle) arms as described in 
(Hickey et al. 2021). In the latter experiments, tumours were harvested 5 days post 
treatment and cryo-sectioned before cross-linking. Tumors from vehicle (GAR15-13, n = 3; 
HCI-005, n = 5), Enobosarm (GAR15-13, n = 3) and DHT (HCI-005, n = 5) were used for PDX 
ChIP-seq. Cross-linking and sonication were carried out as mentioned above for Co-IP 
experiments for both in vitro and in vivo models. Immunoprecipitations were performed 
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using 5 ug/IP of GATA3 (Abcam; ab199428) (for all in vitro and in vivo models) and AR 
(Abcam; ab108341), or 2 ug/IP of H3K27ac (Abcam; ab4729) (only for ER- in vitro models) 
antibodies. Before sequencing the DNA samples of all in vitro and in vivo experiments, 
ChIP-PCR reactions were prepared using iQ SYBR Green Supermix (BIO-RAD) using primers 
listed in Extended-data-5. PCR was performed with the CFX384 Real Time PCR Detection 
System (BIO-RAD) and standard cycling conditions. ChIP-PCR data were analysed by the 
percentage input method and further analysed as fold enrichment over negative control. 
DNA was sequenced using an Illumina NextSeq 500 (High Output) with 75 bp single-end 
reads. Raw data was processed in Galaxy. Briefly, trimmed FASTQ files were aligned to the 
hg19 genome assembly using Bowtie2 (version: 2.3.4.3, default parameters); mapped 
reads with a minimum MAPQ <10 and duplicate reads were removed using SAMtools; 
peaks were called using MACS2 callpeak (version: 2.1.1, default settings), with a pooled 
input sample as the control. Only peaks found in 2 out of the 3 replicates were kept for the 
consensus peak-set. For figures, ChIP-seq data was visualized using the Integrative 
Genomics Viewer (https://igv.org/app/). Heatmaps (Galaxy Version 3.3.2.0.1) and PCAs 
(Galaxy Version 3.3.2.0.0) were generated using Deeptools. Peak annotations were 
performed using Cisgenome (v2.0).  
ChIP-PCR 
T-47D and MDA-MB-453 cells were seeded (9 X 106, 10 X 106 cells/plate, 
respectively) in their normal growth media and transfected with siRNAs against either AR 
(10 nM siAR-1 and siAR-2), GATA3 (10 nM of siGATA3-1 and -2 in T-47D, and 5 nM of 
siGATA3-3 and -4 in MDA-MB-453), or siControl (5 or 10 nM accordingly) at time of 
seeding. Media was changed to appropriate hormone-depleted media containing 5 % DCC-
FBS on the following day. Treating (10 nM DHT vs Ethanol in both cell lines for 4 hours), 
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cross-linking, harvesting, ChIP processing and PCR reactions were performed as previously 
mentioned in the ChIP-seq section.  
RNA-seq 
ZR-75-1, T-47D, MFM-223 and MDA-MB-453 in vitro cells were seeded and treated 
with 10 nM DHT (vs vehicle) for 6 hours prior to collection with TriReagent (Sigma). Three 
independent replicate experiments representing consecutive passages of cells were used 
to generate samples for RNA-seq. RNA was extracted from cells using the Direct-Zol RNA 
kit (Zymo Research). RNA integrity was assessed using the Experion RNA StdSens Analysis 
kit (700-7111, BIO-RAD) on the Experion Automated Electrophoresis System (BIO-RAD) and 
quantified by Nanodrop 2000 (Thermo Fisher Scientific). Total RNA was supplied to the 
Cancer Research UK Cambridge Institute (CRUK-CI) Genomics Core Facility for library 
preparation and high throughput sequencing. Conversion of the RNA into sequencing 
libraries was performed using the TruSeq® Total RNA HT kit (Illumina). Sequencing was 
performed using the Illumina HiSeq 2500 with single-end 40 bp reads. Raw data was 
processed by the CRUK-CI Bioinformatic Core. Reads were aligned to hg19 (TopHat) and 
differential expression analysis was performed using DESeq. 
RNA from the in vivo models (PDXs) was extracted using the RNeasy kit (QIAGEN). 
Extracted RNA from PDXs was sequenced using the Illumina NextSeq 500 and aligned to 
hg19 using CLC Genomics Workbench 11 (QIAGEN) as described previously (Hickey et al. 
2021).  
For RNA-seq validation, total RNA was DNase-treated using the TURBO DNase kit 
(Invitrogen) and reverse transcribed using the iScript cDNA Synthesis kit (BIO-RAD). PCR 
with reverse transcription was performed as per ChIP-PCR but using primers outlined in 
Extended-data-5. Gene expression was calculated by the 2-ΔΔCt method and normalized to 
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the expression of GAPDH (in vitro models) or IPO8 nd PUM1 (tumors), using the CFX 
Manager Software (BIO-RAD). 
Immunohistochemistry (IHC) 
Standard immunohistochemical techniques were performed as previously 
described (Hickey et al. 2015) and employed using the following primary antibodies: AR (N-
20, Santa Cruz SC-816) with the applied dilution of 1:1000; and GATA3 (ab199428, Abcam) 
with the applied dilution of 1:500. Appropriate positive and negative controls were 
included in all experiments. Slides were incubated overnight at 4 ˚C. Slides were scanned 
through Nanozoomer slide scanner (Hamamatsu #C9600). 
Statistical analyses 
Statistical calculations were performed using GraphPad Prism (GraphPad 
Software). Normality was assumed for all statistical tests unless otherwise stated. Multiple 
comparisons were adjusted for Tukey’s test, Student’s t-test and ANOVA tests, where 
appropriate. All tests were two-sided with a 95 % confidence interval and a P value <0.05 
was indicative of statistical significance. All ChIP-PCR experiments for AR, GATA3, and 
H3K27ac and qPCRs in all the models analysed using a two-way ANOVA, followed by 
Tukey’s multiple comparisons test. Rest of the experiments were analysed using a two-way 















Figure-1: GATA3 is a novel AR interacting protein in breast cancer. (A) Up-set plot 
representing common and unique AR interacting proteins among ER+ and ER- breast 
cancer cell lines, identifying GATA3 as one of the common interactors. (B) Pie chart 
showing the 11 AR interacting proteins common to ER+ and ER- in vitro breast cancer 
models, classified based on their molecular functions. (C) Proximity ligation assays (PLA) 
showing AR-GATA3 interactions in T-47D (ER+) and MDA-MB-453 (ER-) breast cancer lines 
comparing DHT-treated cells to vehicle-treated cells. Negative controls represent an assay 
performed without the secondary antibody. Images were captured using confocal-
microscopy (scale bar: 20um). (D) Quantification of total PLA foci (average number of spots 
per 300 counted nuclei) in T-47D (ER+) and MDA-MB-453 (ER-) breast cancer lines after 4 
hours of treatment with DHT. Two-way ANOVA with Student’s t-test was used to 
determine statistically significant differences. Data shown as mean ± SEM of five replicates 
and are representative of one independent experiment; **** p<0.0001. (E) Western blot 
showing AR-GATA3 interaction in 4 ER+ and ER- breast cancer lines. AR was 
immunoprecipitated from breast cancer cells and GATA3 was detected in association with 
AR protein in all models. IgG served as a negative control in all assays. (F) Western blot 
showing AR-GATA3 interactions through immunoprecipitating GATA3 in ER- models. (G) 
PLA images representing AR-GATA3 interactions in normal and malignant (ER+ and ER-) 











Figure-2: Activated AR induces AR and GATA3 nuclear translocation. Representative 
images showing the co-localization of AR and GATA3 in (A) ZR-75-1, (B) T-47D, (C) MFM-
223, and (D) MDA-MB-453 breast cancer cells. Images were captured using a slide scanner 
(Zeiss Axio Scan.Z1) and processed using ZEN 2 (blue edition) software. Negative controls 
for all the in vitro models include an assay without the secondary antibody. All 
representative images were taken with the scale of 10 um and same intensity range for 
each channel. Cells were treated for 4 hours with 10 nM DHT (vs vehicle-treated control 




Figure 3: AR agonist-induced GATA3 cis-regulatory elements are co-occupied by AR at 









Figure-3: AR agonist-induced GATA3 cis-regulatory elements are co-occupied by AR at 
transcriptionally active chromatin loci. Distribution of the AR and GATA3 cistrome upon 
androgen stimulation is shown using two-factor log-ratio (M) plots for (A) T-47D and (B) 
MDA-MB-453 in vitro models and (C) GAR15-13 in vivo PDX model. Peaks are represented 
by coloured dots and classified into 5 different sub-groups: Orange and grey dots represent 
GATA3 and AR binding sites that do not overlap with the other factor, respectively; blue 
dots represent AR agonist-induced GATA3 peaks that are not shared with AR; green dots 
represent AR-GATA3 overlapping peaks that GATA3 peaks are not gained with AR agonist; 
and red dots represent AR-GATA3 peaks that are significantly gained upon AR activation. 
Example Loci associated with AR target genes (ZBTB16, C1orf116, SE3C14L2, RANBP3L) are 
highlighted in black dots and selected from the AR-GATA3 peaks that are induced by AR 
agonist in each model. (D) Motif analysis of AR agonist-induced GATA3 binding sites 
revealed AR as the most highly enriched motif across all in vitro and in vivo breast cancer 
models. Heatmaps showing AR agonist-induced AR-GATA3 binding sites and the associated 
H3K27ac binding events in (E) T-47D, (F) MDA-MB-453, and (G) GAR15-13 breast cancer 
models. (H) Genome browser image displaying averaged AR, GATA3, and H3K27ac ChIP-
seq signals at binding sites associated with AR target genes (SE3C14L2, C1orf116, and 
ZBTB16) in three replicates of T-47D (top), MDA-MB-453 (middle), and GAR15-13 (bottom) 




Figure 4: AR agonist-induced AR-GATA3 binding sites are implicated in development and 












T-47D 2,403 3,088 919 753
MDA-MB-453 5,918 6,028 1,561 1,512









Figure-4: AR agonist-induced AR-GATA3 binding sites are implicated in development and 
differentiation of mammary epithelium. (A) Table showing the number of AR agonist-
induced AR-GATA3 binding sites and their associated genes that are differentially up- or 
down-regulated in both in vitro and in vivo models. Pathway analysis representing 
significant enrichment of pathways including mammary gland epithelium development 
and differentiation in (B) T-47D, (C) MDA-MB-453, and (D) GAR15-13 breast cancer models. 
(E,F) Gene set enrichment plots representing up- and down-regulated hallmark 












Figure-5: GATA3 acts as an AR co-regulator in breast cancer cells. (A) Genome browser 
images showing averaged AR and GATA3 ChIP-seq signals at binding sites associated with 
AR target genes (SEC14L2, C1orf116, and ZBTB16) and genes used as negative controls for 
knock-down experiments (c-FOC, and FKBP5). Peaks represent the average signal of three 
independent replicates of T-47D (top) and MDA-MB-453 (bottom) cells. (B) Bar graphs 
showing the GATA3 ChIP-PCR results following AR knock-down at loci (represented in A) 
associated with AR target genes SEC14L2, C1orf116, ZBTB16, and c-FOC (negative control) 
in T-47D and MDA-MB-453 breast cancer cells transfected with siControl and two different 
siRNAs against AR. (C) Bar graphs representing the AR ChIP-PCR results following GATA3 
knock-down at loci (represented in A) associated with AR target genes SEC14L2, C1orf116, 
ZBTB16, and FKBP5 (negative control) in T-47D and MDA-MB-453 breast cancer cells 
transfected with siControl and two different siRNAs against GATA3. Cells in B and C were 
treated with DHT vs vehicle for 4 hours before harvesting. Two-way ANOVA with Tukey's 
multiple comparisons test was used to determine statistically significant differences in 
both B and C. Data shown as mean ± SD of 3 replicates and are representative of two 




Figure 6: AR agonist-induced AR-GATA3 loci are associated with lineage-restricted genes 







Figure-6: AR agonist-induced AR-GATA3 loci are associated with lineage-restricted genes 
in breast cancer in vitro and in vivo models. Heatmaps representing up- and down-
regulated luminal and basal AR-GATA3 targets upon AR activation in (A) T-47D, (B) MDA-
MB-453, and (C) GAR15-13 in vitro and in vivo breast cancer models, respectively. (D-F) Bar 
graphs representing the effect of AR knock-down and GATA3 knock-down on mRNA 
expression level of the EHF, AQP3, and KDM4B luminal gene markers in DHT-treated cells 
compared to control cells in T-47D, MDA-MB-453. Two-way ANOVA with Tukey's multiple 
comparisons test was used to determine statistically significant differences in D, E and F. 
Data shown as mean ± SD of 3 replicates and are representative of two independent 
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Supplementary figures  
Supplementary 1: GATA3 is a novel AR interacting protein in breast cancer cells 
Description Cell line Replicates ΣCoverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs
rep1 31.52 1 19 19 142
rep2 34.13 1 20 20 162
rep3 29.35 1 18 18 115
rep1 20.54 1 9 9 32
rep2 15.00 1 9 9 34
rep3 16.74 1 11 11 41
rep1 34.67 1 21 21 187
rep2 2.50 1 1 1 2
rep3 31.30 1 19 19 157
rep1 28.48 1 18 18 115
rep2 32.07 1 20 20 156

















Query Cover E value Per. Ident Organism
100% 2.00E-11 100.00% Homo sapiens(taxid:9606)
100% 3.00E-05 100.00% Homo sapiens(taxid:9606)
100% 4.00E-06 100.00% Homo sapiens(taxid:9606)
100% 4.00E-13 100.00% Homo sapiens(taxid:9606)
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Supplementary-1: GATA3 is a novel AR interacting protein in breast cancer cells. (A) AR 
was identified in 3/3 independent biological replicates in the AR RIME results of all the in 
vitro breast cancer models, highlighting the specificity of the RIME experiments. (B) Four 
unique GATA3 peptides were consistently identified in AR RIME data across all the breast 
cancer cell lines. Each unique sequence was blasted for the whole protein dataset of 
UniProtKB/Swiss (swissprot) database. Only peptides with 90-100 % identity, 90-100 % 
coverage and the E-value of 0-1e-2 were included as a confirmed unique peptide for the 
homo sapiens GATA3 protein. (C) The FASTA format of amino-acid sequence of GATA3 
protein is shown according to the UniProtKB/Swiss(swissprot) database. Image shows the 
location of each of the 4 unique peptides listed in B along the GATA3 protein sequence, 















Supplementary-2: Validation of the AR and GATA3 interactions in breast cancer. (A) 
Representative confocal images showing AR-GATA3 interactions in the presence or 
absence of DHT treatment in ZR-75-1 and MFM-223 breast cancer cells. The negative PLA 
control represents an assay performed without the secondary antibody. Bar graphs 
showing the total number of foci per 300 counted nuclei in ZR-75-1 (B) and MFM-223 (C) 
DHT-treated cells compared to the control cells. (D) Bar graphs representing AR-GATA3 
interactions in DHT treated cells in different time-points compared to the unstimulated 
cells. Two-way ANOVA with Student’s t-test was used to determine statistically significant 
differences in B, C and D. Data shown as mean ± SEM of 5 replicates and are representative 
of two independent experiment; ** p=0.001, and **** p<0.0001. (E) Western blot showing 
GATA3 immunoprecipitation in ER+ breast cancer cells, without AR detection in association 
with GATA3 protein. IgG served as a negative control in both assays. (F) Western blotting 
displaying the protein expression levels of AR, ER, and GATA3 in ER+ and ER- breast cancer 
cell lines. (G) Bar chart showing the quantification of total foci in malignant (ER+ n=2 and 
ER- n=2) and non-malignant (n=2) breast cancer tissues. Two-way ANOVA with Tukey's 
multiple comparisons test was used to determine statistically significant differences in G. 
Data shown as mean ± SEM of 3 replicates and are representative of one independent 




Supplementary 3: AR and GATA3 interactions occur in both nucleus and cytoplasm of 








Supplementary-3: AR and GATA3 interactions occur in both nucleus and cytoplasm of the 
breast cells, and estrogen treatment caused moderate GATA3 nuclear translocation. 
(A) Bar charts showing the quantification of nuclear and cytosolic interactions of AR and 
GATA3 in DHT-treated breast cancer cells compared with vehicle treated cells across 4 
breast cancer cell lines. Two-way ANOVA with Student’s t-test was conducted to determine 
statistically significant differences in A. Data shown as mean ± SEM of 5 replicates and are 
representative of two independent experiment; **** p<0.0001. (B) Nuclear and cytosolic 
foci are detected in both normal and malignant ER+ and ER- breast tissues through the PLA 
technique. Representative images of dual IF experiment showing a moderate effect of E2 
on AR and GATA3 nuclear translocation in (C) T-47D and (D) ZR-75-1 breast cancer cells. 












Supplementary-4: Validation of AR and GATA3 expression in GAR15-13 and HCI-005 PDX 
models. (A,B) Immunohistochemistry images representing the positivity of AR and GATA3 
expression in GAR15-13 and (C,D) HCI-005 PDXs in vehicle and AR agonist–treated tissues. 
Images are representative of n=3 independent tissues of AR agonist-treated and n=3 













Supplementary-5: AR activation is the major source of variation in GATA3 ChIP-seq 
datasets. (A-F) Principle component analysis (PCA) clustering the AR agonist-treated cells 
away from the vehicle-treated cells across all the breast cancer models, characterizing the 
trends exhibited by the AR agonists compared with the vehicle treated cells in each model. 
Red, yellow, and green colours representing three replicates of vehicle-treated samples, 
however, light and dark blue and purple representing 3 replicates of DHT/SARM-treated 




Supplementary 6: AR agonism caused significant enrichment of new GATA3 binding sites 








Supplementary-6: AR agonism caused significant enrichment of new GATA3 binding sites 
across all the in vitro and in vivo breast cancer models. Volcano plots (A-F) showing the 
differentially enriched and depleted GATA3 binding sites (FDR ≤ 0.05) upon AR activation 
across all the in vitro and in vivo breast cancer models. The purple dots represent peaks 
that did not undergo a significant change (FDR ≥ 0.05) with AR activation. The pink dots 




Supplementary 7: Distribution of AR and GATA3 ChIP-seq data upon AR activation in 










Supplementary-7: Distribution of AR and GATA3 ChIP-seq data upon AR activation in 
breast cancer cells. Two-factor MA plots representing distribution of the AR and GATA3 
cistromes upon AR activation in (A) ZR-75-1 and (B) MFM-223 in vitro models and the (C) 
HCI-005 in vivo model. Peaks are represented by coloured dots and classified into 5 
different sub-groups: Orange and grey dots represent GATA3 and AR binding sites that do 
not overlap with the other factor, respectively; blue dots represent AR agonist-induced 
GATA3 peaks that are not shared with AR; green dots represent AR-GATA3 overlapping 
peaks that GATA3 peaks are not gained with AR agonist; and red dots represent AR-GATA3 
peaks that are significantly gained upon AR activation. Example loci associated with AR 
target genes (ZBTB16, C1orf116, SE3C14L2, RANBP3L) are highlighted in black dots and 
selected from the AR-GATA3 peaks that are induced by AR agonist in each model. Venn 
diagrams represent the overlap of AR agonist-induced binding sites of AR with the 
differentially enriched GATA3 binding events upon AR activation across the in vitro (D-G) 
and iv vivo (H and I) breast cancer models. (J) Motif analysis of AR agonist-induced GATA3 



















Supplementary-8: Replicate concordance for GATA3, AR, and H3K27ac ChIP-seq 
experiments. Venn diagrams represent the concordance of the 3 biological replicates of 
each vehicle and DHT treated GATA3 ChIP-seq experiment in two ER+ (ZR-75-1 and T-47D) 
and two ER- (MFM-223 and MDA-MB-453) breast cancer in vitro cells (A), as well as 2 
ER+/AR+/GATA3+ GAR15-13, and HCI-005 in vivo PDX models (B). All the in vitro models 
were treated (DHT vs Vehicle) for 4 hours before cross-linking and harvest. The PDX models 
were treated for 5 days before getting processed for ChIP-seq experiments. (C) Venn 
diagrams show the concordance of 3 biological replicates of vehicle and DHT-treated cells 
(4 hours) for AR and H3K27ac ChIP-seq experiments in two ER- (MFM-223 and MDA-MB-
453) breast cancer cell line models. Three replicates of each ChIP-seq experiment are 











Supplementary-9: H3K27ac enrichment at AR-GATA3 binding events upon AR activation. 
Heatmaps depict increased H3K27ac ChIP-seq signals at the AR agonist-induced AR-GATA3 
cis-regulatory elements in (A) ZR-75-1 (ER+ breast cancer cell line), (B) MFM-223 (ER- 
breast cancer cell line), and the (C) HCI-005 ER+/AR+/GATA+ PDX model. Indicative of the 
transcriptionally active state of the chromatin at those specific DHT-induced AR-GATA3 loci 




Supplementary 10: Differentially up- and down-regulated genes associated with AR 












ZR-75-1 3,596 4,038 1,217 932
MFM-223 4,879 5,418 1,645 1,409








Supplementary-10: Differentially up- and down-regulated genes associated with AR 
agonist-induced AR-GATA3 peaks in breast cancer models. (A) Table showing the number 
of AR agonist-induced AR-GATA3 binding sites and their associated genes within a100 kb 
window from the TSS that are differentially up- or down-regulated in ZR-75-1, MFM-223 
cells and HCI-005 PDX breast cancer models. (B-G) Volcano plots showing genes that are 
up- or down-regulated in response to an AR agonist in each of in vitro and in vivo breast 
cancer models. Red dots represent genes that are significantly (FDR ≤ 0.05) up- or down-
regulated after AR activation, and grey dots represent genes not significantly changed 




Supplementary 11: Biological pathways associated with the differentially expressed AR-








Supplementary-11: Biological pathways associated with differentially expressed AR-
GATA3 gene targets in breast cancer in vitro and in vivo models. Bar graph showing GO 
(gene ontology) pathway analysis showing significantly enriched biological pathways 
associated with AR-GATA3 differentially expressed gene targets in (A) ZR-75-1, (B) MFM-




Supplementary 12: Gene set enrichment analysis (GSEA) of AR-GATA3 gene targets in 
breast cancer 
C)
Up-regulated pathways by Enobosarm in GAR15-13 PDX
Down-regulated pathways by
Enobosarm in GAR15-13 PDX
A) B)






Supplementary-12: Gene set enrichment analysis (GSEA) of AR-GATA3 targets in breast 
cancer. GSEA plots representing the up-regulated and down -regulated hallmarks associated with 
the AR-GATA3 up- and down-regulated targets in (A) T-47D, (B) MDA-MB-453, and (C) GAR15-13 




Supplementary 13: AR knock-down significantly suppressed the expression of AR target 







Supplementary-13: AR knock-down significantly ablated DHT-induced expression of AR 
target genes but did not affect level of GATA3 protein expression in breast cancer cells. 
(A) Bar graphs show the effect of AR silencing on mRNA expression levels of SEC14L2, 
C1orf116, and ZBTB16 genes in DHT-treated cells (6 hours) compared with vehicle-treated 
T-47D and MDA-MB-453 breast cancer cell line models. Two-way ANOVA with Tukey's 
multiple comparisons test was conducted to determine statistically significant differences 
in A. Data shown as mean ± SD of 3 replicates and are representative of three independent 
experiments; **** p<0.0001. (B) Immunoblotting images show the efficacy of AR knock-
down in three independent biological replicate experiments in which cells were 
transfected with one of two different siRNAs specific for AR compared with the non-
targeting siControl in T-47D (top) and MDA-MB-453 (bottom) breast cancer cell line 
models. After 2 days of siRNA treatment, cells were treated with DHT or vehicle for 4 hours 
prior to harvest. Both blots were stained for GAPDH as a control for protein loading. (C) 
Bar graphs showing quantification of AR and GATA3 specific bands in Western blots shown 
in (B). Each band is normalized to its respective GAPDH band as well as its corresponding 
treatment control. Two-way ANOVA with Student’s t-test was conducted to determine 
statistically significant differences in C. Data shown as mean ± SD of 2 replicates (3rd 
replicate is removed from the stats of both blots due to the unusual variation compared 





Supplementary 14: GATA3 knock-down significantly reduced the expression of AR target 







Supplementary-14: GATA3 knock-down significantly reduced expression of AR target 
genes but did not affect AR protein expression level in breast cancer cells. (A) Bar graphs 
show the effect of GATA3 silencing on the mRNA expression level of SEC14L2, C1orf116, 
and ZBTB16 AR target genes in DHT-treated cells (6 hours) compared with vehicle-treated 
cells of T-47D and MDA-MB-453 breast cancer models. Two-way ANOVA with Tukey's 
multiple comparisons test was conducted to determine statistically significant differences 
in A. Data shown as mean ± SD of 3 replicates and are representative of three independent 
experiments; * p=0.001, ** p<0.01, *** p<0.001, and **** p<0.0001. (B) Immunoblotting 
images show the efficacy of GATA3 knock-down in three independent biological replicate 
experiments in which cells were transfected with one of two different siRNAs against 
GATA3 compared with the siControl transfected cells in T-47D and MDA-MB-453 breast 
cancer models. Cells were transfected for 2 days then treated with DHT vs Vehicle for 4 
hours prior to harvest. Both blots were stained for GAPDH as a control for protein loading. 
(C) Bar graphs represent quantification of western blot results shown in (B). Each band of 
interest is normalized to its corresponding GAPDH band and also the relative treatment 
control. Two-way ANOVA with Student’s t-test was conducted to determine statistically 
significant differences in C. Data shown as mean ± SD of 2 replicates (3rd replicate is 
removed from the stats of both blots due to the un-usual variation compared with the first 




Supplementary 15: AR agonist-induced AR-GATA3 loci are associated with lineage-







Supplementary-15: AR agonist-induced AR-GATA3 co-occupied genomic loci are 
associated with lineage-restricted genes in breast cancer in vitro and in vivo models. 
Heatmaps representing up- and down-regulated luminal and basal AR-GATA3 gene targets 
upon AR activation in (A) ZR-75-1, (B) MFM-223, and (C) HCI-005 in vitro and in vivo breast 
cancer models, respectively. Up-set plots showing the total number of (D) up-regulated 
luminal genes and (E) down-regulated basal genes in each of in vitro and in vivo models, 




Supplementary 16: GATA3 and AR binding at loci associated with regulation of luminal 







Supplementary-16: GATA3 and AR binding at loci associated with regulation of luminal 
epithelial genes in breast cancer cells. (A) Genome browser images showing averaged AR 
and GATA3 ChIP-seq signals at binding sites associated with luminal epithelial genes (EHF, 
AQP3, and KDM4B). Peaks represent an average signal from three independent ChIP-seq 
replicates of T-47D (top) and MDA-MB-453 (bottom) cells. (B) Bar charts showing GATA3 
ChIP-PCR results following AR knock-down at loci (represented in A) associated with 
regulation of luminal markers EHF, AQP3, and KDM4B in T-47D and MDA-MB-453 breast 
cancer cells. (C) Bar graphs representing the AR ChIP-PCR results following GATA3 knock-
down at loci (represented in A) associated with regulation of luminal markers EHF, AQP3, 
and KDM4B in T-47D and MDA-MB-453 breast cancer cells. Cells in B and C were 
transfected for 2 days before being treated with DHT or vehicle for 4 hours before 
harvesting. Two-way ANOVA with Tukey's multiple comparisons test was used to 
determine statistically significant differences in both B and C. Data shown as mean ± SD of 
3 replicates and are representative of two independent experiments; * p=0.001, ** p<0.01, 





Extended data 1: AR RIME interactome in different breast cancer cell lines 
AR interacting proteins identified by RIME in 3/3 replicates excluding IgG: 
ZR-75.1 
Accession Description 
P50548 ETS domain-containing transcription factor ERF OS=Homo sapiens GN=ERF PE=1 
SV=2 - [ERF_HUMAN] 
P13807 Glycogen [starch] synthase, muscle OS=Homo sapiens GN=GYS1 PE=1 SV=2 - 
[GYS1_HUMAN] 
P63241 Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A PE=1 
SV=2 - [IF5A1_HUMAN] 
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 OS=Homo sapiens GN=FKBP4 PE=1 
SV=3 - [FKBP4_HUMAN] 
P17275 Transcription factor jun-B OS=Homo sapiens GN=JUNB PE=1 SV=1 - 
[JUNB_HUMAN] 
P10275 Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=3 - [ANDR_HUMAN] 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - 
[K1C16_HUMAN] 
P18754 Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 PE=1 SV=1 
- [RCC1_HUMAN] 
P04075 Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 - 
[ALDOA_HUMAN] 
Q8WWM7 Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 - 
[ATX2L_HUMAN] 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 - 
[PABP1_HUMAN] 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 - 
[K2C6A_HUMAN] 
P60866 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 - 
[RS20_HUMAN] 
P98179 RNA-binding protein 3 OS=Homo sapiens GN=RBM3 PE=1 SV=1 - 
[RBM3_HUMAN] 
P84103 Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 - 
[SRSF3_HUMAN] 
Q9Y5S9 RNA-binding protein 8A OS=Homo sapiens GN=RBM8A PE=1 SV=1 - 
[RBM8A_HUMAN] 
P13010 X-ray repair cross-complementing protein 5 OS=Homo sapiens GN=XRCC5 PE=1 
SV=3 - [XRCC5_HUMAN] 
Q15366 Poly(rC)-binding protein 2 OS=Homo sapiens GN=PCBP2 PE=1 SV=1 - 
[PCBP2_HUMAN] 
P60981 Destrin OS=Homo sapiens GN=DSTN PE=1 SV=3 - [DEST_HUMAN] 
P13639 Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - [EF2_HUMAN] 
P38919 Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=4 - 
[IF4A3_HUMAN] 
P62306 Small nuclear ribonucleoprotein F OS=Homo sapiens GN=SNRPF PE=1 SV=1 - 
[RUXF_HUMAN] 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 OS=Homo sapiens 
GN=SLC9A3R1 PE=1 SV=4 - [NHRF1_HUMAN] 
183 
 
P23526 Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 - 
[SAHH_HUMAN] 
P17931 Galectin-3 OS=Homo sapiens GN=LGALS3 PE=1 SV=5 - [LEG3_HUMAN] 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - 
[K1C17_HUMAN] 
P12956 X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 - [XRCC6_HUMAN] 
Q15717 ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - [ELAV1_HUMAN] 
Q12905 Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 - 
[ILF2_HUMAN] 
P60842 Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 - 
[IF4A1_HUMAN] 
O00330 Pyruvate dehydrogenase protein X component, mitochondrial OS=Homo sapiens 
GN=PDHX PE=1 SV=3 - [ODPX_HUMAN] 
P62906 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 SV=2 - 
[RL10A_HUMAN] 
P62244 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 - 
[RS15A_HUMAN] 
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 - [THIO_HUMAN] 
P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 - 
[1433Z_HUMAN] 
Q15056 Eukaryotic translation initiation factor 4H OS=Homo sapiens GN=EIF4H PE=1 
SV=5 - [IF4H_HUMAN] 
Q99471 Prefoldin subunit 5 OS=Homo sapiens GN=PFDN5 PE=1 SV=2 - [PFD5_HUMAN] 
P21291 Cysteine and glycine-rich protein 1 OS=Homo sapiens GN=CSRP1 PE=1 SV=3 - 
[CSRP1_HUMAN] 
Q8N163 Cell cycle and apoptosis regulator protein 2 OS=Homo sapiens GN=CCAR2 PE=1 
SV=2 - [CCAR2_HUMAN] 
Q9BRA2 Thioredoxin domain-containing protein 17 OS=Homo sapiens GN=TXNDC17 PE=1 
SV=1 - [TXD17_HUMAN] 
O14497 AT-rich interactive domain-containing protein 1A OS=Homo sapiens GN=ARID1A 
PE=1 SV=3 - [ARI1A_HUMAN] 
P06753 Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 PE=1 SV=2 - 
[TPM3_HUMAN] 
Q92925 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 2 OS=Homo sapiens GN=SMARCD2 PE=1 SV=3 - 
[SMRD2_HUMAN] 
Q92922 SWI/SNF complex subunit SMARCC1 OS=Homo sapiens GN=SMARCC1 PE=1 SV=3 
- [SMRC1_HUMAN] 
Q13435 Splicing factor 3B subunit 2 OS=Homo sapiens GN=SF3B2 PE=1 SV=2 - 
[SF3B2_HUMAN] 
P52943 Cysteine-rich protein 2 OS=Homo sapiens GN=CRIP2 PE=1 SV=1 - 
[CRIP2_HUMAN] 
Q8TAQ2 SWI/SNF complex subunit SMARCC2 OS=Homo sapiens GN=SMARCC2 PE=1 SV=1 
- [SMRC2_HUMAN] 
Q15427 Splicing factor 3B subunit 4 OS=Homo sapiens GN=SF3B4 PE=1 SV=1 - 
[SF3B4_HUMAN] 




P31946 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 - 
[1433B_HUMAN] 
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 PE=1 
SV=1 - [SMD2_HUMAN] 
Q00341 Vigilin OS=Homo sapiens GN=HDLBP PE=1 SV=2 - [VIGLN_HUMAN] 
Q14498 RNA-binding protein 39 OS=Homo sapiens GN=RBM39 PE=1 SV=2 - 
[RBM39_HUMAN] 
P42766 60S ribosomal protein L35 OS=Homo sapiens GN=RPL35 PE=1 SV=2 - 
[RL35_HUMAN] 
O43390 Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR 
PE=1 SV=1 - [HNRPR_HUMAN] 
Q9BVJ7 Dual specificity protein phosphatase 23 OS=Homo sapiens GN=DUSP23 PE=1 
SV=1 - [DUS23_HUMAN] 
O60336 Mitogen-activated protein kinase-binding protein 1 OS=Homo sapiens 
GN=MAPKBP1 PE=1 SV=4 - [MABP1_HUMAN] 
Q96EP5 DAZ-associated protein 1 OS=Homo sapiens GN=DAZAP1 PE=1 SV=1 - 
[DAZP1_HUMAN] 
P02747 Complement C1q subcomponent subunit C OS=Homo sapiens GN=C1QC PE=1 
SV=3 - [C1QC_HUMAN] 
P32969 60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 - [RL9_HUMAN] 
Q09666 Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 - [AHNK_HUMAN] 
P62899 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 - 
[RL31_HUMAN] 
Q16630 Cleavage and polyadenylation specificity factor subunit 6 OS=Homo sapiens 
GN=CPSF6 PE=1 SV=2 - [CPSF6_HUMAN] 
O00512 B-cell CLL/lymphoma 9 protein OS=Homo sapiens GN=BCL9 PE=1 SV=4 - 
[BCL9_HUMAN] 
P49207 60S ribosomal protein L34 OS=Homo sapiens GN=RPL34 PE=1 SV=3 - 
[RL34_HUMAN] 
P26583 High mobility group protein B2 OS=Homo sapiens GN=HMGB2 PE=1 SV=2 - 
[HMGB2_HUMAN] 
Q3MHD2 Protein LSM12 homolog OS=Homo sapiens GN=LSM12 PE=1 SV=2 - 
[LSM12_HUMAN] 
P98175 RNA-binding protein 10 OS=Homo sapiens GN=RBM10 PE=1 SV=3 - 
[RBM10_HUMAN] 
P14625 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 - [ENPL_HUMAN] 
Q969G3 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 OS=Homo sapiens GN=SMARCE1 PE=1 SV=2 - 
[SMCE1_HUMAN] 
P50914 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 - 
[RL14_HUMAN] 
P46783 40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 - 
[RS10_HUMAN] 
Q15637 Splicing factor 1 OS=Homo sapiens GN=SF1 PE=1 SV=4 - [SF01_HUMAN] 
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 OS=Homo sapiens 
GN=CPSF7 PE=1 SV=1 - [CPSF7_HUMAN] 




Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 family member E OS=Homo 
sapiens GN=ANP32E PE=1 SV=1 - [AN32E_HUMAN] 
P78527 DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC 
PE=1 SV=3 - [PRKDC_HUMAN] 
P62913 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 - 
[RL11_HUMAN] 
P04792 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 - 
[HSPB1_HUMAN] 
Q9UHF7 Zinc finger transcription factor Trps1 OS=Homo sapiens GN=TRPS1 PE=1 SV=2 - 
[TRPS1_HUMAN] 
Q99426 Tubulin-folding cofactor B OS=Homo sapiens GN=TBCB PE=1 SV=2 - 
[TBCB_HUMAN] 
Q99496 E3 ubiquitin-protein ligase RING2 OS=Homo sapiens GN=RNF2 PE=1 SV=1 - 
[RING2_HUMAN] 
P21333 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 - [FLNA_HUMAN] 
P23771 Trans-acting T-cell-specific transcription factor GATA-3 OS=Homo sapiens 
GN=GATA3 PE=1 SV=1 - [GATA3_HUMAN] 
O15504 Nucleoporin-like protein 2 OS=Homo sapiens GN=NUPL2 PE=1 SV=1 - 
[NUPL2_HUMAN] 
P53992 Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 SV=3 - 
[SC24C_HUMAN] 
Q8N5F7 NF-kappa-B-activating protein OS=Homo sapiens GN=NKAP PE=1 SV=1 - 
[NKAP_HUMAN] 
Q66PJ3 ADP-ribosylation factor-like protein 6-interacting protein 4 OS=Homo sapiens 
GN=ARL6IP4 PE=1 SV=2 - [AR6P4_HUMAN] 
P26368 Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 - 
[U2AF2_HUMAN] 
P55072 Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 
SV=4 - [TERA_HUMAN] 
Q7Z5L9 Interferon regulatory factor 2-binding protein 2 OS=Homo sapiens GN=IRF2BP2 
PE=1 SV=2 - [I2BP2_HUMAN] 
P40763 Signal transducer and activator of transcription 3 OS=Homo sapiens GN=STAT3 
PE=1 SV=2 - [STAT3_HUMAN] 
O75131 Copine-3 OS=Homo sapiens GN=CPNE3 PE=1 SV=1 - [CPNE3_HUMAN] 
Q00796 Sorbitol dehydrogenase OS=Homo sapiens GN=SORD PE=1 SV=4 - 
[DHSO_HUMAN] 
P02452 Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 - 
[CO1A1_HUMAN] 
Q00535 Cyclin-dependent-like kinase 5 OS=Homo sapiens GN=CDK5 PE=1 SV=3 - 
[CDK5_HUMAN] 
O43143 Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo sapiens 
GN=DHX15 PE=1 SV=2 - [DHX15_HUMAN] 
Q9H6T0 Epithelial splicing regulatory protein 2 OS=Homo sapiens GN=ESRP2 PE=1 SV=1 - 
[ESRP2_HUMAN] 
O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase OS=Homo sapiens 
GN=SNRNP200 PE=1 SV=2 - [U520_HUMAN] 
O00567 Nucleolar protein 56 OS=Homo sapiens GN=NOP56 PE=1 SV=4 - 
[NOP56_HUMAN] 




P09622 Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 
SV=2 - [DLDH_HUMAN] 
P12270 Nucleoprotein TPR OS=Homo sapiens GN=TPR PE=1 SV=3 - [TPR_HUMAN] 
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 OS=Homo sapiens 
GN=HNRNPUL1 PE=1 SV=2 - [HNRL1_HUMAN] 
P49588 Alanine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=AARS PE=1 SV=2 - 
[SYAC_HUMAN] 
Q9NTZ6 RNA-binding protein 12 OS=Homo sapiens GN=RBM12 PE=1 SV=1 - 
[RBM12_HUMAN] 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=2 - 
[PRP8_HUMAN] 
Q14152 Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens GN=EIF3A 
PE=1 SV=1 - [EIF3A_HUMAN] 
P78347 General transcription factor II-I OS=Homo sapiens GN=GTF2I PE=1 SV=2 - 
[GTF2I_HUMAN] 






AR interacting proteins identified by RIME in 3/3 replicates excluding IgG: 
T-47D 
Accession Description 
P26599 Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 - 
[PTBP1_HUMAN] 
P13807 Glycogen [starch] synthase, muscle OS=Homo sapiens GN=GYS1 PE=1 SV=2 - 
[GYS1_HUMAN] 
Q8N163 Cell cycle and apoptosis regulator protein 2 OS=Homo sapiens GN=CCAR2 PE=1 
SV=2 - [CCAR2_HUMAN] 
Q12905 Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 - 
[ILF2_HUMAN] 
P11142 Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - 
[HSP7C_HUMAN] 
P60866 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 - 
[RS20_HUMAN] 
P10275 Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=3 - [ANDR_HUMAN] 
P17275 Transcription factor jun-B OS=Homo sapiens GN=JUNB PE=1 SV=1 - 
[JUNB_HUMAN] 
O00330 Pyruvate dehydrogenase protein X component, mitochondrial OS=Homo sapiens 
GN=PDHX PE=1 SV=3 - [ODPX_HUMAN] 
P50548 ETS domain-containing transcription factor ERF OS=Homo sapiens GN=ERF PE=1 
SV=2 - [ERF_HUMAN] 
P62306 Small nuclear ribonucleoprotein F OS=Homo sapiens GN=SNRPF PE=1 SV=1 - 
[RUXF_HUMAN] 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 OS=Homo sapiens 
GN=SLC9A3R1 PE=1 SV=4 - [NHRF1_HUMAN] 
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' OS=Homo sapiens 
GN=SNRPB PE=1 SV=2 - [RSMB_HUMAN] 
Q8WXF1 Paraspeckle component 1 OS=Homo sapiens GN=PSPC1 PE=1 SV=1 - 
[PSPC1_HUMAN] 
P09429 High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 - 
[HMGB1_HUMAN] 
Q16629 Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 SV=1 - 
[SRSF7_HUMAN] 
Q15637 Splicing factor 1 OS=Homo sapiens GN=SF1 PE=1 SV=4 - [SF01_HUMAN] 
O60506 Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP 
PE=1 SV=2 - [HNRPQ_HUMAN] 
P13010 X-ray repair cross-complementing protein 5 OS=Homo sapiens GN=XRCC5 PE=1 
SV=3 - [XRCC5_HUMAN] 
P42166 Lamina-associated polypeptide 2, isoform alpha OS=Homo sapiens GN=TMPO 
PE=1 SV=2 - [LAP2A_HUMAN] 
Q96PM9 Zinc finger protein 385A OS=Homo sapiens GN=ZNF385A PE=1 SV=2 - 
[Z385A_HUMAN] 
P98175 RNA-binding protein 10 OS=Homo sapiens GN=RBM10 PE=1 SV=3 - 
[RBM10_HUMAN] 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 




P0CG12 Chromosome transmission fidelity protein 8 homolog isoform 2 OS=Homo 
sapiens GN=CHTF8 PE=1 SV=1 - [CTF8A_HUMAN] 
Q6STE5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 3 OS=Homo sapiens GN=SMARCD3 PE=1 SV=1 - 
[SMRD3_HUMAN] 
P53992 Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 SV=3 - 
[SC24C_HUMAN] 
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 OS=Homo sapiens 
GN=HNRNPUL1 PE=1 SV=2 - [HNRL1_HUMAN] 
Q00341 Vigilin OS=Homo sapiens GN=HDLBP PE=1 SV=2 - [VIGLN_HUMAN] 
Q96EP5 DAZ-associated protein 1 OS=Homo sapiens GN=DAZAP1 PE=1 SV=1 - 
[DAZP1_HUMAN] 
Q14011 Cold-inducible RNA-binding protein OS=Homo sapiens GN=CIRBP PE=1 SV=1 - 
[CIRBP_HUMAN] 
O60336 Mitogen-activated protein kinase-binding protein 1 OS=Homo sapiens 
GN=MAPKBP1 PE=1 SV=4 - [MABP1_HUMAN] 
P09874 Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 - 
[PARP1_HUMAN] 
P23771 Trans-acting T-cell-specific transcription factor GATA-3 OS=Homo sapiens 
GN=GATA3 PE=1 SV=1 - [GATA3_HUMAN] 
O15504 Nucleoporin-like protein 2 OS=Homo sapiens GN=NUPL2 PE=1 SV=1 - 
[NUPL2_HUMAN] 
P49750 YLP motif-containing protein 1 OS=Homo sapiens GN=YLPM1 PE=1 SV=3 - 
[YLPM1_HUMAN] 
P22087 rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 - 
[FBRL_HUMAN] 
P12956 X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 - [XRCC6_HUMAN] 
O00148 ATP-dependent RNA helicase DDX39A OS=Homo sapiens GN=DDX39A PE=1 SV=2 
- [DX39A_HUMAN] 
Q01085 Nucleolysin TIAR OS=Homo sapiens GN=TIAL1 PE=1 SV=1 - [TIAR_HUMAN] 
O43809 Cleavage and polyadenylation specificity factor subunit 5 OS=Homo sapiens 
GN=NUDT21 PE=1 SV=1 - [CPSF5_HUMAN] 
P83731 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 - 
[RL24_HUMAN] 
Q15287 RNA-binding protein with serine-rich domain 1 OS=Homo sapiens GN=RNPS1 
PE=1 SV=1 - [RNPS1_HUMAN] 
P18754 Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 PE=1 SV=1 
- [RCC1_HUMAN] 
Q15942 Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1 - [ZYX_HUMAN] 
Q8TD19 Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2 - 
[NEK9_HUMAN] 
O00512 B-cell CLL/lymphoma 9 protein OS=Homo sapiens GN=BCL9 PE=1 SV=4 - 
[BCL9_HUMAN] 
P20073 Annexin A7 OS=Homo sapiens GN=ANXA7 PE=1 SV=3 - [ANXA7_HUMAN] 
O43143 Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo sapiens 
GN=DHX15 PE=1 SV=2 - [DHX15_HUMAN] 




Q9UBV2 Protein sel-1 homolog 1 OS=Homo sapiens GN=SEL1L PE=1 SV=3 - 
[SE1L1_HUMAN] 
Q9Y2X3 Nucleolar protein 58 OS=Homo sapiens GN=NOP58 PE=1 SV=1 - 
[NOP58_HUMAN] 
Q96T37 Putative RNA-binding protein 15 OS=Homo sapiens GN=RBM15 PE=1 SV=2 - 
[RBM15_HUMAN] 
Q9ULV4 Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 - [COR1C_HUMAN] 
Q9H0D6 5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1 - 
[XRN2_HUMAN] 
O75369 Filamin-B OS=Homo sapiens GN=FLNB PE=1 SV=2 - [FLNB_HUMAN] 
P11387 DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2 - [TOP1_HUMAN] 
Q5M775 Cytospin-B OS=Homo sapiens GN=SPECC1 PE=1 SV=1 - [CYTSB_HUMAN] 






AR interacting proteins identified by RIME in 3/3 replicates excluding IgG: 
MFM-223 
Accession Description 
P17275 Transcription factor jun-B OS=Homo sapiens GN=JUNB PE=1 SV=1 - 
[JUNB_HUMAN] 
P98179 RNA-binding protein 3 OS=Homo sapiens GN=RBM3 PE=1 SV=1 - 
[RBM3_HUMAN] 
Q12905 Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 
SV=2 - [ILF2_HUMAN] 
O00567 Nucleolar protein 56 OS=Homo sapiens GN=NOP56 PE=1 SV=4 - 
[NOP56_HUMAN] 
P07900 Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 
SV=5 - [HS90A_HUMAN] 
P62937 Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 
SV=2 - [PPIA_HUMAN] 
P10275 Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=3 - 
[ANDR_HUMAN] 
P63241 Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A 
PE=1 SV=2 - [IF5A1_HUMAN] 
Q9UKM9 RNA-binding protein Raly OS=Homo sapiens GN=RALY PE=1 SV=1 - 
[RALY_HUMAN] 
Q15717 ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - 
[ELAV1_HUMAN] 
P09874 Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 - 
[PARP1_HUMAN] 
P08238 Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 
SV=4 - [HS90B_HUMAN] 
O43809 Cleavage and polyadenylation specificity factor subunit 5 OS=Homo 
sapiens GN=NUDT21 PE=1 SV=1 - [CPSF5_HUMAN] 
P12956 X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 
PE=1 SV=2 - [XRCC6_HUMAN] 
Q8WXF1 Paraspeckle component 1 OS=Homo sapiens GN=PSPC1 PE=1 SV=1 - 
[PSPC1_HUMAN] 
P50548 ETS domain-containing transcription factor ERF OS=Homo sapiens GN=ERF 
PE=1 SV=2 - [ERF_HUMAN] 
P61956 Small ubiquitin-related modifier 2 OS=Homo sapiens GN=SUMO2 PE=1 
SV=3 - [SUMO2_HUMAN] 
Q92804 TATA-binding protein-associated factor 2N OS=Homo sapiens GN=TAF15 
PE=1 SV=1 - [RBP56_HUMAN] 
Q13263 Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 
PE=1 SV=5 - [TIF1B_HUMAN] 
P43243 Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 - [MATR3_HUMAN] 
Q92925 SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily D member 2 OS=Homo sapiens GN=SMARCD2 PE=1 
SV=3 - [SMRD2_HUMAN] 
Q8N163 Cell cycle and apoptosis regulator protein 2 OS=Homo sapiens GN=CCAR2 
PE=1 SV=2 - [CCAR2_HUMAN] 




P08621 U1 small nuclear ribonucleoprotein 70 kDa OS=Homo sapiens 
GN=SNRNP70 PE=1 SV=2 - [RU17_HUMAN] 
P09429 High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 - 
[HMGB1_HUMAN] 
P98175 RNA-binding protein 10 OS=Homo sapiens GN=RBM10 PE=1 SV=3 - 
[RBM10_HUMAN] 
P62158 Calmodulin OS=Homo sapiens GN=CALM1 PE=1 SV=2 - [CALM_HUMAN] 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 
P0CG48 Polyubiquitin-C OS=Homo sapiens GN=UBC PE=1 SV=3 - [UBC_HUMAN] 
P0C0S5 Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2 - [H2AZ_HUMAN] 
P26368 Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 
SV=4 - [U2AF2_HUMAN] 
P18754 Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 PE=1 
SV=1 - [RCC1_HUMAN] 
P55795 Heterogeneous nuclear ribonucleoprotein H2 OS=Homo sapiens 
GN=HNRNPH2 PE=1 SV=1 - [HNRH2_HUMAN] 
O43684 Mitotic checkpoint protein BUB3 OS=Homo sapiens GN=BUB3 PE=1 SV=1 - 
[BUB3_HUMAN] 
P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - 
[MYL6_HUMAN] 
Q16629 Serine/arginine-rich splicing factor 7 OS=Homo sapiens GN=SRSF7 PE=1 
SV=1 - [SRSF7_HUMAN] 
P32119 Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 - 
[PRDX2_HUMAN] 
O14979 Heterogeneous nuclear ribonucleoprotein D-like OS=Homo sapiens 
GN=HNRNPDL PE=1 SV=3 - [HNRDL_HUMAN] 
Q15942 Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1 - [ZYX_HUMAN] 
P25815 Protein S100-P OS=Homo sapiens GN=S100P PE=1 SV=2 - [S100P_HUMAN] 
Q8WWM7 Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 - 
[ATX2L_HUMAN] 
Q9Y5S9 RNA-binding protein 8A OS=Homo sapiens GN=RBM8A PE=1 SV=1 - 
[RBM8A_HUMAN] 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
P68032 Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 SV=1 - 
[ACTC_HUMAN] 
Q96I24 Far upstream element-binding protein 3 OS=Homo sapiens GN=FUBP3 
PE=1 SV=2 - [FUBP3_HUMAN] 
P62995 Transformer-2 protein homolog beta OS=Homo sapiens GN=TRA2B PE=1 
SV=1 - [TRA2B_HUMAN] 
P23526 Adenosylhomocysteinase OS=Homo sapiens GN=AHCY PE=1 SV=4 - 
[SAHH_HUMAN] 
Q9UBV2 Protein sel-1 homolog 1 OS=Homo sapiens GN=SEL1L PE=1 SV=3 - 
[SE1L1_HUMAN] 
Q99829 Copine-1 OS=Homo sapiens GN=CPNE1 PE=1 SV=1 - [CPNE1_HUMAN] 
O75494 Serine/arginine-rich splicing factor 10 OS=Homo sapiens GN=SRSF10 PE=1 
SV=1 - [SRS10_HUMAN] 




P63104 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 - 
[1433Z_HUMAN] 
P30050 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 - 
[RL12_HUMAN] 
P62316 Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 
PE=1 SV=1 - [SMD2_HUMAN] 
P62249 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 - 
[RS16_HUMAN] 
Q13162 Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 PE=1 SV=1 - 
[PRDX4_HUMAN] 
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 OS=Homo 
sapiens GN=CPSF7 PE=1 SV=1 - [CPSF7_HUMAN] 
Q969G3 SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily E member 1 OS=Homo sapiens GN=SMARCE1 PE=1 
SV=2 - [SMCE1_HUMAN] 
O00512 B-cell CLL/lymphoma 9 protein OS=Homo sapiens GN=BCL9 PE=1 SV=4 - 
[BCL9_HUMAN] 
O14497 AT-rich interactive domain-containing protein 1A OS=Homo sapiens 
GN=ARID1A PE=1 SV=3 - [ARI1A_HUMAN] 
P42167 Lamina-associated polypeptide 2, isoforms beta/gamma OS=Homo sapiens 
GN=TMPO PE=1 SV=2 - [LAP2B_HUMAN] 
Q8WVV9 Heterogeneous nuclear ribonucleoprotein L-like OS=Homo sapiens 
GN=HNRNPLL PE=1 SV=1 - [HNRLL_HUMAN] 
P53992 Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 
SV=3 - [SC24C_HUMAN] 
Q6NXG1 Epithelial splicing regulatory protein 1 OS=Homo sapiens GN=ESRP1 PE=1 
SV=2 - [ESRP1_HUMAN] 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 
- [PABP1_HUMAN] 
Q9ULV4 Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 SV=1 - [COR1C_HUMAN] 
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' OS=Homo 
sapiens GN=SNRPB PE=1 SV=2 - [RSMB_HUMAN] 
Q16630 Cleavage and polyadenylation specificity factor subunit 6 OS=Homo 
sapiens GN=CPSF6 PE=1 SV=2 - [CPSF6_HUMAN] 
P62826 GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 - 
[RAN_HUMAN] 
O60506 Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens 
GN=SYNCRIP PE=1 SV=2 - [HNRPQ_HUMAN] 
Q13151 Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens 
GN=HNRNPA0 PE=1 SV=1 - [ROA0_HUMAN] 
Q6NVV1 Putative 60S ribosomal protein L13a protein RPL13AP3 OS=Homo sapiens 
GN=RPL13AP3 PE=5 SV=1 - [R13P3_HUMAN] 
P09012 U1 small nuclear ribonucleoprotein A OS=Homo sapiens GN=SNRPA PE=1 
SV=3 - [SNRPA_HUMAN] 
Q8NAV1 Pre-mRNA-splicing factor 38A OS=Homo sapiens GN=PRPF38A PE=1 SV=1 - 
[PR38A_HUMAN] 
Q96EP5 DAZ-associated protein 1 OS=Homo sapiens GN=DAZAP1 PE=1 SV=1 - 
[DAZP1_HUMAN] 




P20073 Annexin A7 OS=Homo sapiens GN=ANXA7 PE=1 SV=3 - [ANXA7_HUMAN] 
P60866 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 - 
[RS20_HUMAN] 
Q00341 Vigilin OS=Homo sapiens GN=HDLBP PE=1 SV=2 - [VIGLN_HUMAN] 
O75340 Programmed cell death protein 6 OS=Homo sapiens GN=PDCD6 PE=1 SV=1 
- [PDCD6_HUMAN] 
P46734 Dual specificity mitogen-activated protein kinase kinase 3 OS=Homo 
sapiens GN=MAP2K3 PE=1 SV=2 - [MP2K3_HUMAN] 
P49750 YLP motif-containing protein 1 OS=Homo sapiens GN=YLPM1 PE=1 SV=3 - 
[YLPM1_HUMAN] 
P18206 Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 - [VINC_HUMAN] 
Q06830 Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - 
[PRDX1_HUMAN] 
P36578 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 - 
[RL4_HUMAN] 
Q15427 Splicing factor 3B subunit 4 OS=Homo sapiens GN=SF3B4 PE=1 SV=1 - 
[SF3B4_HUMAN] 
P12532 Creatine kinase U-type, mitochondrial OS=Homo sapiens GN=CKMT1A 
PE=1 SV=1 - [KCRU_HUMAN] 
P0DMV9;P08107 Heat shock 70 kDa protein 1B OS=Homo sapiens GN=HSPA1B PE=1 SV=1 - 
[HS71B_HUMAN] 
P46781 40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 - 
[RS9_HUMAN] 
P23771 Trans-acting T-cell-specific transcription factor GATA-3 OS=Homo sapiens 
GN=GATA3 PE=1 SV=1 - [GATA3_HUMAN] 
P62318 Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 
PE=1 SV=1 - [SMD3_HUMAN] 
Q15287 RNA-binding protein with serine-rich domain 1 OS=Homo sapiens 
GN=RNPS1 PE=1 SV=1 - [RNPS1_HUMAN] 
P62899 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 - 
[RL31_HUMAN] 
P62244 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 - 
[RS15A_HUMAN] 
P49207 60S ribosomal protein L34 OS=Homo sapiens GN=RPL34 PE=1 SV=3 - 
[RL34_HUMAN] 
Q99986 Serine/threonine-protein kinase VRK1 OS=Homo sapiens GN=VRK1 PE=1 
SV=1 - [VRK1_HUMAN] 
P45973 Chromobox protein homolog 5 OS=Homo sapiens GN=CBX5 PE=1 SV=1 - 
[CBX5_HUMAN] 
Q14011 Cold-inducible RNA-binding protein OS=Homo sapiens GN=CIRBP PE=1 
SV=1 - [CIRBP_HUMAN] 
P26373 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 - 
[RL13_HUMAN] 
P62829 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 - 
[RL23_HUMAN] 
P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - 
[RINI_HUMAN] 
Q15637 Splicing factor 1 OS=Homo sapiens GN=SF1 PE=1 SV=4 - [SF01_HUMAN] 




Q8TAQ2 SWI/SNF complex subunit SMARCC2 OS=Homo sapiens GN=SMARCC2 
PE=1 SV=1 - [SMRC2_HUMAN] 
Q01085 Nucleolysin TIAR OS=Homo sapiens GN=TIAL1 PE=1 SV=1 - [TIAR_HUMAN] 
O60336 Mitogen-activated protein kinase-binding protein 1 OS=Homo sapiens 
GN=MAPKBP1 PE=1 SV=4 - [MABP1_HUMAN] 
O15504 Nucleoporin-like protein 2 OS=Homo sapiens GN=NUPL2 PE=1 SV=1 - 
[NUPL2_HUMAN] 
P83731 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 - 
[RL24_HUMAN] 
Q5JTV8 Torsin-1A-interacting protein 1 OS=Homo sapiens GN=TOR1AIP1 PE=1 
SV=2 - [TOIP1_HUMAN] 
Q9UHF7 Zinc finger transcription factor Trps1 OS=Homo sapiens GN=TRPS1 PE=1 
SV=2 - [TRPS1_HUMAN] 
Q9NY12 H/ACA ribonucleoprotein complex subunit 1 OS=Homo sapiens GN=GAR1 
PE=1 SV=1 - [GAR1_HUMAN] 
Q14978 Nucleolar and coiled-body phosphoprotein 1 OS=Homo sapiens 
GN=NOLC1 PE=1 SV=2 - [NOLC1_HUMAN] 
Q01130 Serine/arginine-rich splicing factor 2 OS=Homo sapiens GN=SRSF2 PE=1 
SV=4 - [SRSF2_HUMAN] 
Q09666 Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 - [AHNK_HUMAN] 
O00330 Pyruvate dehydrogenase protein X component, mitochondrial OS=Homo 
sapiens GN=PDHX PE=1 SV=3 - [ODPX_HUMAN] 
Q96KR1 Zinc finger RNA-binding protein OS=Homo sapiens GN=ZFR PE=1 SV=2 - 
[ZFR_HUMAN] 
O15042 U2 snRNP-associated SURP motif-containing protein OS=Homo sapiens 
GN=U2SURP PE=1 SV=2 - [SR140_HUMAN] 
O43823 A-kinase anchor protein 8 OS=Homo sapiens GN=AKAP8 PE=1 SV=1 - 
[AKAP8_HUMAN] 
Q92499 ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 
SV=2 - [DDX1_HUMAN] 
Q14152 Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens 
GN=EIF3A PE=1 SV=1 - [EIF3A_HUMAN] 
Q9NR30 Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 - 
[DDX21_HUMAN] 
O76021 Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 
PE=1 SV=3 - [RL1D1_HUMAN] 
Q9NWB6 Arginine and glutamate-rich protein 1 OS=Homo sapiens GN=ARGLU1 
PE=1 SV=1 - [ARGL1_HUMAN] 
Q9ULJ6 Zinc finger MIZ domain-containing protein 1 OS=Homo sapiens GN=ZMIZ1 
PE=1 SV=3 - [ZMIZ1_HUMAN] 
Q5BKZ1 DBIRD complex subunit ZNF326 OS=Homo sapiens GN=ZNF326 PE=1 SV=2 
- [ZN326_HUMAN] 
P0CG12 Chromosome transmission fidelity protein 8 homolog isoform 2 OS=Homo 
sapiens GN=CHTF8 PE=1 SV=1 - [CTF8A_HUMAN] 
P04196 Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 - 
[HRG_HUMAN] 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 
SV=2 - [PRP8_HUMAN] 
195 
 
P43246 DNA mismatch repair protein Msh2 OS=Homo sapiens GN=MSH2 PE=1 
SV=1 - [MSH2_HUMAN] 





AR interacting proteins identified by RIME in 3/3 replicates excluding IgG: 
MDA-MB-453 
Accession Description 
P07355 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 - [ANXA2_HUMAN] 
P32322 Pyrroline-5-carboxylate reductase 1, mitochondrial OS=Homo sapiens GN=PYCR1 
PE=1 SV=2 - [P5CR1_HUMAN] 
Q92925 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 2 OS=Homo sapiens GN=SMARCD2 PE=1 SV=3 - 
[SMRD2_HUMAN] 
P17275 Transcription factor jun-B OS=Homo sapiens GN=JUNB PE=1 SV=1 - 
[JUNB_HUMAN] 
P10275 Androgen receptor OS=Homo sapiens GN=AR PE=1 SV=3 - [ANDR_HUMAN] 
P05204 Non-histone chromosomal protein HMG-17 OS=Homo sapiens GN=HMGN2 PE=1 
SV=3 - [HMGN2_HUMAN] 
Q15717 ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - [ELAV1_HUMAN] 
Q969G3 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 OS=Homo sapiens GN=SMARCE1 PE=1 SV=2 - 
[SMCE1_HUMAN] 
P63241 Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A PE=1 
SV=2 - [IF5A1_HUMAN] 
P10515 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial OS=Homo sapiens GN=DLAT PE=1 SV=3 - 
[ODP2_HUMAN] 
P11177 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Homo 
sapiens GN=PDHB PE=1 SV=3 - [ODPB_HUMAN] 
P39019 40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 - 
[RS19_HUMAN] 
P49773 Histidine triad nucleotide-binding protein 1 OS=Homo sapiens GN=HINT1 PE=1 
SV=2 - [HINT1_HUMAN] 
P08559 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial OS=Homo sapiens GN=PDHA1 PE=1 SV=3 - [ODPA_HUMAN] 
Q9H3K6 BolA-like protein 2 OS=Homo sapiens GN=BOLA2 PE=1 SV=1 - [BOLA2_HUMAN] 
P50548 ETS domain-containing transcription factor ERF OS=Homo sapiens GN=ERF PE=1 
SV=2 - [ERF_HUMAN] 
P13807 Glycogen [starch] synthase, muscle OS=Homo sapiens GN=GYS1 PE=1 SV=2 - 
[GYS1_HUMAN] 
P62857 40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 SV=1 - 
[RS28_HUMAN] 
O00330 Pyruvate dehydrogenase protein X component, mitochondrial OS=Homo sapiens 
GN=PDHX PE=1 SV=3 - [ODPX_HUMAN] 
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 OS=Homo sapiens GN=FKBP4 PE=1 
SV=3 - [FKBP4_HUMAN] 
Q8TAQ2 SWI/SNF complex subunit SMARCC2 OS=Homo sapiens GN=SMARCC2 PE=1 SV=1 
- [SMRC2_HUMAN] 
Q16401 26S proteasome non-ATPase regulatory subunit 5 OS=Homo sapiens GN=PSMD5 
PE=1 SV=3 - [PSMD5_HUMAN] 
O96019 Actin-like protein 6A OS=Homo sapiens GN=ACTL6A PE=1 SV=1 - 
[ACL6A_HUMAN] 




Q96AE4 Far upstream element-binding protein 1 OS=Homo sapiens GN=FUBP1 PE=1 
SV=3 - [FUBP1_HUMAN] 
Q92481 Transcription factor AP-2-beta OS=Homo sapiens GN=TFAP2B PE=1 SV=2 - 
[AP2B_HUMAN] 
P63165 Small ubiquitin-related modifier 1 OS=Homo sapiens GN=SUMO1 PE=1 SV=1 - 
[SUMO1_HUMAN] 
P10768 S-formylglutathione hydrolase OS=Homo sapiens GN=ESD PE=1 SV=2 - 
[ESTD_HUMAN] 
Q96EP5 DAZ-associated protein 1 OS=Homo sapiens GN=DAZAP1 PE=1 SV=1 - 
[DAZP1_HUMAN] 
P48047 ATP synthase subunit O, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 
- [ATPO_HUMAN] 
P36776 Lon protease homolog, mitochondrial OS=Homo sapiens GN=LONP1 PE=1 SV=2 - 
[LONM_HUMAN] 
Q96DG6 Carboxymethylenebutenolidase homolog OS=Homo sapiens GN=CMBL PE=1 
SV=1 - [CMBL_HUMAN] 
O14979 Heterogeneous nuclear ribonucleoprotein D-like OS=Homo sapiens 
GN=HNRNPDL PE=1 SV=3 - [HNRDL_HUMAN] 
P62888 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 - 
[RL30_HUMAN] 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial OS=Homo sapiens GN=DLD PE=1 
SV=2 - [DLDH_HUMAN] 
Q92785 Zinc finger protein ubi-d4 OS=Homo sapiens GN=DPF2 PE=1 SV=2 - 
[REQU_HUMAN] 
Q9H0D6 5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1 - 
[XRN2_HUMAN] 
P23193 Transcription elongation factor A protein 1 OS=Homo sapiens GN=TCEA1 PE=1 
SV=2 - [TCEA1_HUMAN] 
P42166 Lamina-associated polypeptide 2, isoform alpha OS=Homo sapiens GN=TMPO 
PE=1 SV=2 - [LAP2A_HUMAN] 
Q96C36 Pyrroline-5-carboxylate reductase 2 OS=Homo sapiens GN=PYCR2 PE=1 SV=1 - 
[P5CR2_HUMAN] 
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit OS=Homo 
sapiens GN=PPP1CA PE=1 SV=1 - [PP1A_HUMAN] 
Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 OS=Homo sapiens 
GN=HNRNPUL2 PE=1 SV=1 - [HNRL2_HUMAN] 
P11940 Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 - 
[PABP1_HUMAN] 
Q99873 Protein arginine N-methyltransferase 1 OS=Homo sapiens GN=PRMT1 PE=1 SV=2 
- [ANM1_HUMAN] 
Q13363 C-terminal-binding protein 1 OS=Homo sapiens GN=CTBP1 PE=1 SV=2 - 
[CTBP1_HUMAN] 
O14497 AT-rich interactive domain-containing protein 1A OS=Homo sapiens GN=ARID1A 
PE=1 SV=3 - [ARI1A_HUMAN] 
Q9BZK7 F-box-like/WD repeat-containing protein TBL1XR1 OS=Homo sapiens 
GN=TBL1XR1 PE=1 SV=1 - [TBL1R_HUMAN] 
P00568 Adenylate kinase isoenzyme 1 OS=Homo sapiens GN=AK1 PE=1 SV=3 - 
[KAD1_HUMAN] 
Q13765 Nascent polypeptide-associated complex subunit alpha OS=Homo sapiens 
GN=NACA PE=1 SV=1 - [NACA_HUMAN] 
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P23771 Trans-acting T-cell-specific transcription factor GATA-3 OS=Homo sapiens 
GN=GATA3 PE=1 SV=1 - [GATA3_HUMAN] 
P27635 60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 - 
[RL10_HUMAN] 
Q92922 SWI/SNF complex subunit SMARCC1 OS=Homo sapiens GN=SMARCC1 PE=1 SV=3 
- [SMRC1_HUMAN] 
O15347 High mobility group protein B3 OS=Homo sapiens GN=HMGB3 PE=1 SV=4 - 
[HMGB3_HUMAN] 
P51531 Probable global transcription activator SNF2L2 OS=Homo sapiens GN=SMARCA2 
PE=1 SV=2 - [SMCA2_HUMAN] 
Q13310 Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 SV=1 - 
[PABP4_HUMAN] 
Q9UHF7 Zinc finger transcription factor Trps1 OS=Homo sapiens GN=TRPS1 PE=1 SV=2 - 
[TRPS1_HUMAN] 
P51532 Transcription activator BRG1 OS=Homo sapiens GN=SMARCA4 PE=1 SV=2 - 
[SMCA4_HUMAN] 
Q99829 Copine-1 OS=Homo sapiens GN=CPNE1 PE=1 SV=1 - [CPNE1_HUMAN] 
Q9BVJ7 Dual specificity protein phosphatase 23 OS=Homo sapiens GN=DUSP23 PE=1 
SV=1 - [DUS23_HUMAN] 
Q16543 Hsp90 co-chaperone Cdc37 OS=Homo sapiens GN=CDC37 PE=1 SV=1 - 
[CDC37_HUMAN] 
O43447 Peptidyl-prolyl cis-trans isomerase H OS=Homo sapiens GN=PPIH PE=1 SV=1 - 
[PPIH_HUMAN] 
P61081 NEDD8-conjugating enzyme Ubc12 OS=Homo sapiens GN=UBE2M PE=1 SV=1 - 
[UBC12_HUMAN] 
P18615 Negative elongation factor E OS=Homo sapiens GN=NELFE PE=1 SV=3 - 
[NELFE_HUMAN] 
Q01105 Protein SET OS=Homo sapiens GN=SET PE=1 SV=3 - [SET_HUMAN] 
O60884 DnaJ homolog subfamily A member 2 OS=Homo sapiens GN=DNAJA2 PE=1 SV=1 
- [DNJA2_HUMAN] 
P05388 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 - 
[RLA0_HUMAN] 
Q8WWM7 Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 - 
[ATX2L_HUMAN] 
O94776 Metastasis-associated protein MTA2 OS=Homo sapiens GN=MTA2 PE=1 SV=1 - 
[MTA2_HUMAN] 
P63244 Receptor of activated protein C kinase 1 OS=Homo sapiens GN=RACK1 PE=1 
SV=3 - [RACK1_HUMAN] 
Q9NTK5 Obg-like ATPase 1 OS=Homo sapiens GN=OLA1 PE=1 SV=2 - [OLA1_HUMAN] 
P55317 Hepatocyte nuclear factor 3-alpha OS=Homo sapiens GN=FOXA1 PE=1 SV=2 - 
[FOXA1_HUMAN] 
O95861 3'(2'),5'-bisphosphate nucleotidase 1 OS=Homo sapiens GN=BPNT1 PE=1 SV=1 - 
[BPNT1_HUMAN] 
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 OS=Homo sapiens 
GN=CPSF7 PE=1 SV=1 - [CPSF7_HUMAN] 
Q12824 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily B member 1 OS=Homo sapiens GN=SMARCB1 PE=1 SV=2 - 
[SNF5_HUMAN] 
Q99623 Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 - [PHB2_HUMAN] 
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Q9Y266 Nuclear migration protein nudC OS=Homo sapiens GN=NUDC PE=1 SV=1 - 
[NUDC_HUMAN] 
O95232 Luc7-like protein 3 OS=Homo sapiens GN=LUC7L3 PE=1 SV=2 - [LC7L3_HUMAN] 
Q9UHD8 Septin-9 OS=Homo sapiens GN=SEPT9 PE=1 SV=2 - [SEPT9_HUMAN] 
P49750 YLP motif-containing protein 1 OS=Homo sapiens GN=YLPM1 PE=1 SV=3 - 
[YLPM1_HUMAN] 
Q9Y678 Coatomer subunit gamma-1 OS=Homo sapiens GN=COPG1 PE=1 SV=1 - 
[COPG1_HUMAN] 
Q96JK9 Mastermind-like protein 3 OS=Homo sapiens GN=MAML3 PE=1 SV=4 - 
[MAML3_HUMAN] 
O96013 Serine/threonine-protein kinase PAK 4 OS=Homo sapiens GN=PAK4 PE=1 SV=1 - 
[PAK4_HUMAN] 
Q96FW1 Ubiquitin thioesterase OTUB1 OS=Homo sapiens GN=OTUB1 PE=1 SV=2 - 
[OTUB1_HUMAN] 
P27694 Replication protein A 70 kDa DNA-binding subunit OS=Homo sapiens GN=RPA1 
PE=1 SV=2 - [RFA1_HUMAN] 
P78347 General transcription factor II-I OS=Homo sapiens GN=GTF2I PE=1 SV=2 - 
[GTF2I_HUMAN] 
P98175 RNA-binding protein 10 OS=Homo sapiens GN=RBM10 PE=1 SV=3 - 
[RBM10_HUMAN] 
Q92879 CUGBP Elav-like family member 1 OS=Homo sapiens GN=CELF1 PE=1 SV=2 - 
[CELF1_HUMAN] 
O43681 ATPase ASNA1 OS=Homo sapiens GN=ASNA1 PE=1 SV=2 - [ASNA_HUMAN] 
P29401 Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 - [TKT_HUMAN] 
Q8NFD5 AT-rich interactive domain-containing protein 1B OS=Homo sapiens GN=ARID1B 
PE=1 SV=2 - [ARI1B_HUMAN] 
O60716 Catenin delta-1 OS=Homo sapiens GN=CTNND1 PE=1 SV=1 - [CTND1_HUMAN] 
Q96T60 Bifunctional polynucleotide phosphatase/kinase OS=Homo sapiens GN=PNKP 
PE=1 SV=1 - [PNKP_HUMAN] 
P18583 Protein SON OS=Homo sapiens GN=SON PE=1 SV=4 - [SON_HUMAN] 
P05455 Lupus La protein OS=Homo sapiens GN=SSB PE=1 SV=2 - [LA_HUMAN] 
O60264 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A member 5 OS=Homo sapiens GN=SMARCA5 PE=1 SV=1 - 
[SMCA5_HUMAN] 
Q13283 Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens GN=G3BP1 
PE=1 SV=1 - [G3BP1_HUMAN] 
Q9UNE7 E3 ubiquitin-protein ligase CHIP OS=Homo sapiens GN=STUB1 PE=1 SV=2 - 
[CHIP_HUMAN] 
Q14839 Chromodomain-helicase-DNA-binding protein 4 OS=Homo sapiens GN=CHD4 
PE=1 SV=2 - [CHD4_HUMAN] 
P56545 C-terminal-binding protein 2 OS=Homo sapiens GN=CTBP2 PE=1 SV=1 - 
[CTBP2_HUMAN] 
O43719 HIV Tat-specific factor 1 OS=Homo sapiens GN=HTATSF1 PE=1 SV=1 - 
[HTSF1_HUMAN] 
Q96I25 Splicing factor 45 OS=Homo sapiens GN=RBM17 PE=1 SV=1 - [SPF45_HUMAN] 
Q16539 Mitogen-activated protein kinase 14 OS=Homo sapiens GN=MAPK14 PE=1 SV=3 - 
[MK14_HUMAN] 
P22314 Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 
SV=3 - [UBA1_HUMAN] 
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Q03252 Lamin-B2 OS=Homo sapiens GN=LMNB2 PE=1 SV=4 - [LMNB2_HUMAN] 
Q05048 Cleavage stimulation factor subunit 1 OS=Homo sapiens GN=CSTF1 PE=1 SV=1 - 
[CSTF1_HUMAN] 
P53992 Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 SV=3 - 
[SC24C_HUMAN] 
Q9BZJ0 Crooked neck-like protein 1 OS=Homo sapiens GN=CRNKL1 PE=1 SV=4 - 
[CRNL1_HUMAN] 
Q8IZ83 Aldehyde dehydrogenase family 16 member A1 OS=Homo sapiens 
GN=ALDH16A1 PE=1 SV=2 - [A16A1_HUMAN] 
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A OS=Homo 
sapiens GN=PPP4R3A PE=1 SV=1 - [P4R3A_HUMAN] 
Q8WYA6 Beta-catenin-like protein 1 OS=Homo sapiens GN=CTNNBL1 PE=1 SV=1 - 
[CTBL1_HUMAN] 
Q13523 Serine/threonine-protein kinase PRP4 homolog OS=Homo sapiens GN=PRPF4B 
PE=1 SV=3 - [PRP4B_HUMAN] 
Q8NE71 ATP-binding cassette sub-family F member 1 OS=Homo sapiens GN=ABCF1 PE=1 
SV=2 - [ABCF1_HUMAN] 
O94906 Pre-mRNA-processing factor 6 OS=Homo sapiens GN=PRPF6 PE=1 SV=1 - 
[PRP6_HUMAN] 
Q5M775 Cytospin-B OS=Homo sapiens GN=SPECC1 PE=1 SV=1 - [CYTSB_HUMAN] 
Q14683 Structural maintenance of chromosomes protein 1A OS=Homo sapiens 
GN=SMC1A PE=1 SV=2 - [SMC1A_HUMAN] 
Q96QC0 Serine/threonine-protein phosphatase 1 regulatory subunit 10 OS=Homo sapiens 
GN=PPP1R10 PE=1 SV=1 - [PP1RA_HUMAN] 
Q00341 Vigilin OS=Homo sapiens GN=HDLBP PE=1 SV=2 - [VIGLN_HUMAN] 
Q9H2P0 Activity-dependent neuroprotector homeobox protein OS=Homo sapiens 
GN=ADNP PE=1 SV=1 - [ADNP_HUMAN] 




Extended data 2: Motifs enriched upon AR agonist stimulation in different breast cancer 
models  






















































Extended data 5: List of siRNAs, antibodies, RT-PCT primers, and ChIP-PCR primers 
List of siRNAs: 
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Background: The GATA3 transcription factor is an established regulator of estrogen 
receptor-alpha (ER) signalling in ER+ breast cancer and plays important roles in 
development and differentiation of the mammary gland. Most ER+ breast cancers also 
express the androgen receptor (AR), which has been shown to inhibit ER-driven growth of 
this disease subtype. Recently, GATA3 has been identified as a novel AR interacting protein 
in ER+ breast cancer cells. Therefore, we aimed to investigate how GATA3 influences AR 
signalling in ER+ breast cancer and determine whether it is important for AR-mediated 
growth inhibition. 
Results: In order to assess the effect of hormones in shaping the GATA3 cistrome in ER+ 
breast cancer context, we investigated the GATA3 cistrome in vehicle, E2, DHT, and 
E2+DHT hormone treatment conditions in two ER+ breast cancer cell lines (T-47D and ZR-
75-1). We found that both estrogen and androgen treatment rearranged the GATA3 
cistrome in these models. Pathway analysis showed that E2-induced GATA3 binding events 
mediates ER signalling to induce growth and cell cycle progression in both models. 
However, AR-activation hugely impacts the E2-induced GATA3 binding profile. 
Importantly, we identified that androgen-induced GATA3 cistrome involved in AR-
mediated ER reprogramming and anti-tumor function of AR in ER+ breast cancer cells. 
Conclusions: Our findings show that the GATA3 cistrome is regulated by estrogen and 
androgen hormones in ER+ breast cancer cells. Also, our data identified that androgen 
induction (in the background of estrogens) competitively take GATA3 away from the ER 





Breast cancer is the most common malignancy among women worldwide (Bray et 
al. 2018). The majority of breast cancers (>80 %) express the estrogen receptor-alpha (ER), 
the main nuclear transcription factor that mediates the oncogenic effects of estrogens 
(Perou et al. 2000). ER+ tumours are the most differentiated breast cancer subtypes, with 
a better outcome in comparison to the remaining 20-25 % of breast cancer subtypes, 
collectively referred to as ER- tumours (Fragomeni, Sciallis & Jeruss 2018; Reis-Filho & 
Pusztai 2011). The dependency of breast tumours on ER to sustain their growth underpins 
the use of systemic endocrine treatments that target ER to inhibit its activity (Castrellon 
2017). Therapeutic agents that either inhibit estrogen production (aromatase inhibitors; 
AIs) (Thürlimann et al. 2005), block the binding of estrogen to the ERα (selective estrogen 
receptor modulators (SERMs, e.g. tamoxifen) (Fisher et al. 2005), or degrade ER (e.g. 
Fulvestrant) (Howell 2005; Vergote & Abram 2006) are used as adjuvant therapy for ER+ 
breast cancers and have resulted in significant improvement in breast cancer patient 
survival rates (Howell et al. 2004). Despite this, development of resistance is a major 
clinical issue and patients can relapse months or years after the initial treatment. 
Resistance to adjuvant endocrine therapy occurs in almost 10-15 % of ER+ breast cancer 
patients with early stage disease within 5 years (Dowsett et al. 2010), 30 % within 15 years 
(EBCTCG 2005), and ultimately most patients with advanced or metastatic ER+ breast 
cancers become resistant to endocrine treatments within 2-3 years of commencing 
endocrine therapy (Dixon 2014). Therefore, there is an urgent need to discover new 
therapeutic strategies to treat ER+ breast cancer to circumvent the emergence of 
resistance to current endocrine treatments. 
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Most (>90 %) ER+ breast cancers also express the androgen receptor (AR) (Peters 
et al. 2009). AR has been introduced as an independent predictor of breast cancer survival 
(reviewed at (Cops et al. 2008; Hickey et al. 2012)) with a favourable prognostic indication 
(reviewed at (Hickey et al. 2012; Ricciardelli et al. 2018)), which is significantly associated 
with reduced risk of relapse, longer survival (Yu et al. 2011) and better outcomes among 
patients with ER+ tumours (Park et al. 2011). It has been very recently shown that ligand 
activated AR acts as a tumour suppressor in ER+ breast cancer at all stages of disease 
including endocrine-resistant tumours, which strongly supports an AR agonist strategy for 
treatment (Hickey et al. 2021). AR suppresses endogenous ER activity in ER+ breast cancers 
by impeding the recruitment of ER or its co-activators, SRC-3 and p300, to chromatin, 
therefore suppressing the expression of critical cell cycle associated ER target genes 
(Hickey et al. 2021). AR also up-regulates target genes that may contribute to growth 
inhibition, via sequestration of p300 and SRC-3 away from ER target genes (Hickey et al. 
2021). The latter study focussed on p300 and SRC-3 as co-factors known to be important 
for ER and AR signalling, but other co-factors common to both receptors are likely involved 
in cross-talk between these pathways.  
To elicit transcriptional activity, steroid receptors like ER and AR do not function 
alone, but within a large, multi-protein transcriptional complex. In breast cancer, much is 
known about the ER complex, but little about the AR complex. Among several co-
regulatory proteins, one key transcription factor that has been positively implicated in 
mediating estrogen-induced ER signalling in breast cancer is GATA3, which belongs to the 
GATA family of transcription factors (Eeckhoute et al. 2007; Kong et al. 2011). GATA3 is 
required for morphogenesis of luminal epithelial cells in the normal mammary gland, and 
promotes differentiation (Asselin-Labat et al. 2007). GATA3 has been shown to function in 
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collaboration with the ER transcriptional complex at multiple loci of the genome to 
regulate ER activity (Takaku, Grimm & Wade 2015; Theodorou et al. 2013). Interestingly, 
we recently identified GATA3 as a novel AR interacting protein in breast cancer cells 
regardless of ER status, and showed that it facilitates AR binding and transcriptional activity 
at AR target genes, and co-operates with AR to up-regulate luminal lineage genes (Chapter-
2). Therefore, GATA3 is an important co-regulator of ER and AR signalling in breast cancer. 
Herein, we aimed to specifically examine the role of GATA3 in mediating cross-talk 





Estrogen stimulation of ER+ breast cancer cells rearranges the GATA3 
cistrome  
In order to generate the first comprehensive and reproducible GATA3 cistrome and 
to investigate the effect of estrogens on shaping the GATA3 binding profile in ER+ breast 
cancer context, we conducted GATA3 ChIP-seq experiments using two estrogen (E2)-
dependent ER+ breast cancer cell lines (T-47D and ZR-75-1). T-47D and ZR-75-1 breast 
cancer cell lines were used in this study since they endogenously and exclusively express 
wild-type forms of ER and GATA3. Cells were treated with vehicle or E2 (10 nM) for 4 hours 
following 3 days of hormone deprivation to match conditions previously utilized to 
generate ER consensus cistromes (Hickey et al., 2021). We generated consensus GATA3 
cistromes for both cell lines (E2 vs vehicle) using three consecutive passages of cells 
representing three independent biological replicates, for reproducibility. Peaks identified 
in at least 2 of 3 replicates were included in the consensus cistromes (Supplementary 1-a-
d). We discovered that estrogen stimulation reproducibly shifts the GATA3 cistrome 
towards a new subset of binding sites compared with vehicle-treated cells in both ER+ 
breast cancer cell models (Figure 1-a, Supplementary 1-e), which has never been reported 
previously. Principle component analysis (PCA) confirmed that estrogen treatment was the 
main variable in clustering the stimulated cells away from the controls in both cell line 
models (Figure 1-b, Supplementary 1-f). Integrating the GATA3 data with our publicly 
available E2-treated ER ChIP-seq data from Hickey et al., 2021, revealed that more than 60 
% of ER binding sites are shared with GATA3 cis-regulatory elements in T-47D cells (Figure 
1-c). We also observed about 50 % overlap between ER and GATA3 cistromes for the ZR-
75-1 cell line under estrogenic conditions (Supplementary 2-a). DiffBind analysis revealed 
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406 and 219 GATA3 peaks that were significantly (FDR ≤ 0.05) enriched upon estrogen 
treatment in T-47D and ZR-75-1 cells, respectively (Figure 1-d, Supplementary 2-b). Peak 
annotation analysis for E2-induced GATA3 binding sites revealed 7,872 and 4,148 potential 
gene targets in T-47D and ZR-75-1 cells, respectively. In order to determine which of these 
candidate gene targets are regulated by ER-GATA3 co-occupied loci, we treated T-47D and 
ZR-75-1 cells for 6 hours with vehicle or E2 (10 nM) after 3 days of hormone deprivation 
and performed RNA-seq for differentially expressed genes (DEG). Integration of our 
annotated E2-induced GATA3 gene targets with E2-induced DEG genes identified 2,507 (T-
47D) and 1,415 (ZR-75-1) up-regulated targets (Figure 1-e, Supplementary 2-c). 
Additionally, 2,733 (T-47D) and 1,303 (ZR-75-1) down-regulated targets were identified 
through integration of the ER-GATA3 annotated genes with RNA-seq data (Figure 1-e, 
Supplementary 2-c). Several common up-regulated genes found between two in vitro 
models are well-established ER target genes in breast cancer cells including PgR and GREB1 
(Supplementary 2-d). Visual exploration of the E2-induced GATA3 peaks co-occupied by ER 
through the Integrative Genomics Viewer (IGV) is shown for PgR and GREB1 classic ER 
target genes in T-47D cells (Figure 1-g). PGR has been shown to promote the progression 
of cell cycle and proliferation in breast cancer as a classic ER target (Dressing et al. 2014; 
Kariagina et al. 2013). However, it has been shown that activated PGR has anti-proliferative 
effects that inhibits E2-induced growth of ER+ breast cancer cell line xenografts and ER+ 
primary tumors explants (Mohammed et al. 2015). GREB1 is a critical regulator of estrogen 
dependent breast cancer growth ('Retraction: GREB1 functions as a growth promoter and 
is modulated by IL6/STAT3 in breast cancer' 2014; Cheng, Michalski & Kommagani 2018; 
Haines et al. 2020; Rae et al. 2005). Up-regulated ER-GATA3 targets were positively 
associated with a set of biological processes dominated by Gene Ontology (GO) gene sets 
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including cell cycle and developmental growth (Figure 1-f, Supplementary 2-e). Gene set 
enrichment analysis (GSEA) revealed that ER-GATA3 DEG targets (up and down-regulated 
targets) are associated with enriched Hallmarks for estrogen response early and late, MYC-
targets V1 and V2, E2F targets and G2M checkpoint in T-47D cells (Figure 1-h). Similarly, 
enriched hallmarks were observed in ZR-75-1 cells with ER-GATA3 up-regulated targets 
(Supplementary 2-f). In order to assess the effect of GATA3 knock-down on the mRNA 
expression level of PgR and GREB1 in the condition of E2-treated cells compared with the 
control cells, we conducted qPCR experiments in both T-47D and ZR-75-1 breast cancer 
models (Figure 1-i, Supplementary 2-g). We examined the efficacy of GATA3 knock-down 
at the protein level in both cell lines through western blotting before conducting qPCR 
(Supplementary 2-h). qPCR experiments show that silencing GATA3 did not affect the basal 
expression level of PgR and GREB1 genes, however, it significantly reduced but did not 
abolish the ability of E2 to increase mRNA transcript levels of classic ER target genes. Taken 
together, our results indicate that GATA3 enhances but is not required for ER signalling in 
these ER+ breast cancer models.  
Androgen stimulation of ER+ breast cancer cells also rearranges the GATA3 
cistrome  
Conducting GATA3 ChIP-seq in DHT- versus vehicle-treated ZR-75-1 and T-47D cells 
(Supplementary 1-a-d), we have previously shown that androgens rearrange the GATA3 
binding profile in ER+ breast cancer cells (Chapter-2) (Figure 2-a, Supplementary 3-a). DHT-
treatment increased the size of the GATA3 cistrome in both models (Chapter-2) (Figure 2-
a, Supplementary 3-a). Principle component analysis (PCA) confirmed that DHT treatment 
is as the main variable in clustering the stimulated cells away from the vehicle-treated cell 
in both in vitro models (Chapter-2) (Figure 2-b, Supplementary 3-b). Therefore, for the first 
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time, our data discovered the effect of hormone treatment (estrogens (Chapter-3) and 
androgens (Chapter-2)) on shaping the binding profile of GATA3 transcription factor in ER+ 
breast cancer cells, indicating that GATA3 cistrome is hormone regulated in ER+ breast 
cancer cells. Additionally, AR has been shown to reprogram the ER binding profile in ER+ 
breast cancer models, which is associated with inhibition of tumor growth. Therefore, we 
sought to investigate the effect of AR activation on the E2-induced GATA3 cistrome. We 
studied the E2+DHT GATA3 cistrome compared with E2 GATA3 cistrome (Supplementary 
1-a-d). Although the GATA3 cistromes under E2 and E2+DHT conditions were comparable 
in size (Figure 2-c), dual-receptor activation with E2+DHT treatment clearly shifted GATA3 
binding events in T-47D (Figure 2-c) and ZR-75-1 cells (Supplementary 3-c). Principle 
component analysis (PCA) showed that DHT treatment was the major source of variation 
between replicates of GATA3 ChIP-seq experiments in both ER+ breast cancer models, 
indicating a strong impact of AR activation on the vehicle- and E2-treated GATA3 cistromes 
in breast cancer cells (Figure 2-d, Supplementary 3-d). Interestingly, discriminative motif 
analysis shows that androgen response elements (AREs) were enriched in DHT-induced 
GATA3 binding sites, however; estrogen response elements (EREs) were lost upon 
androgen stimulation in both cell line models (Figure 2-e, Supplementary 3-e), suggesting 
that AR activation redistributed GATA3 from ER binding sites to AR binding sites. DiffBind 
analysis identified 1519 GATA3 sites that were significantly altered upon treatment with 
E2+DHT compared with the E2-treated cells, highlighting the strong effect of androgens in 
modifying the E2-associated GATA3 cistrome (Figure 2-f). A total of 1331 differentially 
GATA3 bound loci were significantly enriched peaks, and 188 were significantly lost 
enrichment upon E2 and DHT co-treatment in T-47D cells (Figure 2-f). We also found 1185 
differentially bound loci for GATA3 (1158 enriched and 28 lost peaks) upon E2+DHT 
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treatment in ZR-75-1 cells (Supplementary 3-f). In order to investigate the overlap of AR 
and GATA3 cistromes upon DHT treatment in ER+ breast cancer cells in the presence of E2, 
we integrated this data with our previously generated AR ChIP-seq data from Hickey et al., 
2021. We investigated the distribution of AR and GATA3 cistromes following E2+DHT 
stimulation in both ER+ breast cancer cells through generating two-factor MA plots, 
revealing five different sub-groups representing shared or unique AR and GATA3 binding 
events (Figure 2-g, Supplementary 3-g). Pink dots in this figure show E2+DHT-induced 
GATA3 binding events that are shared with the AR cistrome in each model (Figure 2-g, 
Supplementary 3-g). Interestingly, more than 94 % of E2+DHT-induced GATA3 loci are co-
occupied with E2+DHT-induced AR sites in both breast cancer cell models (Figure 2-h, 
Supplementary 3-h). This suggests a potent interplay between AR and GATA3 that may 
contribute to AR cross-talk with ER in breast cancer cells. RANBP3L and CA12 are AR target 
genes that showed significant enrichment of GATA3 peak upon E2+DHT treatment 
compared with the E2-treated cells. However, PgR, GREB1, and MYB are examples of ER 
target genes that GATA3 peaks did not altered by E2+DHT treatment in both ER+ breast 
cancer cells (Figure 2-g, Supplementary 3-g).  
AR-induced ER-reprogramming is mediated through a switch in GATA3 co-
regulatory function 
To investigate the effect of AR activation on GATA3 and ER cistromes in an 
integrated manner, we used our publicly available ER and AR cistromes generated under 
E2 and E2+DHT treatment conditions (Hickey et al. 2021). We overlapped the significant 
E2+DHT-induced GATA3 peaks with 17,992 and 1530 significantly (FDR ≤ 0.05) E2+DHT-
enriched peaks for AR and ER in T-47D cells, compared with E2-treated cells (Figure 3-a). 
Surprisingly, all the common E2+DHT-induced ER and GATA3 binding events were co-
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occupied by AR, suggesting that the ER and GATA3 binding sites gained with E2+DHT 
treatment are AR-dependent (Figure 3-a). According to our previous findings, AR-mediated 
inhibition of ER genomic signalling partially occurred due to recruitment of ER to AR 
binding sites associated with tumour suppressor genes (Hickey et al. 2021). We also 
examined the contribution between GATA3, AR and ER binding events at DHT-induced AR-
ER sites that are co-occupied with GATA3 loci in T-47D (Figure 3-b), and ZR-75-1 
(Supplementary 4-a,b). We observed androgen induced enrichment of the H3K27ac ChIP-
seq signal at AR-GATA3-ER co-occupied loci, indicative of a more transcriptionally active 
chromatin state in both T-47D (Figure 3-b), and ZR-75-1 cells (Supplementary 4-c). 
Interestingly, assessing the accessibility of the chromatin at E2+DHT-induced AR loci 
including the AR-ER shared site depleted from GATA3 indicated no enrichment upon DHT-
treatment, suggesting a role for GATA3 in mediating chromatin structure at AR-GATA3-ER 
loci in T-47D (Figure 3-c) and ZR-75-1 (Supplementary 4-d) upon E2+DHT treatment. We 
integrated annotated AR-GATA3-ER targets with our previously published RNA-seq data 
(Hickey et al. 2021) and found 537 and 211 AR-GATA3-ER gene targets that were 
differentially expressed in response to E2+DHT versus E2 treatment in T-47D (343 up-
regulated genes and 194 down-regulated genes) and ZR-75-1 (133 up-regulated genes and 
44 down-regulated genes) cells, respectively. In order to assess the biological processes 
associated with these DEG genes, we performed GSEA pathway analysis and found that 
AR-GATA3-ER up-regulated targets are enriched in epithelium development, cell-cell 
signalling, and regulation of cell death pathways (Figure 3-d, Supplementary 4-e). GSEA 
analysis showed that the down-regulated AR-GATA3-ER target genes were negatively 
associated with cell growth gene sets in both of the cell line models (Figure 3-e, 
Supplementary 4-f). Taken together, these data suggest that GATA3 may contribute with 
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the AR-ER cross-talk in ER+ breast cancer cells through mediating the chromatin 
accessibility.  
In order to assess the potential involvement of GATA3 in regulating the AR good 
outcome signature genes described in Hickey et al., 2021, we investigated whether AR-
GATA3-ER targets overlap the AR signature genes (Hickey et al. 2021). The AR signature 
was derived from in vivo models and positively predicted disease survival in multiple large 
clinical cohorts of ER+ breast cancer, outperforming existing pan-cancer or breast cancer-
specific signatures. We found that ~40 % of DEG AR signature genes, overlap with the DEG 
AR-GATA3-ER targets including ZBTB16, SEC14L2, CLDN8, and EAF2, suggesting a role for 
GATA3 in regulation of AR signature genes (Supplementary 5) in T-47D cells. We also 
assessed the effect of GATA3 knock-down on the expression level of AR signature genes in 
the condition of E2+DHT treatment compared with the E2-treated cells. Silencing GATA3 
significantly reduced the E2+DHT-induced expression of both targets, however, it did not 
abolish the AR regulation on the expression level of these targets completely in both T-47D 
(Figure 3-f) and ZR-75-1 cells (Supplementary 4-g).  
Together, our data suggest that AR activation relocates GATA3 and ER away from 
shared ER binding sites associated with proliferative genes, and induces a new subset of 
binding events that are common between all three transcription factors, implicating 
GATA3 in AR-driven tumour suppression in ER+ breast cancer cells, possibly through 
mediating the chromatin accessibility. 
GATA3 knockdown reduces the growth inhibitory effects of androgens in E2-
stimulated ER+ breast cancer cells 
To further investigate GATA3 involvement in AR-mediated growth inhibitory effects 
in ER+ breast cancer cells, we silenced GATA3 in ER+ breast cancer cell lines (mKATE red 
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nuclear tag labelled T-47D and ZR-75-1) to examine proliferation in real time in response 
to E2 and E2+DHT hormone stimulation. Transduction of T-47D and ZR-75-1 cells with 
mKATE red nuclear tag facilitated real-time imaging of cell growth. We simultaneously 
seeded and transfected the tagged cells with specific siRNAs to GATA3 (siGATA3) or to a 
non-targeting control (siControl). Growth assay experiments for both mKATE_T-47D and 
mKATE_ZR-75-1 cells showed that silencing GATA3 significantly reduced basal growth in 
both cell line models (Figure 4-a-c), suggesting a key role for GATA3 in growth of the breast 
cancer cells independent of ER and/or AR. Furthermore, we observed a dramatic 
morphology change after GATA3 knock-down irrespective to hormone stimulation in both 
cell lines (Figure 4-d). Knock-down of GATA3 caused genesis of gained multinuclear cells 
sharing one common cytoplasm. These observations suggest a new role for GATA3 in cell 
cycle progression and normal cytokinesis, which needs to be further studied in future. 
Silencing GATA3 blunted but not abolish the growth stimulatory effect of estrogens, and 
growth-inhibitory effects of androgens in both ER+ breast cancer cells (Figure 4-a-c). 
Therefore, we suggest that in the condition of estrogen stimulation, GATA3 functions as 
an ER co-regulator in inducing the growth of the cells; however, upon androgen stimulation 
GATA3 functions as an AR co-regulator, mediating the mechanism by which AR suppresses 
the growth of ER+ breast cancer cells. In order to investigate the effect of GATA3 knock-
down on AR-mediated suppression of genes involved in E2-induced growth stimulation of 
ER+ breast cancer cells, we assessed the effect of GATA3 knock-down on the mRNA 
expression level of PgR and GREB1 genes conducting qPCR experiment for E2 and E2+DHT-
stimulated cells in both T-47D and ZR-75-1 breast cancer models (Figure 4-d,e). Together 
with what we have shown in Figure 1, our data show that silencing GATA3 significantly 
impairs the stimulatory effect of estrogens (Figure 1-h,i) and the inhibitory effects of 
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androgens (Figure 4-d,e) in regulating the mRNA transcriptional level of selected growth-
associated genes. However, consistent with our growth assay results, GATA3 depletion did 
not abolish the effect of estrogens and androgens in increasing or reducing the mRNA 
expression level of selected targets, respectively (Figure 1-h,i, Figure 4-d,e). The androgen-
induced switch in the GATA3 collaborative role from being an ER co-regulator to an AR co-
regulator significantly affect the mRNA expression of the growth-associated ER-GATA3 
target genes like PgR and GREB1 in both T-47D and ZR-75-1 breast cancer cells (Figure 4-
d,e), which in turn, involves in the E2-induced growth suppression of ER+ breast cancer 
cells. Collectively, these results suggest that GATA3 is a common ER and AR co-regulator 
that mediates both ER and AR signalling in regulating the growth of ER+ breast cancer cells 
in response to estrogen or androgen stimulation. 
 
Discussion 
Herein, we explored the effect of estrogens and combination of estrogens and 
androgens in redistribution of the GATA3 binding profile in ER+ breast cancer cells. We 
showed that GATA3 mediates both ER and AR signalling to induce the growth or to repress 
the E2-induced growth in response to ER and/or AR activation in ER+ breast cancer cells. 
Also, we showed that GATA3 involved in AR-mediated ER reprogramming in ER+ breast 
cancer cells. 
In this study, we generated robust, reproducible GATA3 cistromes under different 
hormonal conditions in two ER+ breast cancer cell lines. While GATA3 ChIP-seq has been 
previously performed in ER+ breast cancer cells, there are issues with the data that limit 
their utility. For example, Kong et al., 2011 generated GATA3 cistromic data in estrogen-
232 
 
treated MCF-7 cells compared with the untreated cells, but this cell line expresses both 
wild-type and mutant GATA3 proteins that are both pulled down with the antibodies 
available for GATA3 ChIP-seq. Also, the latter study provided the vehicle and E2-treated 
GATA3 cistromes only in one replicate (Kong et al. 2011). Additionally, Theodorou et al., 
2013 provide the GATA3 ChIP-seq in unstimulated MCF-7 breast cancer cells and following 
estrogen treatment, each in five replicates. In this study, GATA3 binding was introduced 
almost exclusively estrogen independent, however, regardless of using a non-appropriate 
cell model (MCF-7), when we analysed the public data provided from the paper we found 
that estrogen treatment hugely increased and rearranged the GATA3 binding profile in 
these cells (Supplementary 6-e). Therefore, in order to investigate the exclusive role of 
wild-type GATA3 in ER+ breast cancer cells we used T-47D and ZR-75-1 cells that exclusively 
express wild-type GATA3, and to generated a reproducible data we conducted all our ChIP-
seq experiments in 3 biological replicates. We previously examined effect of androgen 
stimulation on GATA3 cistrome in breast cancer context in the same ER+ breast cancer 
models (Chapter-2). Collectively, our data indicated that estrogen- and androgen-
stimulation of ER+ breast cancer cells rearrange GATA3 cistrome. We showed that E2-
induced GATA3 binding sites hugely overlap with E2-induced ER cistrome, and are 
associated with a set of biological processes involved in cell cycle progression and growth 
in ER+ breast cancer cells. However, almost all E2+DHT-induced GATA3 binding sites were 
shared with AR in both breast cancer cell models, suggesting that GATA3 mediates AR 
signalling in ER+ breast cancer cells. The GATA family of transcription factors have been 
shown to prominently contribute to the development of many cancer types in human 
patients. For example, GATA2 is an AR co-regulator playing a key role in prostate cancer 
progression (He et al. 2014). GATA2 enhanced AR signalling in LNCaP cells and is critical for 
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AR expression and transcriptional activity in these cells. Silencing GATA2 markedly 
depleted AR mRNA and protein expression levels in different PC cell lines. Although 
androgens and AR suppressed GATA2 expression in PC, indicative a negative feedback loop 
between AR and GATA2, our data showed that AR and GATA3 does not regulate the 
expression of each other in breast cancer contexts (Chapter-2). Similar to GATA2 and AR in 
PC (He et al. 2014), we have shown that GATA3 and AR physically interact with each other 
in breast (Chapter-2). The colocalization of AR and GATA2 on chromatin was associated 
with recruitment of key transcriptional mediators including SRC-3 and p300 as well as with 
increased for epigenetic marks of active transcription, H3K27ac (He et al. 2014). 
Interestingly, AR interacts and takes the ER co-regulators SRC-3 and p300 away from the 
ER targets in breast cancer context (Hickey et al. 2021), while reprogramming ER cistrome 
in ER+ breast cancer cells. Taken together, since GATA3 is important for the function of 
both ER and AR transcription factors and has overlapping binding sites with both factors, 
our findings suggest that it is possible that the activated AR (with the background of 
estrogen) sequester GATA3 from the its motifs near to EREs at ER target genes to open up 
the nucleosome and facilitate its binding to AREs at AR target genes. Since AR interacts 
with all three SRC-3, p300, and GATA3 factors, a main question is still remaining to be 
discover that which of these three factors is most important in AR-mediated ER 




Materials and Methods 
Cell culture 
ZR-75-1 (CRL-1500TM) and T-47D (HTB-133TM) breast cancer cell lines were obtained 
from ATCC (Manassas, VA, USA). Both cell lines were routinely tested for mycoplasma 
infection and authenticity confirmed by short tandem repeat profiling. Both cell lines were 
maintained in RPMI-1640 medium (Invitrogen) containing 10 % Foetal Bovine Serum (FBS) 
and 2 nM L-Glutamine (Sigma) and were incubated at 37 ˚C and 5 % CO2. For hormone 
stimulation experiments, cells were starved for 72 hours in 5 % dextran-coated charcoal 
stripped (DCC) FBS medium prior to hormone addition. 
Western blotting 
Cells were harvested at the indicated time-points by scraping and lysed into 
Radioimmunoprecipitation assay (RIPA) buffer. Protein concentration was quantified using 
BCA protein assay (Thermo Scientific). Proteins were separated by SDS-PAGE on 10 % 
Criterion TGX Stain Free-gels (BioRad) and then transferred to nitrocellulose blotting 
membranes (GE Healthcare). Blocking was carried out in 5 % skim milk in TBST for 2 hours. 
Immunoblotting for GATA3 (Abcam; ab199428) and GAPDH (Merck Millipore; mab374) 
(Supplementary 6-a) was performed overnight and membranes were washed with PBS + 
0.1% Tween-20. HRP-coupled secondary antibodies (goat anti-rabbit (Dako; 1:2000) or 
rabbit anti-mouse (Dako; 1:2000)) were detected with Clarity Western ECL Substrate (Bio-
RAD) and visualised using a BioRad ChemiDoc imaging system.  
siRNA knockdown experiments  
Pre-designed siRNAs against GATA3 and a negative control siRNA (Allstar-Neg. 
Control siRNA) were used for the purpose of siGATA3 studies (Supplementary 6-b). Cells 
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were transfected with siRNAs by reverse transfection using RNAiMAX (Invitrogen) (0.5 
µl/cm2) at the time of seeding for 48 hours according to the manufacturer's protocols 
(Thermo Fisher Scientific, Waltham, MA, USA).  
RNA extraction and quantitative real-time PCR (qPCR) 
Cells were seeded at 0.5 x 106 cells/well in 6-well plates and simultaneously 
transfected with either 10 nM of siRNAs against GATA3 or siControl (10 nM). After 48 hours 
of transfection, the media was changed to hormone-depleted medium supplemented with 
5 % DCC FBS. After 72 hours (media refreshed at each day), both cell line models were 
treated for 6 hours with vehicle, 10 nM E2, or 10 nM E2+DHT before harvest. Total RNA 
was extracted using Trizol followed by DNase treatment using the TURBO DNase Kit 
(Invitrogen). Reverse transcription was performed on 500 ng of the total RNA using the 
iScript cDNA Synthesis Kit (Bio-Rad). The resulting cDNA was diluted 1:10 and used for qRT-
PCR. Primers are listed in supplementary-6 (Supplementary 6-c). mRNA levels were 
normalised to GAPDH using the ΔΔCt method in Bio-Rad CFX-manager software, as 
previously described (Hickey et al. 2021). 
ChIP-sequencing (ChIP-seq) 
ZR-75-1 and T-47D cells were seeded in 15 cm plates at 9 x 106 cells/plate, in their 
normal maintenance medium. Media was changed to phenol-red-free medium 
supplemented with 5 % DCC -stripped FBS after 24 hours and cells were allowed to grow 
for a further 2 days prior to treatment with daily media changes. Cells were treated with 
either vehicle, 10 nM E2, 10 nM DHT, or 10 nM E2+DHT for 4 hours prior to fixation and 
harvest. Each experiment was done as three independent biological replicates 
representing consecutive passages of cells. Cells were cross-linked with 1 % formaldehyde, 
quenched with 2 M Glycine pH 7.5, and collected by scraping. The cells were suspended in 
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lysis buffer (10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1 % Na-
Deoxycholate, and 0.5 % N-lauryl sarcosine) in the presence of protease inhibitors 
(Complete(R), Roche) and sonicated for 10 cycles of ‘30 seconds on, 30 seconds off’, using 
a Diagenode Bioruptor. Immunoprecipitations were performed using 5 µg/IP of GATA3 
(Abcam; ab199428) antibodies excluding the DNA input samples (Supplementary 6-d). 
Before sequencing the ChIP’d DNA samples, ChIP-PCR reactions were prepared using iQ 
SYBR Green Supermix (BIO-RAD) to test experimental efficacy at positive control sites. PCR 
was performed with the CFX384 Real Time PCR Detection System (BIO-RAD) and standard 
cycling conditions. ChIP-PCR data were analysed by the percentage input method and 
further analysed as fold enrichment over a negative control. DNA was sequenced using an 
Illumina NextSeq 500 (High Output) with 75 bp single-end reads. Raw data was processed 
in Galaxy. Trimmed FASTQ files were aligned to the hg19 genome assembly using Bowtie2 
(version: 2.3.4.3, default parameters), mapped reads with a minimum MAPQ <10 and 
duplicate reads were removed using SAMtools. Peaks were called using MACS2 callpeak 
(version: 2.1.1, default settings) with a pooled input sample as the control. Only peaks 
found in 2 out of the 3 replicates were kept for the consensus peakset. For figures, ChIP-
seq data was visualized using the Integrative Genomics Viewer (https://igv.org/app/). 
Heatmaps (Galaxy Version 3.3.2.0.1) and PCAs (Galaxy Version 3.3.2.0.0) were generated 
using Deeptools. Peak annotations were performed using Cisgenome (v2.0).  
m-KATE red nuclear tag generation 
Second generation, 3-package plasmid system was conducted to generate the m-
KATE nuclear tag lentiviruses using the packaging vector of psPAX2, envelope vector of 
VSVG pSD11 pMD2.G, and the transfer plasmid encoding the insert of interest. HEK-293 
cells were transfected with transfer plasmid and packaging plasmids using the PEI 
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transfection methodology. The media supplemented with transfection mix was changed 
to Opti-MEM media after 12 hours of incubation at 37 ˚C. Media containing viral particles 
was collected after 48 hours, purified and filtered to concentrate the m-KATE virus. 
Stable cell line generation 
Lentiviral titration has been done for each cell line to ensure that preps are applied 
in sufficient quantities to obtain desired transduction efficiencies. The optimal titration for 
the red nuclear tag virus in both breast cancer lines was 105 IFU/ml (Infectious units (IFU)). 
Both ER+ (ZR-75-1 and T-47D) breast cancer cell lines were transduced with the red nuclear 
tag virus. Transduced lines were expanded and selected through culturing in media 
supplemented with G418 antibiotic. Selected cells were used for the purpose of the growth 
assays.  
Cell growth assays 
Tagged T-47D (10 X 103) and ZR-75-1 (11 X 103) cells were seeded in 96-well plates 
in hormone stripped serum (5 % DCC FBS) in three technical replicates (in each of the two 
experiments) and simultaneously transfected with one of two different siRNAs to GATA3 
(10 nM) or a siControl (10 nM) for 48 hours. Transfected media was removed from all wells 
and fresh hormone depleted media supplemented with different hormone treatments 
(vehicle, 10 nM E2 or 10 nM E2+DHT) was added to plates. Plates were scanned every 2 
hours with the objective of 10 X for the duration of the experiment (9 days). 10 images 
from different time-points were selected to train the IncuCyte to count the cells in each of 
the models. 
Statistical analyses 
Statistical calculations were performed using GraphPad Prism (GraphPad 
Software). Normality was assumed for all statistical tests. All tests were two-sided with a 
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95 % confidence interval and a P value <0.05 was indicative of statistical significance. All 
qPCRs and growth assays in both models analysed using a two-way ANOVA, followed by 


















Figure-1: Estrogen stimulation of ER+ breast cancer cells rearranges the GATA3 cistrome. 
a) Venn diagram shows the effect of estrogen (E2) treatment on the GATA3 binding profile. 
b) Principle component analysis (PCA) clustered the E2-treated cells away from the vehicle-
treated cells in the T-47D breast cancer cell line model. Grey dots represent three 
independent biological replicates of vehicle-treated samples; blue dots represent 3 
replicates of E2-treated samples. c) Venn diagram shows the overlap of ER and GATA3 
cistromes under E2 treatment. d) Volcano plot shows the differentially enriched and 
depleted GATA3 binding sites (FDR ≤ 0.05) upon ER activation in T-47D breast cancer cells. 
The purple dots represent peaks that did not undergo a significant change (FDR ≥ 0.05) 
with ER activation. The pink dots represent significant (FDR ≤ 0.05) changes to GATA3 peaks 
in each model. e) Volcano plot depicts the differentially expressed E2-induced ER-GATA3 
gene targets in T-47D cells. f) Integrative genomics viewer (IGV) snap shot shows averaged 
ER and GATA3 ChIP-seq signals at binding sites associated with ER target genes (PgR, and 
GREB1). g) Bar graph shows the biological pathways that are associated with E2 up-
regulated ER-GATA3 gene targets in T-47D breast cancer model. h) Gene set enrichment 
analysis (GSEA) plots represent the associated Hallmarks with E2 up-regulated ER-GATA3 
targets in T-47D cells. i) Bar graphs represent the effect of GATA3 knock-down on the 
mRNA expression level of PgR and GREB1 genes under E2-stimulation condition compared 
with the vehicle cells in T-47D breast cancer model. Two-way ANOVA with Tukey's multiple 
comparisons test was used to determine statistically significant differences in i. Data 












































Figure-2: Androgens redistribute the GATA3 binding profile in ER+ breast cancer cells. a) 
Venn diagram shows the effect of DHT treatment on the GATA3 cistrome. b) PCA plot 
shows the clustering of DHT-treated cells away from the vehicle-treated cells in T-47D 
breast cancer model. Grey dots represent three independent replicates of vehicle-treated 
samples; pink dots represent 3 replicates of DHT-treated samples in T-47D cells. c) Venn 
diagram shows the potent effect of DHT on re-distributing the E2-stimulated GATA3 
cistrome. d) PCA plot shows the effect of hormones (estrogens and androgens) on 
clustering the treated cells in T-47D cells. Colours represent three replicates of different 
treatments. e) Motif analysis of E2+DHT-induced GATA3 binding sites revealed enrichment 
of the AR motif and loss of ER motif in T-47D breast cancer model. f) Volcano plot shows 
the differentially enriched and depleted GATA3 binding sites (FDR ≤ 0.05) upon AR 
activation in the presence of E2 in T-47D breast cancer cells. The purple dots represent 
peaks that did not undergo a significant change (FDR ≥ 0.05) with AR activation. The pink 
dots represent significant (FDR ≤ 0.05) changes to GATA3 peaks in each model. g) Two-
factor MA plot represents distribution of the AR and GATA3 cistromes upon E2+DHT 
stimulation in T-47D cells . Peaks are represented by coloured dots and classified into 5 
different sub-groups: grey and yellow dots represent AR and GATA3 binding sites that do 
not overlap with the other factor, respectively; blue dots represent E2+DHT-induced 
GATA3 peaks that are not shared with AR; green dots represent GATA3 binding sites that 
were not altered by E2+DHT stimulation but AR was recruited to these loci; and pink dots 
represent AR-GATA3 peaks that are significantly gained upon E2+DHT stimulation. Example 
loci associated with AR-GATA3-ER target genes (RANBP3L and CA12 represented loci from 
pink group, PgR, GREB1, and MYB represented loci from green group) that are highlighted 
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in black dots in T-47D cells. h) Venn diagram depicts the overlap of E2+DHT-induced GATA3 

















Figure-3: AR-induced ER-reprogramming is mediated through a switch in GATA3 co-
regulatory function. a) Venn diagram shows the overlap of DHT-induced AR, GATA3, and 
ER cistromes in T-47D cells in the presence of E2. b) Heatmap represents the contribution 
of E2+DHT-induced GATA3 peaks on E2+DHT-induced shared AR-ER binding sites in T-47D 
cells, and the H3K27ac enrichment at AR-GATA3-ER co-occupied loci in T-47D cells. c) 
Graph depicts the density of H3K27ac enrichment in at E2+DHT-induced AR sites depleted 
from GATA3 compared with the E2 stimulation condition in T-47D cells. d) Bar graph shows 
the biological pathways that are associated with up-regulated AR-GATA3-ER targets upon 
E2+DHT treatment in T-47D cells. e) GSEA analysis shows that down-regulated AR-GATA3-
ER targets are negatively associated with cell growth genes in T-47D cells. f) Bar charts 
represent the effect of GATA3 knock-down on the mRNA expression level of SEC14L2 and 
ZBTB13 tumour-suppressor AR targets under E2+DHT-stimulation compared with the E2-
treated cells in the T-47D breast cancer model. Two-way ANOVA with Tukey's multiple 
comparisons test was used to determine statistically significant differences in f. Data 




Figure 4: GATA3 depletion reduces the growth inhibitory effects of androgens in E2-









Figure-4: GATA3 depletion reduces the hormonal effects of estrogen and  androgen in 
ER+ breast cancer cells. IncuCyte-generated graphs show the effect of GATA3 knock-down 
on the growth rate of T-47D (a, c) and ZR-75-1 (b, c) cells under different hormone 
treatment conditions (vehicle, E2, and E2+DHT). Two-way ANOVA with Tukey's multiple 
comparisons test was used to determine statistically significant differences in c. Data 
shown as mean ± SEM of 3 replicates and are representative of two independent 
experiments; ** p<0.01, *** p<0.001, and **** p<0.0001. d) Images show the effect of 
GATA3 knock-down on morphology of the T-47D and ZR-75-1 cells. e) Bar graphs show the 
effect of GATA3 knock-down on hormone regulation of the ER target genes PgR and GREB1 
in T-47D (e) and ZR-75-1 (f) cells. Data shown as mean ± SEM of 3 replicates of two 
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Supplementary figures  
Supplementary 1: GATA3 cistrome in different hormone treated conditions in ER+ breast 







T47D ER+ BC line  _   GATA3 ChIP-seq
on Bowtie files on RmDup files MACS2 Callpeak Consensus
QC passed reads %mapped QC passed reads %mapped # Peaks # Peaks
VEH1 26032395 100.00% 24571905 100.00% 92,192
77,109VEH2 27298092 100.00% 25795187 100.00% 83,858
VEH3 27727376 100.00% 26279645 100.00% 68,720
E2-1 26509596 100.00% 25088842 100.00% 83,590
81,964E2-2 27273976 100.00% 25819969 100.00% 84,440
E2-3 28481670 100.00% 26890871 100.00% 90,547
DHT1 30787698 100.00% 29135527 100.00% 71,311
81,567DHT2 27841145 100.00% 26353541 100.00% 86,591
DHT3 26317137 100.00% 24936265 100.00% 100,000
ED1 28443308 100.00% 26883074 100.00% 77,791
79,162ED2 27656170 100.00% 26185310 100.00% 83,174
ED3 27367601 100.00% 25931067 100.00% 87,711
INPUT 27107030 100.00% 25761594 100.00% _ _
ZR-75.1 ER+ BC line  _   GATA3 ChIP-seq
on Bowtie files on RmDup files MACS2 Callpeak Consensus
QC passed reads %mapped QC passed reads %mapped # Peaks # Peaks
VEH1 25052184 98.89 23585902 98.82 53,568
48,807VEH2 24193204 98.84 22801542 98.77 44,043
VEH3 18284448 98.87 17348458 98.81 57,348
E2-1 27164574 98.83 25500639 98.75 56,569
47,290E2-2 26685893 98.8 25168979 98.72 39,456
E2-3 24283078 98.85 22833295 98.78 52,207
DHT1 24560421 98.95 22986082 98.88 56,152
58,037DHT2 25770427 99 24189405 98.93 69,127
DHT3 26573908 98.94 24960138 98.88 57,024
ED1 19412651 98.96 18301158 98.89 65,496
48,864ED2 21120075 98.84 19463879 98.74 39,674
ED3 23992413 98.92 22528153 98.85 50,768




Supplementry-1: GATA3 cistrome in different hormone treated conditions in ER+ breast 
cancer cells. Venn diagrams represent the concordance of the 3 biological replicates of 
each vehicle, E2, DHT, and E2+DHT treated GATA3 ChIP-seq experiment in two ER+ breast 
cancer in vitro cells, T-47D (a) and ZR-75-1 (b). Tables provide information regards the 
GATA3 ChIP-seq data files that have been processed through GALAXY Australia in T-47D (c) 
and ZR-75-1 (d) cells. Size of the consensus files for each treatment condition in both ER+ 
breast cancer cells have been shown in tables c and d. e) Venn diagram shows the effect 
of estrogen treatment on the arrangement of GATA3 binding profile in ZR-75-1 cells. f) PCA 
clustering the estrogen-treated cells away from the vehicle-treated cells in ZR-75-1 breast 
cancer model, characterizing the trends exhibited by the E2 compared with the vehicle 
treated cells in this model. Grey representing three replicates of vehicle-treated samples, 




Supplementary 2: Estrogen stimulation of ZR-75-1 cells rearranges the GATA3 cistrome  
a c
ZR-75-1 T-47D











Supplementry-2: Estrogen stimulation of ZR-75-1 cells rearranges the GATA3 cistrome. 
a) Venn diagram represents the overlap ER and GATA3 cistromes under E2 treatment in 
ZR-75-1 cells. b) Volcano plot shows the differentially enriched and depleted GATA3 
binding sites (FDR ≤ 0.05) upon ER activation in ZR-75-1 breast cancer cells. The purple dots 
represent peaks that did not undergo a significant change (FDR ≥ 0.05) with ER activation. 
The pink dots represent significant (FDR ≤ 0.05) changes to GATA3 peaks in this model. c) 
Volcano plot depicts the differentially expressed ER-GATA3 targets in ZR-75-1 cells. d) Venn 
diagram show the overlap of up-regulated ER-GATA3 targets in two ER+ breast cancer cells, 
T-47D and ZR-75-1. e) Bar graph shows the biological pathways that are associated with 
ER-GATA3 targets in ZR-75-1 breast cancer model. f) Gene set enrichment analysis (GSEA) 
plots represent the associated Hallmarks with up-regulated ER-GATA3 targets in ZR-75-1 
cells. g) Bar charts represent the effect of GATA3 knock-down on the mRNA expression 
level of PgR and GREB1 genes under E2-stimulation condition compared with the vehicle 
cells in ZR-75-1 breast cancer model. Two-way ANOVA with Tukey's multiple comparisons 
test was used to determine statistically significant differences in g. Data shown as mean ± 
SEM of 3 independent experiments; **** p<0.0001. h) Western blotting images show the 
efficacy of GATA3 silencing in both T-47D and ZR-75-1 cells, also images represent the 





Supplementary 3: Androgens redistribute the GATA3 binding profile in ZR-75-1 breast 










0 10 20 30 40-10-20-30






















Supplementry-3: Androgens redistribute the GATA3 binding profile in ZR-75-1 breast 
cancer cells. a) Venn diagram shows the effect of DHT treatment on the GATA3 cistrome. 
b) PCA plot shows the clustering of DHT-treated cells away from the vehicle-treated cells 
in ZR-75-1 breast cancer model. Grey dots represent three independent replicates of 
vehicle-treated samples; pink dots represent 3 replicates of DHT-treated samples in ZR-75-
1 cells. c) Venn diagram shows the potent effect of DHT on re-distributing the E2-
stimulated GATA3 cistrome. d) PCA plot shows the effect of hormones (estrogens and 
androgens) on clustering the treated cells in ZR-75-1 cells. Colours represent three 
replicates of different treatments. e) Motif analysis of E2+DHT-induced GATA3 binding 
sites revealed enrichment of the AR motif and loss of ER motif in ZR-75-1 breast cancer 
model. f) Volcano plot shows the differentially enriched and depleted GATA3 binding sites 
(FDR ≤ 0.05) upon AR activation in the presence of E2 in ZR-75-1 breast cancer cells. The 
purple dots represent peaks that did not undergo a significant change (FDR ≥ 0.05) with AR 
activation. The pink dots represent significant (FDR ≤ 0.05) changes to GATA3 peaks in each 
model. g) Two-factor MA plot represents distribution of the AR and GATA3 cistromes upon 
E2+DHT stimulation in ZR-75-1 cells . Peaks are represented by coloured dots and classified 
into 5 different sub-groups: grey and yellow dots represent AR and GATA3 binding sites 
that do not overlap with the other factor, respectively; blue dots represent E2+DHT-
induced GATA3 peaks that are not shared with AR; green dots represent GATA3 binding 
sites that were not altered by E2+DHT stimulation but AR was recruited to these loci; and 
pink dots represent AR-GATA3 peaks that are significantly gained upon E2+DHT 
stimulation. Example loci associated with AR-GATA3-ER target genes (RANBP3L and CA12 
represented loci from pink group, PgR, GREB1, and MYB represented loci from green 
group) that are highlighted in black dots in ZR-75-1 cells. h) Venn diagram depicts the 
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overlap of E2+DHT-induced GATA3 binding sites with E2+DHT-induced AR events in ZR-75-
1 cells.  
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Supplementry-4: AR-induced ER-reprogramming is mediated through a switch in GATA3 
co-regulatory function. a) Venn diagram shows the overlap DHT-induced AR, GATA3, and 
ER cistromes in ZR-75-1 cells. b) Heatmap represents the contribution of DHT-induced 
GATA3 peaks on DHT-induced shared AR-ER binding sites in ZR-75-1. c) Read density plots 
represent the H3K27ac enrichment in E2- and E2+DHT-treated ZR-75-1 cells. d) Heatmap 
show the density of H3K27ac enrichment in at E2+DHT-induced AR sites depleted from 
GATA3 compared with the E2 stimulation condition in ZR-75-1 cells. e) Bar graph shows 
the biological pathways that are associated with up-regulated AR-GATA3-ER targets upon 
E2+DHT treatment in ZR-75-1 cells. f) GSEA analysis represents that down-regulated AR-
GATA3-ER targets are associated with down-regulation of cell growth in ZR-75-1 cells. g) 
Bar graphs represent the effect of GATA3 knock-down on the mRNA expression level of 
SE14L2 and ZBTB16 tumour-suppressor AR targets under E2+DHT-stimulation compared 
with the E2-treated cells in ZR-75-1 breast cancer model. Two-way ANOVA with Tukey's 
multiple comparisons test was used to determine statistically significant differences in f. 










Supplementry-5: Shared DEG AR signatures with AR-GATA3 targets in T-47D cells. Table 
depicts the up- and down-regulated AR signature genes that are common with AR-GATA3 




Supplementary 6: List of antibodies, siRNAs and primers used in this study 
Western blotting
Company Cat numbers Spices Dilluton factor
GATA3 Abcam ab199428 Rabbit 1 in 500
GAPDH Merck Millipore mab374 Mouse 1 in 2000
Scene Anti-scene Company
siGATA3-JC-1 AAACUAGGUCUGAUAUUCAUU UGAAUAUCAGACCUAGUUUU Sigma
siGATA3-JC-2 CUUUAUUGCAUCUGGGUAG CUACCCAGAUGCAAUAAAG Sigma





SEC14L2 GCCGAATCCAGATGACTATTTTCT GATGTTGTCAATGTCCTTTTGCTT 55 Sigma
ZBTB16 GAGATCCTCTTCCACCGCAAT CCGCATACAGCAGGTCATC 55 Sigma
PgR ACAACCACCAGTCACCTTCC CCATCCACACGCTCCAGAAT 55 Sigma
GREB1 CATCTCTGCCCTTTGAAACAAAA GGGCATCACCCGAAACAAG 55 Sigma
ChIP-seq
Company Cat numbers Spices Volume













4. Chapter-4: General discussion 
4.1. Introduction  
The majority of breast cancers are dependent on estrogen for their growth and 
approximately 80 % of tumours express the ER, which is the main nuclear transcription 
factor that mediates the oncogenic effects of estrogens (Lim et al. 2016). ER elicits its 
transcriptional activity within a transcriptional complex comprised of multiple factors 
(Mohammed et al. 2013; Papachristou et al. 2018). In the recent past, the GATA3 
transcription factor has been characterized as an important regulator of ER signalling in 
ER+ breast cancer that functions in collaboration with the ER transcriptional complex at 
multiple loci of the genome to regulate ER activity (Theodorou et al. 2013). GATA3 has an 
important role in mediating enhancer accessibility at regulatory regions involved in ER-
mediated transcription (Theodorou et al. 2013). GATA3 is expressed exclusively in the 
luminal epithelial cells of the mammary gland (Shackleton et al. 2006) and plays an 
essential role in mammary development and specification (Kouros-Mehr, Bechis, et al. 
2008; Kouros-Mehr et al. 2006). In the adult mammary glands of mice, GATA3 expression 
is necessary to maintain the differentiated state of luminal epithelial cells after completion 
of mammary development (Kouros-Mehr et al. 2006). The majority of breast cancers also 
express AR (Hickey, TE et al. 2021). AR has been shown to inhibit estrogen-induced growth 
of ER+ breast cancers (Hickey, TE et al. 2021) and its expression is associated with improved 
disease-free survival and more benign clinical and pathologic factors (e.g. lower tumor 
grade and smaller tumor) in ER- BC (Hu, XQ et al. 2017; Luo et al. 2010). ER and AR share 
co-regulatory proteins including FOXA1 (Robinson, JL & Carroll 2012), SRC-3 and P300 
(Hickey, TE et al. 2021) supporting my hypothesis that since GATA3 is an important factor 
in ER signalling, it might also play key role in AR signalling in breast cancers. To date, the 
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role of GATA3 in AR signalling in the context of BC, in the presence or absence of ER, has 
not been investigated. Therefore, in my PhD thesis I explored the role of GATA3 in AR 
signalling using a variety of models representing different breast cancer subtypes to 
determine whether GATA3 is important for AR-mediated growth inhibition of ER+ breast 
cancer subtypes and to explore its role in the context of ER- breast cancer. In summary, my 
findings show that GATA3 is a novel AR interacting protein in normal and malignant breast 
epithelial cells and co-operates with AR in driving luminal-lineage identity in ER+ and ER- 
breast cancer cell lines. My findings provide a mechanistic explanation for the association 
between AR and luminal gene profiles in clinical breast cancers. Also, my data provides 
novel insight into the cross-talk between ER, GATA3, and AR in ER+ BC, highlighting the 
signalling complexity of these TFs in this disease. Findings of this thesis show the 
involvement of GATA3 in AR-mediated tumour-suppression in ER+ breast cancer contexts, 
which in turn highlights the role of common co-regulators like GATA3 in mediating AR and 
ER cross-talk in breast cancer progression. 
 
4.2. Major findings of this thesis 
4.2.1. GATA3 is a novel AR interacting protein independent of ER expression 
in normal mammary tissues and different BC subtypes. 
AR functions within a transcriptional complex along with several co-regulatory 
proteins that are implicated in a diverse number of cellular functions, however, no study, 
to date has investigated the AR interacting proteins in different breast cancer subtypes. 
Therefore, for the purpose of this thesis, I used an unbiased proteomic technique called 
RIME (Mohammed et al. 2016) to identify proteins that interact with AR while bound to 
chromatin and discovered GATA3 as a novel AR interacting factor across different breast 
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cancer subtypes (Chapter-2). The interaction of AR and GATA3 transcription factors was 
confirmed through PLA and Co-IP techniques in both ER+ and ER- cell lines and clinical 
samples of ER+ and ER- breast cancer (Chapter-2). Additionally, my findings show that AR 
activation with DHT induces nuclear translocation both AR and GATA3 compared with the 
vehicle-treated cells in ER+ and ER- breast cancer models, which suggests that AR and 
GATA3 function is a complex in breast cancer (Chapter-2). I also observed AR and GATA3 
interactions in normal breast clinical samples, which suggests a key role for the AR-GATA3 
complex in normal mammary gland function (Chapter-2). Taken together, studying a 
comprehensive catalogue of AR interacting proteins in various breast cancer cell models 
provided a basis for the in-depth and quantitative characterisation of protein interactome 
dynamics of AR complex networks deciphering the mechanisms involved in this disease. 
Identifying GATA3 as an AR interacting protein, possibly within a functional complex with 
AR, suggests a new insight into the complexity of the AR transcription factor networks in 
breast cancer. Cooperative action of transcription factors creates complex gene regulatory 
networks to maintain cell characteristics. Disruption of these regulatory networks is often 
associated with human diseases such as cancer. for instance, alteration to the expression 
and activity of AR co-regulators including FOXA1 is an important mechanism in disease 
progression in both prostate (Paltoglou et al. 2017) and breast cancer (Robinson, J et al. 
2011). AR plays oncogenic functions in male oesophageal squamous cell carcinoma (ESCC). 
In a very recent research, GATA3 has been shown to form a complex with ligand-activated 
AR on chromatin in ESCC cell line models, increased recruitment of corepressors SMRT and 
HDAC3 leading to pronounced repression of tumor suppressor genes (e.g., DUSP4 and 
FOSB) and enhanced ESCC growth (Huang, et al. 2021). Also, GATA3 positivity is highly 
correlated with AR expression regardless of ER presence in breast cancer tumours (Boto & 
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Harigopal 2018; Kim et al. 2016). Therefore, further investigations around the importance 
of AR and GATA3 interactions in breast cancer may reveal how any alteration in GATA3 
expression, as an AR co-regulator, would affect the AR signalling in various breast cancer 
contexts.  
 
4.2.2. Stimulation of breast cancer cells with estrogen or androgen 
hormones reprograms the GATA3 cistrome in breast cancer cell line 
models. 
It has never been reported previously whether hormone stimulation (estrogens 
and/or androgens) may affect the GATA3 binding profile and function in breast cancer. 
Therefore, in order to explore the possible effect of hormone stimulations on the GATA3 
cistrome, I mapped the genome-wide binding profile of GATA3 through ChIP-seq 
experiments under different hormone treatment conditions following a period of hormone 
depletion, including vehicle, E2, DHT and E2+DHT treatments, in two ER+ and two ER- 
breast  cancer cell line models (Chapter-2 and 3). I also performed GATA3 ChIP-seq in two 
ER+ PDX models of breast cancer that had been treated with vehicle or an AR agonist 
(Chapter-2). My findings clearly show that estrogen shifts the GATA3 cistrome towards a 
new subset of binding sites compared with the vehicle-treated cells in ER+ breast cancer 
cell line models, T-47D and ZR-75-1 (Chapter-3). Also, AR-agonist induction of ER+ and ER- 
breast cancer cell lines and ER+ PDX breast tumours show a potent effect of AR agonists 
(DHT or Enobosarm) in redistributing the GATA3 cistrome in these models (Chapter-2 and 
3). Interestingly, GATA3 ChIP-seq data associated with E2+DHT treatment in ER+ breast 
cancer cells, T-47D and ZR-75-1, compared with the E2-treated cells show that AR 
activation rearranges the E2-induced GATA3 binding events in these models (Chapter-3), 
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demonstrating an antagonistic effect. Generally, my findings, for the first time, 
demonstrate that GATA3 binding profile is hormone regulated (by estrogens (Chapter-3) 
and androgens (Chapter-2)) in breast cancer context. Therefore, this would shed a light 
into the fact that there may be a same hormonal effect on chromatin binding preferences 
of other AR and / or ER co-regulators in breast cancer, which mediate the signalling and 
function of the master regulators driving breast cancers. Also, this highlights the 
importance of selecting appropriate models and having precise experimental design for 
investigating transcription factors function in a complex in hormone-regulated cancers like 
breast disease. 
 
4.2.3. GATA3 is bound and plays a regulatory role at genomic loci associated 
with AR-mediated growth inhibition in ER+ BC to inhibit E2-stimulated 
growth. 
My data show that the E2-induced GATA3 cistrome has a high degree of overlap 
with the E2-induced ER cistrome, an association that is important for regulation of genes 
associated with cell cycle progression and growth of ER+ breast cancer cell (Chapter-3). 
However, dual-receptor activation (ER and AR) with E2+DHT treatment clearly shifted E2-
induced GATA3-ER binding events in ER+ breast cancer cells away from growth regulatory 
loci. These data suggest that the potent interplay between ligand-activated AR and GATA3 
facilitates the ability of AR signalling to antagonise ER signalling in ER+ breast cancer cells 
(Chapter-3). Interestingly, AR-GATA3-ER co-occupied loci are associated with up-regulated 
targets upon E2+DHT treatment, and were positively enriched in gene sets associated with 
epithelium development, cell-cell signalling, and regulation of cell death pathways. In 
contrast, down-regulated AR-GATA3-ER gene targets were negatively associated with cell 
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growth gene sets in both of the ER+ cell line models. Also, my data show that AR-ER loci 
co-occupied with GATA3 are located in transcriptional active chromatin upon DHT 
treatment, however, loci depleted from GATA3 does not show enrichment of H3K27ac, an 
indicative of active sites. Together, my findings suggest that AR activation relocates GATA3 
away from shared ER binding sites associated with proliferative genes, and induces a new 
subset of binding events that are common between all three transcription factors, 
implicating GATA3 in AR-driven tumour suppression in ER+ breast cancer cells (Chapter-3), 
possibly through facilitating AR DNA binding. 
 
4.2.4. A collaborative role for GATA3 and AR in promotion of luminal 
epithelial differentiation in breast cells regardless of ER expression. 
My findings show that the majority of GATA3 binding events induced by AR 
activation were co-occupied by AR and associated with an increase in H3K27ac signal, 
indicative of an active transcriptional state of chromatin at these loci (Chapter-2). This 
finding is consistent with the effect of AR activation on interaction and nuclear 
translocation of GATA3 in breast cancer cells across all ER+/ER- cell line models (Chapter-
2). Common AR-GATA3 active loci were associated with genes within biological gene sets 
involved in development and differentiation of mammary epithelial tissue including 
mammary gland development, mammary gland duct morphogenesis and epithelial cell 
differentiation (Chapter-2). Performing GATA3 ChIP-PCR following AR knock-down showed 
that silencing AR abolished DHT-induced enrichment of GATA3 at representative loci, 
indicating that GATA3 binding at these AR target genes is dependent on AR. The reciprocal 
experiment with GATA3 knock-down, showed that AR binding was decreased but not 
abolished at these loci, indicating that GATA3 facilitates, but is not critical for AR binding 
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(Chapter-2). Accordingly, GATA3 knock-down significantly reduced expression levels of the 
representative AR target genes, indicating that the reduction of AR binding at associated 
loci had a functional impact on AR transactivation capacity. Investigation of AR-GATA3 
regulated targets revealed an association with up-regulation of luminal epithelial markers 
and down-regulation basal epithelial markers, indicative of luminal phenotype promotion 
(Chapter-2). Mechanistically, my data revealed that DHT stimulation induces AR-mediated 
translocation of GATA3 into the nucleus, resulting in a gain of new GATA3 binding sites, 
where GATA3 co-regulates AR function in promoting the expression of luminal epithelial 





4.3. Future directions 
4.3.1. Investigating the structural basis of AR and GATA3 protein-protein 
interaction 
Protein-protein interactions (PPIs) are physical contacts of high specificity 
established between two or more protein molecules that play a key role in predicting the 
function of a particular target protein and the ability to drug it (Ivanov, Khuri & Fu 2013). 
Thus, pathway perturbation, through the disruption of PPIs critical for cancer, offers a 
novel and effective strategy to curtail the transmission of oncogenic signals (Ivanov, Khuri 
& Fu 2013). As our understanding of cancer biology has significantly increased in recent 
years, interest in targeting PPIs as anti-cancer strategies has increased as well. This thesis 
provided the first data demonstrating the AR-GATA3 interaction in breast cancer, however, 
it did not investigate whether this is a direct interaction without having any bridging factor 
in between. Also, I did not investigate the details of AR-GATA3 protein interactions to 
assess which domains of these factors are required for their protein interaction properties. 
In addition, I did not explore the possible effect of GATA3 mutations in disrupting AR-
GATA3 interaction and its consequences in breast cancer progression. Therefore, it would 
be critical to further investigate the basis of AR-GATA3 interactions and possible effect of 
GATA3 mutations on this interaction in order to better understand the role of AR-GATA3 
interactions breast cancer biology. 
 
4.3.2. AR-GATA3 function in normal mammary glands 
AR has been suggested to increase in the population of luminal MECs in mouse 
mammary glands treated with Enobosarm (Tarulli et al. 2019). Also, a significant increase 
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in the proportion of p63+ basal MECs and decrease in ER+ luminal MECs was observed in 
AR-null mammary epithelium of mice, suggesting an alteration in the balance of MEC 
differentiation (Tarulli et al. 2019). AR transcription factor is shown to be enriched in breast 
cancer cells that were engrafted in the mammary gland through intraductal injection that 
maintains luminal profiles in cancer cells (Sflomos et al. 2016). Also, in human breast 
cancer, AR signalling has been shown to promote the maintenance of a luminal state. 
Additionally, AR lineage tracing studies in mouse prostate identified AR expressing basal 
cells that are required for re-population of the luminal niche after regression (Xie et al. 
2017). In addition, GATA3 express in the differentiated luminal epithelial cells lining the 
breast ductal structures  and associated with luminal cell identity and function in mammary 
glands (Kouros-Mehr et al. 2006; Kouros-Mehr & Werb 2006). Interestingly, my data 
confirm that the AR-GATA3 interaction occurs in normal clinical breast tissues as well as in 
malignant breast cancer cells, which suggests a key role for the AR-GATA3 complex in 
normal breast biology. According to the important role of AR-GATA3 complex in promoting 
the luminal phenotype in breast cancer context, I propose that their interaction in normal 
mammary would be critical in inducing the luminal cell fate determination of the breast 
cells. I suggest to investigate the details of AR-GATA3 interactions during mammary gland 
development using MMTV-Cre mice models that may lack one or two copy(ies) of their 
GATA3 and / or AR genes and study that how would deletion of each factor influence the 
population of both alveolar and ductal progenitor cells compared with the basal 




4.3.3. Investigating the effect of GATA3 depletion on mRNA expression level 
of basal lineage targets 
My findings identified numerous up-regulated luminal epithelial markers as well as 
down-regulated basal marker genes, indicative of luminal phenotype promotion within 
transcriptionally active regions of chromatin at common AR-GATA3 regulated loci. My data 
showed that silencing AR significantly abolished DHT-induced enrichment of GATA3 at 
representative loci associated with luminal genes in both ER+ and ER- breast cancer 
models, and that silencing GATA3 negatively impacted the DHT-induced enrichment of AR 
binding at the selected luminal representative loci. Also, knock-down of AR or GATA3 
significantly reduced the DHT-induced mRNA expression level of luminal genes in vitro. 
However, due to the lack of reagents, and COVID-19 related lab restrictions, I did not have 
a chance to expand my ChIP-PCR and qPCR experiments to examine the effect of AR and 
GATA3 knock-down on binding enrichment of the other factor and on the mRNA 
expression levels of their basal target genes. However, I believe this would be critical to be 
able to make a definite conclusion with regard to the role of the AR-GATA3 complex in 
promotion of luminal phenotype in breast cancer context. Although I could not process the 
experiments related to the basal genes, I expect to see that AR knock-down abolishes DHT-
induced enrichment of GATA3 at basal representative loci and also that GATA3 knock-
down negatively impacted the DHT-induced enrichment of AR binding at the selected basal 
representative loci in both ER+ and ER- breast cancer models. Also, I expect that silencing 
AR or GATA3 would increase mRNA expression level of basal makers in both ER+ and ER- 




4.3.4. Exploring the role of GATA3 in cytokinesis and cell cycle progression 
of breast cancer cells 
While assessing the effect of GATA3 knock-down on the growth-stimulatory and / 
or growth-inhibitory effect of estrogens and androgens in ER+ breast cancer cell 
proliferation, respectively, I observed dramatic morphology changes in both T-47D and ZR-
75-1 ER+ breast cancer cells upon GATA3 silencing, causing multinuclear cells in a common 
cytoplasm. Failure to complete cytokinesis has been proposed to promote tumorigenesis 
(Fujiwara et al. 2005; Ganem, Storchova & Pellman 2007; Steigemann et al. 2009) by 
leading to tetra-ploidy and ensuing chromosomal instability (Caldwell, Green & Kaplan 
2007; Fujiwara et al. 2005; Ganem, Storchova & Pellman 2007). For instance, GATA6 is 
another member of the GATA family of transcription factors that has been shown to 
function in early embryonic stem cell differentiation (Cai et al. 2009). GATA6 is usually lost 
in ovarian cancer and leads in cytokinesis failure, deformation of the nuclear envelope and 
formation of polyploid and aneuploid cells (Cai et al. 2009). Thus, GATA6 is also linked to 
tumorigenesis. Also, the cytokinesis regulator FYVE-CENT is usually mutated in breast 
cancers (Sjöblom et al. 2006). Depletion of FYVE-CENT results in an increased number of 
binuclear and multinuclear profiles, as well as cells arrested in cytokinesis, indicating its 
important role in cytokinesis (Sagona et al. 2010). Therefore, I suggest that depletion of 
GATA3 in these ER+ breast cell line models caused a failure in completion of normal 
cytokinesis, which in turn led to polynuclear giant cells irrespective to the hormone 
treatment condition of the cells. I believe that it would be crucial to further investigate the 




4.3.5. Assessing the effect of GATA3 ectopic expression in ER+ and ER- 
breast cancer cells 
I have generated nine doxycycline-inducible ER+ (T-47D and ZR-75-1) and ER- 
(MDA-MB-453) breast cancer lines, that are able to over-express wild-type or T308 mutant 
GATA3 protein as well as cells expressing the negative control insertion (Appendix-5.1.1). 
T308 GATA3 mutation is a truncation mutation in ZnFn2 domain of the gene, that can 
recapitulate the clinical consequences of other mutations with a similar truncated protein 
product like what we see in MCF-7 cells. According to the recent large-scale genomic 
profiling of breast tumors, frequent mutations has been identified in GATA3 (Pereira et al. 
2016). More than 10 % of breast tumors carry GATA3 mutations (Ciriello et al. 2015). 
However, it is having been difficult to specifically investigate the role of mutant GATA3 due 
to lack of specific antibodies that exclusively pick the mutant form away from the wild-type 
GATA3 protein (e.g. in MCF-7 cells and primary tumours). Currently, available GATA3 ChIP 
specific antibodies detect both mutant and wild-type forms. R330fs GATA3 (a 
heterozygous frameshift mutation at arginine 330 of ZnFn2 domain of GATA3 and naturally 
exists in MCF-7 cells) mutant disrupts the cooperative action with ER, FOXA1, and 
rearrange ER and FOXA1 chromatin localization, which is associated with altered chromatin 
architecture and differential gene expression in GATA3 mutant cells (Takaku et al. 2020). 
Although, I did not get a chance to investigate the role of ectopic expression of wild-type 
and T308 mutant GATA3 in association with breast cancer progression, I strongly believe 
that my generated transduced breast cancer cell lines are among the best models for 
future mutation-related studies including: 
280 
 
a)  Investigating the effect of mutant GATA3 on its interactions with other 
transcription factors (e.g. AR, ER), AR signalling, AR binding profile, and AR function 
in different breast cancer contexts, 
b) Assessing the effect of mutant GATA3 on shaping the GATA3 cistrome and its 
functional consequences in breast cancer cells in response to ER and or AR 
activation, 
c) Examining the effect of over-expression of wild-type and / or mutant GATA3 on 
growth rate of ER+ and ER- breast cancer cells. 
 
4.4. Concluding remarks  
Taken together, this study aimed to reveal the role of GATA3 in AR signalling in the 
context of breast cancer, and to characterise the cross-talk between AR and GATA3 in the 
presence or absence of activated ER. My data show a cooperative role for AR and GATA3 
in suppressing estrogen-induced tumour growth of ER+ breast cancer and in driving the 
luminal-lineage identity in normal mammary glands and all breast cancer contexts. Also, 
my findings provide novel insight into the complexity of ER, GATA3, and AR cross-talk in 
breast cancer, preparing a basis for further investigations into AR and GATA3 co-operative 









5. Chapter-5: Appendix 
5.1. Appendix – Generating stable knock-down of factors in 
breast cancer cell lines 
5.1.1. Appendix-1: Plasmid constructs 
The composition and construction of plasmid vectors generated for future 








pDONR221 was the entry clone used in Gateway cloning containing Kan resistance 
gene (for selection in BUG culture) that accepted our sequence of interest (e.g. wtGATA3, 






pER365 was the destination vector used in Gateway cloning containing Amp 
resistance gene (for selection in BUG culture) and puroR resistance gene (for selection in 
cell culture) that received our sequences of interest (e.g. wtGATA3, mutGATA3, or the GUS-






pDRM7-tet-GATA3-wt-lenti was the final construct containing puroR resistance 
gene (for selection in cell culture) and the sequence of wtGATA3 to over-express the wild-















pDRM8-tet-GATA3-T308-lenti was the final construct containing puroR resistance 
gene (for selection in cell culture) and the sequence of mutGATA3 to over-express the 
















pDRM10-tet-GUS-lenti was the final construct containing puroR resistance gene 












5.1.2. Appendix-2: Generating lentiviral transfer plasmid encoding the 
insert of interest, viral transfection, and transduction in desired cell 
lines 
Second generation, 3-package plasmid system was conducted to generate the 
desired recombinant lentiviruses using the packaging vector of psPAX2, envelope vector of 
VSVG pSD11 pMD2.G, and the transfer plasmid encoding the insert of interest. HEK-293 
cells were transfected with transfer plasmid and packaging plasmids that provides all the 
viral proteins required for virus particle production within a packaging cell, using the PEI 
transfection methodology. 10 uM chloroquine was added to the normal media of the HEK-
293 cells in order to increase the efficacy of transfection. The media supplemented with 
transfection mix was changed to Opti-MEM media after 12 hours of incubation at 37 ˚C. 
Media containing viral particles was collected after 48 hours, purified and filtered to 
concentrate the virus.  
Lentiviral titration has been done for each cell line to ensure that preps are applied 
in sufficient quantities to obtain desires transduction efficiencies. Two ER+ (ZR-75-1 and T-
47D) and one ER- (MDA-MB-453) breast cancer cell lines were transduced with the 
appropriate Doxycycline inducible viruses (e.g. wtGATA3, mutGATA3, or the GUS negative 
control vector). The optimal titration for all the generated viruses in all the breast cancer 
lines were 105 IFU/ml (Infectious units (IFU)). 
Transduced lines were expanded and selected through culturing in media 
supplemented with puromycin. Selected cells finally induced with different doses of 
Doxycycline in various induction timepoints to select the best dose/timepoint for further 
experiments. The efficacy of induction has been checked through western blotting. ZR-75-
1 and MDA-MB-453 breast cancer cells had the most wtGATA3 or mutGATA3 protein 
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expression level after 12 hours of induction with 1 ug/ml of Doxycycline. T-47D breast 
cancer cells had the most wtGATA3 or mutGATA3 protein expression level after 12 hours 
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